Afya Limited (AFYA) 20-F 28 Apr 23 2022 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2022 shares
Entity Addresses [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38992
Entity Registrant Name	AFYA LIMITED
Entity Central Index Key	0001771007
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	Alameda Oscar Niemeyer
Entity Address, Address Line Two	No. 119
Entity Address, City or Town	Minas Gerais
Entity Address, Country	BR
Entity Address, Postal Zip Code	504
Title of 12(b) Security	Class A common shares, par value US$0.00005 per share
Trading Symbol	AFYA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Auditor Firm ID	1448
Auditor Name	ERNST & YOUNG
Auditor Location	Belo Horizonte, Brazil
Class A Ordinary Shares [Member]
Entity Addresses [Line Items]
Entity Common Stock, Shares Outstanding	47,920,068
Class B Ordinary Shares [Member]
Entity Addresses [Line Items]
Entity Common Stock, Shares Outstanding	45,802,763
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Alameda Oscar Niemeyer
Entity Address, Address Line Two	No. 119
Entity Address, City or Town	Minas Gerais
Entity Address, Country	BR
Entity Address, Postal Zip Code	504
City Area Code	55
Local Phone Number	3515-7550
Contact Personnel Name	Virgilio Deloy Capobianco Gibbon
Contact Personnel Email Address	ir@afya.com.br

Consolidated statements of fina

Consolidated statements of financial position - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	R$ 1093082	R$ 748562
Trade receivables	452,831	378,351
Inventories	12,190	11,827
Recoverable taxes	27,809	25,579
Other assets	51,745	42,533
Total current assets	1,637,657	1,206,852
Non-current assets
Trade receivables	42,568	27,442
Other assets	191,756	180,306
Investment in associate	53,907	48,477
Property and equipment	542,087	419,808
Right-of-use assets	690,073	663,686
Intangible assets	4,041,491	3,900,835
Total non-current assets	5,561,882	5,240,554
Total assets	7,199,539	6,447,406
Current liabilities
Trade payables	71,482	59,098
Loans and financing	145,202	128,720
Lease liabilities	32,459	24,955
Accounts payable to selling shareholders	261,711	239,849
Notes payable	62,176	14,478
Advances from customers	133,050	114,585
Labor and social obligations	154,518	131,294
Taxes payable	26,221	26,715
Income taxes payable	16,151	11,649
Other liabilities	2,719	15,163
Total current liabilities	905,689	766,506
Non-current liabilities
Loans and financing	1,737,699	1,246,156
Lease liabilities	737,066	689,130
Accounts payable to selling shareholders	266,967	439,977
Notes payable		58,248
Taxes payable	92,888	96,598
Provision for legal proceedings	195,854	148,287
Other liabilities	13,218	2,486
Total non-current liabilities	3,043,692	2,680,882
Total liabilities	3,949,381	3,447,388
Equity
Share capital	17	17
Additional paid-in capital	2,375,344	2,375,344
Share-based compensation reserve	123,538	94,101
Treasury shares	(304,947)	(152,630)
Retained earnings	1,004,886	631,317
Equity attributable to equity holders of the parent	3,198,838	2,948,149
Non-controlling interests	51,320	51,869
Total equity	3,250,158	3,000,018
Total liabilities and equity	R$ 7199539	R$ 6447406

Consolidated statements of inco

Consolidated statements of income and comprehensive income - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Profit or loss [abstract]
Revenue	R$ 2329057	R$ 1719371	R$ 1201191
Cost of services	(859,552)	(652,300)	(434,654)
Gross profit	1,469,505	1,067,071	766,537
General and administrative expenses	(798,153)	(622,615)	(402,855)
Other expenses, net	(7,252)	(3,561)	(347)
Operating income	664,100	440,895	363,335
Finance income	102,042	64,566	62,290
Finance expenses	(349,893)	(243,796)	(98,269)
Finance result	(247,851)	(179,230)	(35,979)
Share of income of associate	12,184	11,797	7,698
Income before income taxes	428,433	273,462	335,054
Income taxes expenses	(35,677)	(31,179)	(27,067)
Net income	392,756	242,283	307,987
Other comprehensive income
Total comprehensive income	392,756	242,283	307,987
Income attributable to
Equity holders of the parent	373,569	223,326	292,075
Non-controlling interests	19,187	18,957	15,912
Total comprehensive income	R$ 392756	R$ 242283	R$ 307987
Basic earnings per share
Per common share	R$ 4.14	R$ 2.39	R$ 3.15
Diluted earnings per share
Per common share	R$ 4.12	R$ 2.37	R$ 3.12

Consolidated statements of chan

Consolidated statements of changes in equity - BRL (R$) R$ in Thousands	Issued capital [member]	Additional paid-in capital [member]	Treasury shares [member]	Reserve of share-based payments [member]	Retained earnings [member]	Equity attributable to owners of parent [member]	Non-controlling interests [member]	Total
Beginning balance, value at Dec. 31, 2019	R$ 17	R$ 1931047		R$ 18114	R$ 115916	R$ 2065094	R$ 48632	R$ 2113726
IfrsStatementLineItems [Line Items]
Net income					292,075	292,075	15,912	307,987
Total comprehensive income					292,075	292,075	15,912	307,987
Capital increase		17,531				17,531		17,531
Treasury shares
Issuance of common shares in follow-on public offering		389,170				389,170		389,170
Shares issuance cost		(19,704)				(19,704)		(19,704)
Share-based compensation		5,444		32,610		38,054		38,054
Dividends declared							(12,984)	(12,984)
Ending balance, value at Dec. 31, 2020	17	2,323,488		50,724	407,991	2,782,220	51,560	2,833,780
IfrsStatementLineItems [Line Items]
Net income					223,326	223,326	18,957	242,283
Total comprehensive income					223,326	223,326	18,957	242,283
Capital increase		74,500				74,500		74,500
Treasury shares			(213,722)			(213,722)		(213,722)
Treasury shares transferred from exercise of options		(21,861)	55,197			33,336		33,336
Treasury shares transferred from shares contribution on business combination		(783)	5,895			5,112		5,112
Share-based compensation				43,377		43,377		43,377
Dividends declared							(18,648)	(18,648)
Ending balance, value at Dec. 31, 2021	17	2,375,344	(152,630)	94,101	631,317	2,948,149	51,869	3,000,018
IfrsStatementLineItems [Line Items]
Net income					373,569	373,569	19,187	392,756
Total comprehensive income					373,569	373,569	19,187	392,756
Treasury shares			(152,317)			(152,317)		(152,317)
Share-based compensation				29,437		29,437		29,437
Dividends declared							(19,736)	(19,736)
Ending balance, value at Dec. 31, 2022	R$ 17	R$ 2375344	R$ 304947	R$ 123538	R$ 1004886	R$ 3198838	R$ 51320	R$ 3250158

Consolidated statements of cash

Consolidated statements of cash flows - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Income before income taxes	R$ 428433	R$ 273462	R$ 335054
Adjustments to reconcile income before income taxes
Depreciation and amortization	206,220	154,220	108,744
Write-off of property and equipment	1,697	1,604
Write-off of intangible assets	25	2,374
Allowance for doubtful accounts	42,708	47,819	32,081
Share-based compensation expense	31,274	43,377	32,610
Net foreign exchange differences	852	17,973	4,613
Net loss (gain) on derivatives			(20,739)
Accrued interest	200,081	108,437	25,543
Interest on lease liability	88,571	67,212	44,458
Share of income of associate	(12,184)	(11,797)	(7,698)
Provision for legal proceedings	(766)	10,664	5,354
Changes in assets and liabilities
Trade receivables	(129,165)	(79,665)	(164,286)
Inventories	(363)	(3,720)	(3,110)
Recoverable taxes	(2,230)	(2,327)	(13,709)
Other assets	(1,048)	(19,425)	(23,902)
Trade payables	9,975	14,479	4,475
Taxes payables	(3,915)	(14,902)	(552)
Advances from customers	8,387	36,009	(1,951)
Labor and social obligations	21,247	23,449	11,125
Other liabilities	(12,811)	(2,693)	22,771
Total	876,988	666,550	390,881
Income taxes paid	(33,089)	(35,683)	(19,374)
Net cash flows from operating activities	843,899	630,867	371,507
Investing activities
Acquisition of property and equipment	(168,132)	(125,869)	(89,832)
Acquisition of intangibles assets	(128,892)	(150,931)	(47,753)
Dividends received	6,754	11,770
Acquisition of subsidiaries, net of cash acquired	(301,199)	(1,017,125)	(919,965)
Restricted cash		8,103	14,788
Net cash flows used in investing activities	(591,469)	(1,274,052)	(1,042,762)
Financing activities
Payments of loans and financing	(118,378)	(158,076)	(155,090)
Issuance of loans and financing	496,885	809,539	605,041
Payments of lease liabilities	(113,512)	(87,751)	(55,455)
Treasury shares	(152,317)	(213,722)
Capital increase			5,444
Proceeds from shares public offering			389,170
Share issuance costs			(19,704)
Proceeds from exercise of stock options		33,336
Dividends paid to non-controlling interests	(19,736)	(18,648)	(12,984)
Net cash flows from (used in) financing activities	92,942	364,678	756,422
Net foreign exchange differences	(852)	(17,973)	16,666
Net increase in cash and cash equivalents	344,520	(296,480)	101,833
Cash and cash equivalents at the beginning of the period	748,562	1,045,042	943,209
Cash and cash equivalents at the end of the period	R$ 1093082	R$ 748562	R$ 1045042

Corporate information

Corporate information	12 Months Ended
	Dec. 31, 2022
Corporate Information
Corporate information	1 Corporate information Afya Limited (“Afya”), collectively with its subsidiaries referred to as the “Company”, is a holding company incorporated under the laws of the Cayman Islands on March 22, 2019. Afya Limited became the holding company of Afya Participações S.A. (hereafter referred to as “Afya Brazil”), formerly denominated NRE Participações S.A., through the completion of the corporate reorganization in July 2019. Up to that date, Afya Limited did not have commenced operations and had only nominal assets and liabilities and no material contingent liabilities or commitments. Accordingly, Afya Limited’s consolidated financial information substantially reflects the operations of Afya Brazil after the corporate reorganization. The Company completed its initial public offering (IPO) on July 19, 2019, and its shares are listed on the Nasdaq under the symbol “AFYA.” The Company is formed by a network of higher education and post-graduate institutions focused on medicine located in 18 Brazilian states forming the largest educational group by the number of medical seats in the country. In non-regulated education, Afya provides services that comprise the development and sale of electronically distributed educational courses on medicine science, related printed and soft skills educational content. The Company also offers solutions to empower the physicians in their daily routine including supporting clinic decisions through mobile app subscription, delivering practice management tools through a SaaS (“Software as a Service”) model and supporting the patient-physician relationship. On February 23, 2022, Afya announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education (“MEC”) authorized the operations of the medical schools in Abaetetuba, in the State of Pará, and Itacoatiara, in the State of Amazonas, both under Mais Médicos II program. With the authorizations, Afya reaches its third and fourth authorized schools to start operating under the Mais Medicos II program. Each medical school will contribute with 50 seats. On March 16, 2022, MEC authorized the operations of the medical schools in Bragança, in the State of Pará, and Manacapuru, in the State of Amazonas, both under Mais Médicos II program. With the authorizations, Afya reaches its fifth and sixth authorized schools to start operating under the Mais Medicos II program. Each medical school will contribute with 50 seats. On March 18, 2022, Afya announced that MEC authorized the increase of 28 seats of Centro Universitário São Lucas, in Ji-Parana located in the state of Rondônia. The earn-out related to the seats approval is R$ 800 On December 29, 2022, Afya announced that MEC authorized the increase of 64 medical seats of Faculdade Santo Agostinho, in the city of Itabuna, located in the state of Bahia. No additional commitment is required regarding this authorization. Issuance of additional common shares On February 6, 2020, Afya completed its follow-on public offering of 3,019,928 9,406,812 The offering price was US$ 27.50 83,048 358,286 78,846 339,648 4,202 18,638 On March 10, 2020, the underwriters exercised their option to acquire additional 240,552 6,615 30,884 6,387 29,819 228 1,066 Afya transferred US$ 68,060 294,312 Bertelsmann Increases Stake in Afya On May 5, 2022, Afya was notified of the closing of the transaction where Bertelsmann SE& Co. KGaA, or “Bertelsmann” acquired 6,000,000 26.90 57.5 33.0 31.0 18.0 Acquisitions in 2022 ( i) On March 4, 2022, Afya Brazil acquired BMV Atividades Médicas Ltda. (“Além da Medicina”). A See Note 5. (ii) On April 5, 2022, Afya Brazil acquired Cardiopapers Soluções Digitais Ltda. (“CardioPapers”). See Note 5. (iii) On May 23, 2022, Afya Brazil acquired . See Note 5. COVID-19 In December 2019, a novel strain of coronavirus (COVID-19) was reported to have emerged in Wuhan, China. COVID-19 has since spread to most of the countries around the globe, including every state in Brazil. On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and on March 20, 2020 the Brazilian federal government declared a national emergency with respect to COVID-19. Since March 17, 2020, there has been some interruption of our on-campus activities due to Brazilian government authorities’ mandatory lockdowns. We managed to rapidly adapt our business to these unusual times, and although there has been an interruption of our on-campus activities, we are offering our non-practical educational activities to our students through our online platform (rather than on-site). Regarding the offering of practical classes, we quickly resumed our in-hospital and health care residency programs for fifth and sixth-year students, which represents the largest portion of our practical curriculum. By the date of issuance of these financial statements all of the lockdown restrictions have been revoked by Brazilian authorities in our campus locations and the Company has also successfully retaken all of its face to face operations. During 2020, some of the Brazilian states issued decrees granting discounts to our students because of COVID-19. These mandatory discounts have been suspended as their constitutionality has been challenged in the superior courts. On November 18, 2021, the Brazilian Federal Court of Justice (STF) decided, by a majority of votes, that any lawsuit with decisions to apply linear discounts in monthly tuition fees for private universities with respect to the COVID-19 pandemic are unconstitutional. Therefore, the Company shall not apply linear discounts on any active monthly tuition fees that are related to the effects of the Covid-19 pandemic. Regarding the discounts granted by the date of issuance of these financial statements, the Company is charging back the students as final legal decisions were given by the Brazilian Federal Court of Justice. For the year ended December 31, 2022, the Company has invoiced R$ 9,926 33,081 Conflict between Russia and Ukraine. As a result of the current geopolitical tensions and conflict between Russia and Ukraine, and the recent recognition by Russia of the independence of the self-proclaimed republics of Donetsk and Luhansk in the Donbas region of Ukraine, the governments of the United States, the European Union, Japan and other jurisdictions have recently announced the imposition of sanctions on certain industry sectors and parties in Russia, Belarus and the regions of Donetsk and Luhansk, as well as enhanced export controls on certain products and industries. These and any additional sanctions and export controls, as well as any counter responses by the governments of Russia or other jurisdictions, could adversely affect, directly or indirectly, the global supply chain, with negative implications on the availability of raw materials, energy prices, and our customers, as well as the local and global financial markets and financial services industry and the global economy in general. As of the date of these financial statements, the conflict between Russia and Ukraine has not brought significant impact over Afya’s operations and results.

Significant accounting policies

Significant accounting policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Significant accounting policies	2 Significant accounting policies 2.1 Basis for preparation of the consolidated financial statements The Company’s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments and contingent consideration (earn-outs) that have been measured at fair value. Afya Limited is a holding company, as such the primary source of revenue derives from its interest on the operational companies in Brazil. As result, the Brazilian Real has been assessed as the Company`s functional currency. The consolidated financial statements are presented in Brazilian reais (“BRL” or “R$”), which is the Company’s functional and presentation currency. All amounts are rounded to the nearest thousand. These consolidated financial statements as of and for the year ended December 31, 2022 were authorized for issue by the Board of Directors on March 20, 2023. 2.2 Basis consolidation The table below is a list of the Company’s subsidiaries and associate: Schedule of Company’s subsidiaries and associate Direct and indirect interest Name Principal activities Location Investment type December 31, 2022 December 31, 2021 Afya Participações S.A. (“Afya Brazil”) Holding Nova Lima - MG Subsidiary 100 100 Instituto Tocantinense Presidente Antônio Carlos Porto S.A. – (“ITPAC Porto”) Undergraduate degree programs Porto Nacional - TO Subsidiary 100 100 Instituto Tocantinense Presidente Antônio Carlos S.A. – (“ITPAC Araguaina”) Undergraduate degree programs Araguaína - TO Subsidiary 100 100 União Educacional do Vale do Aço S.A. – (“UNIVAÇO”) Medicine undergraduate degree program Ipatinga - MG Subsidiary 100 100 IPTAN - Instituto de Ensino Superior Presidente Tancredo de Almeida Neves S.A. (“IPTAN”) Undergraduate degree programs São João Del Rei - MG Subsidiary 100 100 Instituto de Educação Superior do Vale do Parnaíba S.A. (“IESVAP”) Undergraduate degree programs Parnaíba - PI Subsidiary 80 80 Centro de Ciências em Saúde de Itajubá S.A. (“CCSI”) Medicine undergraduate degree program Itajubá - MG Subsidiary 60 60 Instituto de Ensino Superior do Piauí S.A. (”IESP”) Undergraduate and graduate degree programs Teresina - PI Subsidiary 100 100 Centro Integrado de Saúde de Teresina (“CIS”) Outpatient care Teresina - PI Subsidiary 100 100 FADEP - Faculdade Educacional de Pato Branco Ltda. (“FADEP”) Undergraduate degree programs Pato Branco - PR Subsidiary 100 100 Medcel Editora e Eventos S.A. (“Medcel”) Medical education content São Paulo - SP Subsidiary 100 100 Instituto Educacional Santo Agostinho S.A. (“FASA”) Undergraduate degree programs Montes Claros - MG Subsidiary 100 100 ESMC Educação Superior Ltda. (“ESMC”) Undergraduate degree programs Montes Claros - MG Subsidiary 100 100 Instituto de Pesquisa e Ensino Médico do Estado de Minas Gerais Ltda. (“IPEMED”) Graduate Belo Horizonte - MG Subsidiary 100 100 Instituto Paraense de Educação e Cultura Ltda (“IPEC”) Medicine degree programs Marabá - PA Subsidiary 100 100 Sociedade Universitária Redentor S.A. (“UniRedentor”) Undergraduate and graduate degree programs Itaperuna - RJ Subsidiary 100 100 Centro Universitário São Lucas Ltda. (“UniSL”) Undergraduate degree programs Porto Velho - RO Subsidiary 100 100 Peb Med Instituição de Pesquisa Médica e Serviços Ltda (“PebMed”) Content and clinical tools and online platform Rio de Janeiro - RJ Subsidiary 100 100 Faculdade de Ensino Superior da Amazônia Reunida – (“FESAR”) Undergraduate degree programs Redenção – PA Subsidiary 100 100 Centro Superior de Ciências da Saúde S/S Ltda. (“FCMPB”) Medicine degree programs João Pessoa – PB Subsidiary 100 100 MedPhone Tecnologia em Saúde Ltda. (“MedPhone”) Content and clinical tools and online platform Recife – PE Subsidiary - 100 iClinic Desenvolvimento de Software Ltda (“iClinic”) Electronic Medical Record, Clinical Management System Ribeirão Preto - SP Subsidiary 100 100 Medicinae Solutions S.A. (“Medicinae”) Healthcare payments and financial services Rio de Janeiro – RJ Subsidiary 100 100 Medical Harbour Aparelhos Médico Hospitalares e Serviços em Tecnologia Ltda. (“Medical Harbour”) Educational health and medical imaging Florianópolis – SC Subsidiary 100 100 Cliquefarma Drogarias Online Ltda.(“Cliquefarma”) Online platform São Paulo – SP Subsidiary 100 100 Shosp Tecnologia da Informação Ltda. (“Shosp”) Electronic Medical Record, Clinical Management System Rio de Janeiro – RJ Subsidiary 100 100 Sociedade Padrão de Educação Superior Ltda. (“UnifipMoc”) Undergraduate degree programs Montes Claros - MG Subsidiary 100 100 Nucleo de Atenção à Saúde e de Práticas Profissionalizantes (“NASPP) Outpatient care Montes Claros - MG Subsidiary 100 100 Companhia Nilza Cordeiro Herdy de Educação e Cultura. (“Unigranrio”) Undergraduate and graduate degree programs Duque de Caxias - RJ Subsidiary 100 100 Policlínica e Centro de Estética Duque de Caxias Ltda. (“Policlínica”) Outpatient care Duque de Caxias - RJ Subsidiary 100 100 Sociedade Educacional de Palhoça S/A Ltda. (“SOCIESP”) Basic Education Palhoça - SC Subsidiary 100 100 Instituto de Ensino Superior de Palhoça S/S Ltda. (“IESP PALHOÇA”) Undergraduate degree programs Palhoça - SC Subsidiary 100 100 RX PRO Soluções de Tecnologia Ltda. (“RX PRO”) Marketing for pharmaceutical industry São Paulo – SP Subsidiary 100 100 RX PRO LOG Transporte e Logística Ltda. (“RX PRO LOG”) Marketing for pharmaceutical industry São Paulo – SP Subsidiary 100 100 BMV Atividades Médicas Ltda. (“Além da Medicina”) Medical education content São Paulo – SP Subsidiary 100 - Cardiopapers Soluções Digitais Ltda (“CardioPapers”) Medical education content Recife – PE Subsidiary 100 - Quasar Telemedicina Desenvolvimento de Sistemas Computacionais Ltda. (“Glic”) Patient physician relationship Barueri – SP Subsidiary 100 - União Educacional do Planalto Central S.A. (“UEPC”) Undergraduate degree programs Brasília - DF Associate 30 30 * See Note 5 for further details of the business combinations during 2022. ** Medphone was merged by Afya Participações in October 2022. The financial information of the acquired subsidiaries is included in the Company’s consolidated financial statements beginning on the respective acquisition dates. The Company consolidates the financial information for all entities it controls. Control is achieved when the Company is exposed to, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and it ceases when the Company loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Company gains control until the date the Company ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries in order to bring their accounting policies in line with the Company’s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions are eliminated in full on consolidation. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Company loses control over a subsidiary, it derecognizes the related assets (including goodwill), liabilities, non-controlling interest and other components of equity, while any resulting gain or loss is recognized in the statement of income. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statements of financial position, consolidated statements of income and comprehensive income and consolidated statements of changes in equity. 2.3 Summary of significant accounting policies This note provides a description of the significant accounting policies adopted in the preparation of these consolidated financial statements in addition to other policies that have been disclosed in other notes to these consolidated financial statements. These policies have been consistently applied to all periods presented. The accounting policies have been consistently applied to all consolidated companies. a) Business combinations and goodwill Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree. For each business combination, the Company elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets. Acquisition-related costs are expensed as incurred and included in general and administrative expenses. When the Company acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as of the acquisition date. Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed). If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, the Company re-assesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognized at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then the gain is recognized in the consolidated statement of income. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company’s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquire are assigned to those units. Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained. b) Current versus non-current classification The Company presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is: · Expected to be realized or intended to be sold or consumed in the normal operating cycle; · Held primarily for the purpose of trading; · Expected to be realized within twelve months after the reporting period; or · Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current. A liability is current when: · It is expected to be settled in the normal operating cycle; · It is held primarily for the purpose of trading; · It is due to be settled within twelve months after the reporting period; or · There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The Company classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities. c) Fair value measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: (i) in the principal market for the asset or liability; or (ii) in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: · Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities. · Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. · Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable. For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. At each reporting date, the Company analyzes the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Company’s accounting policies. For this analysis, the Company verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents. The Company also compares the change in the fair value of each asset and liability with relevant external sources to determine whether the change is reasonable. For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above. d) Financial instruments – initial recognition and measurement A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. i) Financial assets Initial recognition and measurement The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Company’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, are measured at the transaction price determined under IFRS 15. In order for a financial asset to be classified and measured at amortized cost or fair value through OCI (Other Comprehensive Income), it needs to give rise to cash flows that are “solely payments of principal and interest (SPPI)” on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. The Company’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset. Subsequent measurement For purposes of subsequent measurement, financial assets are classified as: financial assets at amortized cost or financial assets at fair value through profit or loss. There are no financial assets designated as fair value through OCI. Financial assets at amortized cost The Company measures financial assets at amortized cost if both of the following conditions are met: • The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of income when the asset is derecognized, modified or impaired. Financial assets at fair value through profit or loss Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified and measured at fair value through profit or loss, irrespective of the business model. Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of income. This category includes derivative instruments. Derecognition A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company’s statement of financial position) when: • The rights to receive cash flows from the asset have expired; or • The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ‘pass-through’ arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay. Impairment of financial assets Further disclosures relating to impairment of financial assets are also provided in the following notes: • Significant accounting estimates and assumptions – Note 3 • Trade receivables – Note 7 The Company recognizes an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms. For trade receivables, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognizes an allowance for credit losses based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. The Company considers a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before considering any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows. ii) Financial liabilities Initial recognition and measurement Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company’s financial liabilities include trade payables, loans and financing, notes payable, lease liabilities, advances from costumers and accounts payable to selling shareholders. Subsequent measurement The measurement of financial liabilities depends on their classification, as described below: Financial liabilities at fair value through profit or loss Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes, when applicable, derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Gains or losses on liabilities held for trading are recognized in the statement of income. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. Loans and borrowings After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the statement of income when the liabilities are derecognized as well as through the EIR amortization process. Amortized cost is calculated by considering any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance expenses in the statement of income. Derecognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of income. Offsetting of financial instruments Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously. e) Cash and cash equivalents Cash and cash equivalents in the statement of financial position comprise cash at banks and on hand, and short-term financial investments with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term financial investments, as they are considered an integral part of the Company’s cash management. f) Restricted cash Restricted cash in the statement of financial position comprise of financial investments in investment funds that serve as collateral for loan agreements and other commitments. g) Inventories Inventories are valued at the lower of cost and net realizable value. The costs of inventories are based on the average cost method and include costs incurred in the purchase of inventories and other costs incurred in bringing them to their current location and condition. Costs of purchased inventory are determined after deducting any discounts and recoverable taxes. h) Property and equipment Property and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Subsequent expenditures are capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows: Schedule of estimated useful lives of the assets Building 25 Machinery and equipment 10 Vehicles 4 Furniture and fixtures 10 IT equipment 5 Library books 10 Laboratories and clinics 10 Leasehold improvements 5 20 An item of property and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefit is expected from its use or disposal. Any gain or loss arising on the derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of income when the asset is derecognized. The residual values, useful lives and methods of depreciation of property and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate. i) Leases As from January 1, 2019, the determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the contract. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset (or assets) and the arrangement conveys a right to use the asset (or assets), even if that asset is (or those assets are) not explicitly specified in an arrangement. Company as a lessee The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of use assets are subject to impairment. Lease liabilities At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets The Company applies the short-term lease recognition exemption to its short-term leases of properties (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered of low value. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term. j) Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles are not capitalized and the related expenditure is reflected in the statement of income in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in the statement of income in the expense category that is consistent with the function of the intangible assets. Intangible assets with indefinite useful lives are not amortized, but are tes

Significant accounting estimate

Significant accounting estimates and assumptions	12 Months Ended
	Dec. 31, 2022
Significant Accounting Estimates And Assumptions
Significant accounting estimates and assumptions	3 Significant accounting estimates and assumptions The preparation of the Company’s consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Accounting estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are recognized prospectively. Other disclosures relating to the Company’s exposure to risks and uncertainties includes: · Financial instruments risk management objectives and policies – Note 13.4 · Sensitivity analyses disclosures – Note 13.4.1 Estimates and assumptions The key assumptions about the future and other key sources of estimated uncertainty as of the reporting date that include a significant risk of a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances that arise and that are beyond the Company’s control. Such changes are reflected in the assumptions when they occur. Identification and fair-value measurement of assets and liabilities acquired in a business combination Business combinations are accounted for using the acquisition method. Such method requires recognizing and measuring the identifiable assets acquired, the liabilities assumed and any non-controlling interest in the acquiree. The Company, as the acquirer, must classify or designate the identifiable assets and liabilities assumed on the basis of its own contractual terms, economic conditions, operating and accounting policies and other relevant conditions as at the acquisition date. Such assessment requires judgments from the Company on the methods used to determine the fair value of the assets acquired and liabilities assumed, including valuation techniques that may require prospective financial information inputs. Impairment of non-financial assets Impairment exists when the carrying value of an asset or cash generating unit (“CGU”) or group of CGUs exceeds its recoverable amount, defined as the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on data available from binding sales transactions, conducted at arm’s length, for similar assets or observable market prices less incremental costs of disposing of the asset. The value in use calculation is based on a discounted cash flow model (“DCF” model). The cash flows are derived from the budget for the next five years and do not include restructuring activities to which the Company has not yet committed or significant future investments that will enhance the performance of the assets of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as to expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and indefinite lived intangible assets recognized by the Company. The key assumptions used to determine the recoverable amount for each CGU, including a sensitivity analysis, are disclosed and further explained in Note 12. Share-based compensation Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the share option or appreciation right, volatility and dividend yield and making assumptions about them. For the measurement of the fair value of equity-settled transactions, the Company uses the Binomial model. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 16 (b). Leases - Estimating the incremental borrowing rate The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate (IBR) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Company ‘would have to pay’, which requires estimation when no observable rates are available (such as for subsidiaries that do not enter into financing transactions) or when they need to be adjusted to reflect the terms and conditions of the lease (for example, when leases are not in the subsidiary’s functional currency). The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.

Segment information

Segment information	12 Months Ended
	Dec. 31, 2022
Segment Information
Segment information	4 Segment information The Company has three reportable segments as follows: • Undergrad, which provides educational services through undergraduate courses related to medicine, other health sciences and other undergraduate programs; • Continuing Education, which provides specialization programs and graduate courses in medicine; and • Digital Services, which provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine and digital prescription for physicians), doctor-patient relationship and provides access, demand and efficiency for the healthcare players. Segment information is presented consistently with the internal reports provided to the Company's Chief Executive Officer (CEO), which is the Chief Operating Decision Maker (CODM) and is responsible for allocating resources, assessing the performance of the Company's operating segments, and making the Company's strategic decisions. No operating segments have been aggregated to form the above reportable operating segments. There is only one geographic region, and the results are monitored and evaluated as a single business. The following tables presents assets and liabilities information for the Company’s operating segments as of December 31, 2022 and December 31, 2021, respectively: Schedule of assets and liabilities information for the company's operating segments Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2022 Total assets 6,775,829 149,254 275,564 7,200,647 (1,108) 7,199,539 Current assets 1,461,802 61,673 115,290 1,638,765 (1,108) 1,637,657 Non-current assets 5,314,027 87,581 160,274 5,561,882 - 5,561,882 Total liabilities and equity 6,775,829 149,254 275,564 7,200,647 (1,108) 7,199,539 Current liabilities 711,896 57,605 137,296 906,797 (1,108) 905,689 Non-current liabilities 2,938,960 63,990 40,742 3,043,692 - 3,043,692 Equity 3,124,973 27,659 97,526 3,250,158 - 3,250,158 Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2022 Other disclosures Investments in associate 53,907 - - 53,907 - 53,907 Capital expenditures (*) 247,634 8,827 61,694 318,155 - 318,155 (*) Some of the capital expenditures are considered non-cash transactions (refer to note 24). Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2021 Total assets 6,072,135 105,629 272,122 6,449,886 (2,480) 6,447,406 Current assets 1,048,869 42,737 117,726 1,209,332 (2,480) 1,206,852 Non-current assets 5,023,266 62,892 154,396 5,240,554 - 5,240,554 Total liabilities and equity 6,072,135 105,629 272,122 6,449,886 (2,480) 6,447,406 Current liabilities 645,657 32,300 91,029 768,986 (2,480) 766,506 Non-current liabilities 2,551,175 47,705 82,002 2,680,882 - 2,680,882 Equity 2,875,303 25,624 99,091 3,000,018 - 3,000,018 Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2021 Other disclosures Investments in associate 48,477 - - 48,477 - 48,477 As of December 31, 2021 Capital expenditures (*) 220,202 25,682 56,095 301,979 - 301,979 (*) Some of the capital expenditures are considered non-cash transactions (refer to note 24). The following tables present the statements of income for the Company’s operating segments for the years ended December 31, 2022, 2021 and 2020: Schedule of operating income for each operating segment December 31, 2022 Undergrad Continuing Education Digital Services Total reportable segments Elimination (inter-segment transactions) Total External customer 2,037,889 108,806 182,362 2,329,057 - 2,329,057 Inter-segment - - 7,622 7,622 (7,622) - Revenue 2,037,889 108,806 189,984 2,336,679 (7,622) 2,329,057 Cost of services (763,185) (56,554) (47,435) (867,174) 7,622 (859,552) Gross profit 1,274,704 52,252 142,549 1,469,505 - 1,469,505 General and administrative expenses (798,153) Other expenses, net (7,252) Operating income 664,100 Finance income 102,042 Finance expenses (349,893) Share of income of associate 12,184 Income before income taxes 428,433 Income taxes expenses (35,677) Net income 392,756 December 31, 2021 Undergrad Continuing Education Digital Services Total reportable segments Elimination (inter-segment transactions) Total External customer 1,498,408 72,983 147,980 1,719,371 - 1,719,371 Inter-segment - - 3,978 3,978 (3,978) - Revenue 1,498,408 72,983 151,958 1,723,349 (3,978) 1,719,371 Cost of services (554,995) (50,773) (50,510) (656,278) 3,978 (652,300) Gross profit 943,413 22,210 101,448 1,067,071 - 1,067,071 General and administrative expenses - - - - - (622,615) Other expenses, net - - - - - (3,561) Operating income - - - - - 440,895 Finance income - - - - - 64,566 Finance expenses - - - - - (243,796) Share of income of associate - - - - - 11,797 Income before income taxes - - - - - 273,462 Income taxes expenses - - - - - (31,179) Net income - - - - - 242,283 December 31, 2020 Undergrad Continuing Education Digital Services Total reportable segments Elimination (inter-segment transactions) Total External customer 1,002,461 107,197 91,533 1,201,191 - 1,201,191 Inter-segment - - 1,619 1,619 (1,619) - Revenue 1,002,461 107,197 93,152 1,202,810 (1,619) 1,201,191 Cost of services (381,964) (40,000) (14,309) (436,273) 1,619 (434,654) Gross profit 620,497 67,197 78,843 766,537 - 766,537 General and administrative expenses - - - - - (402,855) Other expenses, net - - - - - (347) Operating income - - - - - 363,335 Finance income - - - - - 62,290 Finance expenses - - - - - (98,269) Share of income of associate - - - - - 7,698 Income before income taxes - - - - - 335,054 Income taxes expenses - - - - - (27,067) Net income - - - - - 307,987 Seasonality of operations Undergrad’s tuition revenues are related to the enrollment process and monthly tuition fees charged to students over the period; thus, does not have significant fluctuations during the semester. Continuing Education revenues are related to monthly intake and tuition fees and do not have a considerable concentration in any period. Digital Services is comprised mainly of Medcel, Pebmed, and iClinic revenues. While Pebmed and iClinic do not have significant fluctuation regarding seasonality, Medcel’s revenue is concentrated in the first and last quarter of the year due to the enrollments of Medcel’s clients’ period. In addition, the majority of Medcel’s revenues are derived from printed books and e-books, which are recognized at the point in time when control is transferred to the customer. Consequently, the Digital Services segment generally has higher revenues and results of operations in the first and last quarters of the year than in the second and third quarters.

Business combinations

Business combinations	12 Months Ended
	Dec. 31, 2022
Business Combinations
Business combinations	5 Business combinations 5.1 Acquisitions in 2022 The fair values of the identifiable assets acquired and liabilities assumed as of acquisition date were: Schedule of fair values of the identifiable assets acquired and liabilities assumed Assets Além da Medicina CardioPapers Glic Cash and cash and equivalents 298 3,648 151 Trade receivables 1,705 1,350 94 Other assets 266 1 36 Property and equipment 37 43 - Intangible assets 20,299 28,655 15,395 22,605 33,697 15,676 Liabilities Trade payables 705 1,703 1 Labor and social obligations 79 60 - Taxes and contributions payable 1,182 352 91 Advances from customers 6,185 3,893 - Other liabilities - - 574 8,151 6,008 666 Total identifiable net assets at fair value 14,454 27,689 15,010 Goodwill arising on acquisition 12,335 14,324 15,587 Purchase consideration transferred 26,789 42,013 30,597 Cash paid 14,952 34,924 21,602 Contingent consideration 11,074 7,422 8,995 Consideration to be transferred (Price adjustment) 763 (333) - Analysis of cash flows on acquisition: Transaction costs of the acquisition (included in cash flows from operating activities) 227 274 222 Cash paid net of cash acquired with the subsidiary (included in cash flows from investing activities) 14,654 31,276 21,451 Net of cash flow on acquisition 14,881 31,550 21,673 (a) Acquisition of Além da Medicina On March 4, 2022, Afya Brazil acquired 100 The aggregate purchase price of R$26,789 is comprised by: i) R$14,952 paid in cash on the transaction closing date; ii) an earn-out (“contingent consideration”) of up of R$ 19,200 is payable in connection with revenue target achievements for 2023 and 2024; and iii) price adjustment related to net debt of R$763 in favor of selling shareholders. The contingent consideration of R$11,074 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. A The acquisition of A Transaction costs to date amount to R$ 227 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The Company did not recognize deferred taxes related to the business combination because the tax basis and the accounting basis, including fair value adjustments, were the same at the date of the business combination. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule Of Acquisition Of AlemDa Medicina Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Educational content Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. From the date of acquisition, A 12,859 1,448 2,529 867 (b) Acquisition of CardioPapers On April 5, 2022, Afya Brazil acquired 100 The aggregate purchase price of R$42,013 is comprised by: i) R$34,924 paid in cash on the transaction closing date; ii) an earn-out (“contingent consideration”) of up of R$15,000 is payable in connection with revenue target achievements for 2023 and 2024 and other goals; and iii) price adjustment related to net debt of R$333 in favor of Afya Brazil. The contingent consideration of R$7,422 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. CardioPapers is the main medical content and education platform in the Cardiology field, offering courses and books developed by physicians and for physicians, covering all phases of the medical career, aligned with Afya's overall business strategy. The acquisition of CardioPapers Transaction costs to date amount to R$ 274 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The Company did not recognize deferred taxes related to the business combination because the tax basis and the accounting basis, including fair value adjustments, were the same at the date of the business combination. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition cardiopapers Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Educational content Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Copyrights Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. From the date of acquisition, CardioPapers 9,934 2,352 2,117 2,041 (c) Acquisition of Glic On May 23, 2022, Afya Brazil acquired 100 The aggregate purchase price of R$30,597 is comprised by: i) R$21,602 paid in cash on the transaction closing date and ii) an earn-out (“contingent consideration”) of up of R$12,000 is payable in connection with revenue target achievements for 2023 and 2024 and product development goals. The contingent consideration of R$8,995 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. Glic is a free diabetes care and management app solution for physicians and patients that uses technology to improve diabetes education and daily routine practices, connecting users, devices and healthcare providers. The acquisition of Glic Transaction costs to date amount to R$ 222 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The Company did not recognize deferred taxes related to the business combination because the tax basis and the accounting basis, including fair value adjustments, were the same at the date of the business combination. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of glic Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. From the date of acquisition, Glic 389 1,539 173 700 5.2 Acquisitions in 2021 The fair values of the identifiable assets acquired and liabilities assumed as of each acquisition date were: Schedule of preliminary fair values of the identifiable assets acquired and liabilities acquired Assets iClinic Medicinae Medical Harbour Cliquefarma Shosp Unifipmoc Unigranrio (i) RXPRO (ii) Cash and cash and equivalents 1,659 201 47 1,009 397 6,140 34,755 91 Restrict cash 6,050 - - - - - - - Trade receivables 1,201 - 159 501 - 34,309 26,622 1,211 Inventories - - - - - - 352 246 Recoverable taxes 72 15 - - 1 1,295 738 112 Other assets 20 - 2 - - 702 12,159 366 Right-of-use assets 88 - - - - 52,079 87,265 82 Property and equipment 473 17 34 - 5 24,277 40,775 42 Indemnification assets 1,252 - - - - 7,331 71,669 - Intangible assets 84,987 4,518 7,359 14,991 4,856 227,534 510,356 6,330 95,802 4,751 7,601 16,501 5,259 353,667 784,691 8,480 Liabilities Trade payables 619 - 6 8 1 985 6,197 1,060 Loans and financing - - 299 580 - 30,179 5,533 - Labor and social obligations 1,414 159 4 102 89 5,306 22,854 62 Taxes and contributions payable 77 4 1 307 123 758 94,025 100 Provision for legal proceedings 1,252 - - - - 7,331 71,669 - Leases liabilities 88 - - - - 52,079 87,265 82 Advances from customers 400 - 35 3 167 10,745 3,387 - Other liabilities - - - - - 5,739 4,878 - 3,850 163 345 1,000 380 113,122 295,808 1,304 Total identifiable net assets at fair value 91,952 4,588 7,256 15,501 4,879 240,545 488,883 7,176 Goodwill arising on acquisition 99,168 4,584 4,022 6,588 3,022 87,777 130,073 38,446 Purchase consideration transferred 191,120 9,172 11,278 22,089 7,901 328,322 618,956 45,622 Cash paid 119,620 5,600 5,000 16,166 5,855 328,322 375,670 30,263 Contingent consideration - 3,572 6,278 2,923 1,592 - - 10,171 Consideration to be transferred - - - - 454 - 243,286 76 Paid in shares 71,500 - - 3,000 - - - 5,112 Analysis of cash flows on acquisition: Transaction costs of the acquisition (included in cash flows from operating activities) 856 117 144 336 188 177 10,990 264 Cash paid net of cash acquired with the subsidiary (included in cash flows from investing activities) 117,961 5,399 4,953 15,157 5,458 322,182 340,915 30,172 Net of cash flow on acquisition 118,817 5,516 5,097 15,493 5,646 322,359 351,905 30,436 (*) There are 40 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$50,000. (**) There are 82 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$90,200. (i) During the measurement period, the goodwill for the acquisition of Unigranrio was adjusted by R$39,100 (R$130,073 initial goodwill) as a result of an increase of liabilities regarding tax contingencies. (ii) During the measurement period, R$8,637 of goodwill (R$38,446 initial goodwill) arising from the acquisition of RXPRO was reduced, in connection with management’s view of remote likelihood of RXPRO achieving the revenue goals stablished at the terms of the earn-out. (a) Acquisition of iClinic On January 21, 2021, Afya Brazil acquired 100 The aggregate purchase price of R$191,120 is comprised of: (i) 62.6% was paid in cash, and (ii) 37.4% was settled with Afya's shares on the transaction closing date. iClinic is a SaaS model physician focused technology company and the leading medical practice management software in Brazil. iClinic empower doctors to be more independent and have more control over their careers by digitalizing their daily routine, so they can increase their productivity and deliver better healthcare services. With the acquisition of iClinic to our platform, Afya will make another step to become the one stop shop for physicians in Brazil. The acquisition of iClinic was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 856 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. Afya Brazil measured the acquired lease liabilities using the present value of the remaining lease payments at the date of acquisition. The right-of-use assets were measured at an amount equal to the lease liabilities and adjusted to reflect the unfavorable terms of the lease relative to market terms. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of Uniredentor Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. iClinic has contributed R$ 16,456 8,250 1,158 1,320 (b) Acquisition of Medicinae On March 25, 2021, Afya Brazil acquired 100 The aggregate purchase price of R$9,172 is comprised by: i) R$ 5,600 of which 100% was paid in cash on the transaction closing date; and ii) an earn-out (“contingent consideration”) of up of R$ 4,400 is payable in connection with product development goals for 2021 and revenue achievements for 2022. The contingent consideration of R$3,572 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. The acquisition will expand Afya’s digital health services, as it offers a unique financial platform that allows healthcare professionals all over Brazil to manage receivables in an efficient and scalable way using FIDC (Receivables Investment Fund). Medicinae relieves a number of challenges in the healthcare payments industry, as reduces long payment cycles for professionals and consolidates financial information, improving the consumer financial experience. Afya’s intention is to grow the Digital Services segment. The acquisition of Medicinae was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 117 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of UniSL Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Medicinae has contributed R$ 359 1,518 105 113 (c) Acquisition of Medical Harbour On April 8, 2021, Afya Brazil acquired 100 The aggregate purchase price of R$11,278 is comprised by: i) R$ 5,000 of which 100% was paid in cash on the transaction closing date; and ii) an earn-out (“contingent consideration”) of up to R$ 9,000 is payable in connection with product development goals for 2021 and 2022 and revenue achievements for 2023. The contingent consideration of R$6,278 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. This acquisition enables Afya to start providing a high quality solution to study the human body, allowing efficient classes and remote practical sessions with greater student acceptance and scalability. Additionally, Afya will be able to distribute Medical Harbour solutions to all of its ecosystem, creating B2C and B2B growth opportunities. The acquisition of Medical Harbour was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 144 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of PEBMED Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Medical Harbour has contributed R$ 484 1,945 would have been increased by R$ 268 127 (d) Acquisition of Cliquefarma On April 16, 2021, Afya Brazil acquired 100 The aggregate purchase price of R$ 22,089 is comprised by: (i) R$ 16,166 paid in cash; (ii) R$3,000 settled with Afya's shares on the transaction closing date; and (iii) an earn-out (“contingent consideration”) of R$ 3,000 is payable in relation to product development. The contingent consideration of R$2,923 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. Users of Cliquefarma can easily search for medications or healthcare products and compare prices from over 15,000 pharmacies in Brazil. The traffic generated is monetized through a cost-per-click model, where drugstores pay for each click on their advertisements, a cost-per-acquisition, where drugstores pay for each concluded sale. The acquisition of Cliquefarma will enhance the Digital Services segment, creating the opportunity to leverage traffic and GMV with prescriptions generated from Afya’s physician ecosystem. The acquisition of Cliquefarma was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 336 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of FESAR Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Cliquefarma has contributed R$ 3,268 1,752 1,435 926 (e) Acquisition of Shosp On May 13, 2021, Afya Brazil acquired 100 The aggregate purchase price of R$7,901 is comprised by: i) R$ 5,855 was paid in cash; ii) R$ 454 of consideration to be transferred; and iii) an earn-out (“contingent consideration”) of up to R$ 1,793 is payable in relation to product development. The contingent consideration of R$1,592 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. The acquisition of Shosp was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 188 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of Medphone Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Shosp has contributed R$ 1,376 448 306 82 (f) Acquisition of UNIFIPMoc On June 1, 2021, Afya Brazil acquired 100 The aggregate purchase price is R$ 328,322 and the total amount was paid in cash. There are 40 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$ 50,000. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and thus the contingent consideration was not measured at acquisition date. Should the additional seats be approved it will result in additional licenses, which will be measured accordingly if and when approved. UNIFIPMoc is a post-secondary education institution with government authorization to offer on-campus, undergraduate courses in medicine in the states of Minas Gerais and Bahia. The acquisition is in line with the Company’s strategy to focus on medical education, including medical school. The acquisition of UNIFIPMoc was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 177 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Undergrad segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of FCMPB Intangible assets acquired Valuation technique Licenses With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. The valuation technique for property and equipment consists of determining the fair value of an asset by using methodologies like replacement costs, market value, remaining useful life and physical depreciation. UNIFIPMoc has contributed R$ 69,887 19,458 46,150 12,847 (g) Acquisition of UNIGRANRIO On August 4, 2021, Afya Brazil acquired 100 The aggregate original purchase price of R$ 626,116 of which 60% was paid in cash on the transaction closing date, and 40% is payable in cash in four equal installments through 2022 to 2025, adjusted by the CDI rate, was adjusted by R$7,160, because of the actual net debt, to R$618,956. There are 82 additional seats still pending approval which, if approved by MEC, will result in a potential additional payment of up to R$90,200. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and thus the contingent consideration was not measured at acquisition date. Should the additional seats be approved it will result in additional licenses, which will be measured accordingly if and when approved. Unigranrio is a post-secondary education institution with governmental authorization to offer on-campus, undergraduate degrees and graduate programs in medicine and health, as well as other courses, in the State of Rio de Janeiro and Santa Catarina The acquisition of Unigranrio was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 10,990 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Undergrad segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of Unigranrio Intangible assets acquired Valuation technique Licenses With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. The valuation technique for property and equipment consists of determining the fair value of an asset by using methodologies like replacement costs, market value, remaining useful life and physical depreciation. Unigranrio has contributed R$ 123,369 33,450 150,456 22,191 (h) Acquisition of RXPRO On October 1, 2021, Afya Brazil acquired 100 The aggregate purchase price of R$45,622 is comprised by: i) R$ 30,263 was paid in cash; ii) R$ 76 to be paid as price adjustment, iii) R$5,112 settled with Afya's treasury shares on the transaction closing date; and (iv) an earn-out (“contingent consideration”) of R$ 21,000 is payable in relation to revenue achievements. The contingent consideration of R$10,171 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. The acquisition of RXPRO was accounted for under IFRS 3 – Business Combinations. Transaction costs to date amount to R$ 264 At the acquisition date, the fair value of the trade receivables acquired equals its carrying amount. The goodwill recognized includes the value of expected synergies arising from the acquisition, which is not separately recognized. Goodwill is allocated entirely to Digital Services segment. The goodwill recognized is not expected to be deductible for income taxes purposes. The valuation techniques used for measuring the fair value of separately identified intangible assets acquired were as follows: Schedule of acquisition of RXPRO Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterio

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2022
Cash and cash equivalents [abstract]
Cash and cash equivalents	6 Cash and cash equivalents Schedule of cash and cash equivalents 2022 2021 Cash and bank deposits 57,509 88,487 Cash equivalents 1,035,573 660,075 Cash and cash equivalents 1,093,082 748,562 Cash equivalents correspond mainly to financial investments in Bank Certificates of Deposit (“CDB”) with highly rated financial institutions and investments funds managed by highly rated financial institutions. As of December 31, 2022, the average interest rate on these investments is equivalent to 99.21 100.38 24,447 23,228

Trade receivables

Trade receivables	12 Months Ended
	Dec. 31, 2022
Trade Receivables
Trade receivables	7 Trade receivables Schedule of trade accounts receivable 2022 2021 Tuition fees 356,074 279,915 Educational content (a) 50,913 69,227 FIES 62,325 61,342 Educational credits (b) 27,535 5,375 Mobile app subscription (c) 27,675 20,946 Others 14,923 14,001 539,445 450,806 (-) Allowance for doubtful accounts (44,046) (45,013) 495,399 405,793 Current 452,831 378,351 Non-current 42,568 27,442 (a) Related to trade receivables from sales of printed books, e-books and medical courses through digital platform from Medcel, Além da Medicina and CardioPapers. (b) Related to trade receivables from special financing programs and balances outstanding from previous acquisitions. (c) Related to trade receivables from mobile applications subscriptions for digital medical content. As of December 31, 2022 and 2021, the aging of trade receivables was as follows: Schedule of aging of trade accounts receivable 2022 2021 Neither past due nor impaired 261,025 184,382 Past due 1 to 30 days 56,280 68,932 31 to 90 days 90,734 69,299 91 to 180 days 80,522 55,764 More than 180 days 50,884 72,429 539,445 450,806 The changes in the allowance for doubtful accounts for the years ended December 31, 2022, 2021 and 2020, was as follows: Schedule of allowance for doubtful accounts 2022 2021 2020 Balances at the beginning of the period (45,013) (32,980) (14,763) Additions (42,708) (47,819) (32,081) Write-offs 43,675 35,786 13,864 Balances at the end of the period (44,046) (45,013) (32,980)

Related parties

Related parties	12 Months Ended
	Dec. 31, 2022
Related Parties
Related parties	8 Related parties The table below summarizes the balances and transactions with related parties: Schedule of balances and transactions with related parties 2022 2021 Assets Trade receivables (a) 917 692 Other assets (b) 1,975 - Total 2,892 692 Current 2,892 692 Non-current - - Liabilities Accounts payable to selling shareholders (c) 30,653 54,556 Total 30,653 54,556 Current 30,653 27,278 Non-current - 27,278 2022 2021 2020 Other income UEPC (a) 477 752 104 477 752 104 Lease RVL Esteves Gestão Imobiliária S.A. 20,394 15,336 11,288 UNIVAÇO Patrimonial Ltda. 3,409 3,210 2,915 IESVAP Patrimonial Ltda. 4,920 4,560 3,470 28,723 23,106 17,673 (a) Refers to sales of educational content from Medcel to UEPC; (b) Refers to amounts to be reimbursed from Bertelsmann SE& Co. KGaA regarding the transaction on which the control of Afya was acquired; (c) Refers to amounts to be payable to our shareholder Nicolau Carvalho Esteves regarding the agreement to which Afya Brazil acquired the right to develop ITPAC Garanhuns medical school, a greenfield unit. The amount represents 50% of the transaction, due in two equal annual installments, adjusted by the CDI rate. Lease agreements with RVL Esteves Gestão Imobiliária S.A. Afya Brazil has entered into lease agreements with RVL Esteves Gestão Imobiliária S.A. (“RVL”), an entity controlled by the shareholder Nicolau Carvalho Esteves and of which Mr. Renato Esteves is an executive officer, as described below: On June 21, 2016, RVL entered into lease agreements (as amended on April 26, 2018) with ITPAC Araguaína and ITPAC Porto, pursuant to which RVL agreed to lease campuses to those entities in the cities of Araguaína and Porto Nacional, both located in the State of Tocantins. The lease agreements are adjustable in accordance with the provisions of each lease agreement. The lease agreements are for an initial term of 20 On November 1, 2016, RVL entered into a lease agreement with Afya Brazil, pursuant to which RVL agreed to lease to Afya Brazil certain offices located in the city of Nova Lima, State of Minas Gerais, where Afya Brazil’s principal executive offices are located. On February 9, 2019, the agreement was amended to extend lease terms and adjust the lease amounts, subject to certain discount conditions set forth in the lease agreement and adjustable in accordance with the provisions of the lease agreement. The lease agreement is for an initial term of five years, and may be renewable for an additional five years subject to the provisions of the lease agreement. On September 6, 2018, RVL entered into a lease agreement with ITPAC Araguaína, pursuant to which RVL agreed to lease to ITPAC the new ITPAC campus by RVL in the city of Palmas, State of Tocantins. The lease agreement is for an amount equal to 7.5 20 20 On October 30, 2019, RVL entered into a lease agreement with IPTAN, pursuant to which RVL agreed to lease to IPTAN the new IPTAN medical campus, currently under construction by RVL in the city of Santa Inês, State of Maranhão. The lease agreement is for a monthly amount equal to (i) up to June 2020, R$12 and (ii) from July 2020 until March 2024, 6.5% of the monthly revenue of IPTAN during the prior semester, adjusted in accordance with the provisions of the lease agreement. The lease agreement is for an initial term of 5 years starting when the campus becomes operational, and may be renewable for an additional 5 years subject to the provisions of the lease agreement. As of December 31, 2022, the campus is fully operational. On August 02, 2021, RVL entered into a lease agreement with ITPAC Araguaína, pursuant to which RVL agreed to lease to ITPAC the new ITPAC Garanhuns medical campus, in the city of Garanhuns, State of Pernambuco. The lease agreement is for a monthly amount equal to (i) up to June 2022, R$ 40 6.5 The lease payments in connection with the lease agreements with RVL totaled R$ 20,394 15,336 11,288 Lease agreement with UNIVAÇO Patrimonial Ltda. On July 14, 2016, UNIVAÇO Patrimonial Ltda., an entity controlled by the shareholder Nicolau Carvalho Esteves and of which Ms. Rosângela Esteves is the chief executive officer, entered into a lease agreement with UNIVAÇO, a subsidiary of Afya Brazil, pursuant to which UNIVAÇO Patrimonial Ltda. agreed to lease the UNIVAÇO campus to UNIVAÇO, located in the city of Ipatinga, State of Minas Gerais. The lease agreement is adjustable in accordance with the provisions of the lease agreement. The lease agreement is for an initial term of 20 years, and is renewable for an additional 20 3,409 3,210 2,915 Lease agreement with IESVAP Patrimonial Ltda. On April 25, 2018, IESVAP Patrimonial Ltda., an entity controlled by the shareholder Nicolau Carvalho Esteves and of which Mr. Renato Esteves is an executive officer, entered into a lease agreement with IESVAP, a subsidiary of Afya Brazil, pursuant to which IESVAP Patrimonial Ltda. agreed to lease the IESVAP campus to IESVAP located in the city of Parnaíba, State of Piauí. The lease agreement is for an amount equal to 7.5 20 20 4,920 4,560 3,470 Key management personnel compensation Key management personnel compensation included in the Company’s consolidated statement of income comprised the following: Schedule of key management personnel compensation included in the Company’s consolidated statement of income 2022 2021 2020 Short-term employee benefits 13,564 11,933 9,629 Share-based compensation plan 13,116 20,251 23,989 26,680 32,184 33,618 Compensation of the Company’s key management includes short-term employee benefits comprised by salaries, labor and social charges, and other ordinary short-term employee benefits. The costs of key management personnel are shared by the Company’s subsidiaries in accordance with internal policies. The amounts disclosed in the table above are the amounts recognized as an expense in general and administrative expenses during the reporting period related to key management personnel. The executive officers participate in share-based compensation plans described in Note 16(b).

Other assets

Other assets	12 Months Ended
	Dec. 31, 2022
Other Assets
Other assets	9 Other assets As of December 31, 2022, the Company has R$243,501 (R$ 222,839 on December 31, 2021) accounted for as Other assets as follow: Schedule of Other Assets 2022 2021 Indemnification assets (a) 145,300 135,355 Judicial deposits 12,693 18,825 Prepaid expenses 18,441 10,110 Other FIES receivables 26,440 21,450 Other 40,627 37,099 Total 243,501 222,839 Current 51,745 42,533 Non-current 191,756 180,306 (a) Under the terms of the Share Purchase and Sale Agreements ("Agreements") between the Company and the selling shareholders of certain subsidiaries acquired, the Company assesses that the selling shareholders are exclusively responsible for any provisions (including labor, tax and civil), which are or will be the subject of a claim by any third party, arising from the act or fact occurred, by action or omission, prior to or on the closing dates of the acquisitions.

Investment in associate

Investment in associate	12 Months Ended
	Dec. 31, 2022
Investment In Associate
Investment in associate	10 Investment in associate The Company holds a 30% interest in UEPC, a medical school located in the Federal District that offers higher education and post-graduate courses, both in person and long-distance learning. The Company’s interest in UEPC is accounted for using the equity method. The following table illustrates the summarized financial information of the Company’s investment in UEPC: Schedule of investments 2022 2021 Current assets 32,651 33,976 Non-current assets 122,378 109,805 Current liabilities (22,840) (35,049) Non-current liabilities (96,442) (91,086) Equity 35,747 17,646 Company’s share in equity – 30% 10,724 5,294 Goodwill 43,183 43,183 Carrying amount of the investment 53,907 48,477 2022 2021 2020 Net revenue 138,584 127,618 113,965 Cost of services (57,421) (57,935) (55,926) General and administrative expenses (34,991) (24,025) (27,341) Finance results (4,103) (4,585) (4,882) Income before income taxesz 42,069 41,073 25,816 Income taxes expenses (1,456) (1,748) (252) Net income for the period 40,613 39,325 25,564 Company’s share of income for the period 12,184 11,797 7,698 2022 2021 2020 Opening balance 48,477 51,410 45,634 Dividends received (6,754) (11,770) - Dividends receivable (included in Other assets) - (2,960) (1,922) Share of income 12,184 11,797 7,698 Closing balance 53,907 48,477 51,410 The Company tests at least annually the recoverability of the carrying amount of goodwill. As of December 31, 2022 and 2022, no impairment had to be recognized for this goodwill.

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2022
Property And Equipment
Property and equipment	11 Property and equipment Schedule of detailed information about property, plant and equipment Cost Building Machinery and equipment Lands Vehicles Furniture and fixtures IT equipment Library books Laboratories and clinics Leasehold improvements Construction in progress Total As of January 1, 2020 - 44,329 7,005 707 21,438 15,994 18,139 1,049 30,911 36,731 176,303 Additions - 13,806 672 - 4,550 9,657 1,012 - 54,748 5,387 89,832 Business combinations 6,771 8,973 5,724 508 3,061 2,493 2,473 - 12,787 5,090 47,880 Transfer 19,148 1,395 - - 82 367 - (1,049) 23,559 (43,502) - As of December 31, 2020 25,919 68,503 13,401 1,215 29,131 28,511 21,624 - 122,005 3,706 314,015 Additions 1,384 10,268 5,451 111 21,075 19,511 3,392 - 4,720 59,957 125,869 Business combinations - 12,810 - 346 16,684 10,138 5,142 - 17,425 3,078 65,623 Write-off * 62 (14,213) - (205) 2,862 (4,985) (86) - (550) (417) (17,532) Transfer 25,068 3 - - 82 9 - - 9,376 (34,538) - As of December 31, 2021 52,433 77,371 18,852 1,467 69,834 53,184 30,072 - 152,976 31,786 487,975 Additions 527 36,486 - 968 26,047 15,766 645 - 2,667 85,026 168,132 Business combinations - 45 - - - 35 - - - - 80 Write-off * 13 (8,159) - (933) 500 (6,992) - - - (78) (15,649) Transfer 38,884 (5,353) - (449) (5,669) 6,600 6,645 - (9,797) (30,046) 815 As of December 31, 2022 91,857 100,390 18,852 1,053 90,712 68,593 37,362 - 145,846 86,688 641,353 Depreciation As of January 1, 2020 - (13,793) - (59) (5,890) (6,537) (8,663) (386) (1,655) - (36,983) Depreciation - (5,065) - (112) (2,199) (4,314) (2,154) (78) (2,729) - (16,651) Transfer - (464) - - - - - 464 - - - As of December 31, 2020 - (19,322) - (171) (8,089) (10,851) (10,817) - (4,384) - (53,634) Depreciation (1,673) (7,215) - (196) (5,601) (7,529) (3,416) - (4,831) - (30,461) Write-off * - 10,146 - 147 1,194 3,458 633 - 350 - 15,928 As of December 31, 2021 (1,673) (16,391) - (220) (12,496) (14,922) (13,600) - (8,865) - (68,167) Depreciation (3,472) (11,166) - (284) (7,725) (10,140) (3,415) - (8,849) - (45,051) Write-off * - 5,474 - 791 153 7,350 67 - 117 - 13,952 Transfer (606) 1,453 - 1 9,719 (4,125) (5,940) - (502) - - As of December 31, 2022 (5,751) (20,630) - 288 (10,349) (21,837) (22,888) - (18,099) - (99,266) Net book value As of December 31, 2022 86,106 79,760 18,852 1,341 80,363 46,756 14,474 - 127,747 86,688 542,087 As of December 31, 2021 50,760 60,980 18,852 1,247 57,338 38,262 16,472 - 144,111 31,786 419,808 * Refers to items written-off as result of lack of expectation of future use, in connection with the Company’s physical inventory procedures. The Company assesses at each reporting date, whether there is an indication that a property and equipment asset may be impaired. If any indication exists, the Company estimates the asset’s recoverable amount. There were no indications of impairment of property and equipment as of and for the ended December 31, 2022, 2021 and 2020.

Intangible assets and goodwill

Intangible assets and goodwill	12 Months Ended
	Dec. 31, 2022
Intangible assets and goodwill [abstract]
Intangible assets and goodwill	12 Intangible assets and goodwill Schedule of intangible assets Goodwill Licenses with indefinite useful life (i) Trademark Customer relationships Software Education content Developed technology Educational platform Software in progress Other Total Cost As of January 1, 2020 459,409 703,772 32,111 125,413 9,389 17,305 - 12,191 2,050 - 1,361,640 Additions - - - - 4,175 - - 15,227 247 19,649 Disposals - - - - (460) - - - - (460) Business combinations 351,247 747,498 42,903 158,126 3,117 - 355 484 - 1,303,730 As of December 31, 2020 810,656 1,451,270 75,014 283,539 16,221 17,305 355 27,902 2,297 - 2,684,559 Additions (iv) - 108,000 - 684 3,044 - 996 39,686 23,700 - 176,110 Write-off * - - - - 1,020 - - (2,743) (417) - (2,140) Business combinations 373,680 606,136 58,355 147,054 1,474 - 33,046 11,599 3,267 - 1,234,611 As of December 31, 2021 1,184,336 2,165,406 133,369 431,277 21,759 17,305 34,397 76,444 28,847 - 4,093,140 Additions (ii) (i) 39,100 24,408 - 80 1,423 11,231 32,879 14,761 26,141 - 150,023 Write-off - - (22) - (381) (7) - (9) (28) - (447) Remeasurement (iii) (8,637) - - - - - - - - - (8,637) Transfer - - (2,472) 530 20,466 38,433 17,953 (35,499) (40,226) - (815) Business combinations 42,246 - 51,185 3,929 33 2,627 5,520 - - 1,055 106,595 As of December 31, 2022 1,257,045 2,189,814 182,060 435,816 43,300 69,589 90,749 55,697 14,734 1,055 4,339,859 Amortization As of January 1, 2020 - - (1,150) (37,872) (4,536) (4,876) - (868) - (49,302) Amortization - - (2,352) (47,960) (2,180) (2,816) (32) (7,367) - (62,707) Disposals - - - - 460 - - - - 460 As of December 31, 2020 - - (3,502) (85,832) (6,256) (7,692) (32) (8,235) - - (111,549) Amortization - - (5,027) (56,438) (5,844) (8,980) (625) (3,608) - - (80,522) Write-off - - - - (599) - - 365 - - (234) As of December 31, 2021 - - (8,529) (142,270) (12,699) (16,672) (657) (11,478) - - (192,305) Amortization - - (6,426) (70,093) (4,943) (9,634) (9,436) (5,874) - (79) (106,485) Write-off - - - - 365 57 - - - - 422 Transfer - - - - (313) - 313 - - - As of December 31, 2022 - - (14,955) (212,363) (17,277) (26,562) (10,093) (17,039) - (79) (298,368) Net book value As of December 31, 2022 1,257,045 2,189,814 167,105 223,453 26,023 43,027 80,656 38,658 14,734 976 4,041,491 As of December 31, 2021 1,184,336 2,165,406 124,840 289,007 9,060 633 33,740 64,966 28,847 - 3,900,835 * Refers to intangible assets written-off as result of lack of expectation of future use. (i) On March 18, 2022, Afya announced that MEC authorized the increase of 28 seats of Centro Universitário São Lucas, in Ji-Parana located in the state of Rondônia. The earn-out related to the seats approval is R$800 per seat, adjusted by the CDI rate from the closing until the payment date, of which 50% was paid in April 2022 and the remaining amount is payable in cash in two equal installments through 2024. (ii) During the measurement period, the goodwill for the acquisition of Unigranrio was adjusted by R$39,100 (R$130,073 initial goodwill) as a result of an increase of liabilities regarding tax contingencies. (iii) During the measurement period, R$8,637 of goodwill (R$38,446 initial goodwill) arising from the acquisition of RXPRO was reduced, in connection with management’s view of remote likelihood of RXPRO achieving the revenue goals stablished at the terms of the earn-out. (iv) On November 05, 2021 Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") authorized the operation of 120 medical school seats in Garanhuns, for which our shareholder Nicolau Carvalho Esteves entered into an agreement with Afya Brazil pursuant to which he assigned to Afya Brazil the right to develop the ITPAC Garanhuns greenfield unit, a medical school in the city of Garanhuns, State of Pernambuco. Management assessed the aspects of such transaction and concluded that the transaction does not fall under the definition of business, but an acquisition of license with indefinite useful life recognized in intangible assets. Total purchase price was R$108,000 of which 50% was paid in cash on the transaction closing date and 50% in two equal annual installments, adjusted by the CDI rate. Licenses with indefinite useful life include intangible assets acquired through business combinations. The licenses for medicine and other courses granted by the Ministry of Education (“MEC”) to the companies acquired have no expiration date and the Company has determined that these assets have indefinite useful lives. For impairment testing goodwill and licenses with indefinite useful lives acquired through business combinations are allocated to CGUs. The Company performed its annual impairment test on December 31, 2022, 2021 and 2020. The Company tests at least annually the recoverability of the carrying amount of goodwill and licenses with indefinite useful lives for each CGU. The Company determines the recoverable amount of its CGUs based on the value-in-use. The process of estimating these values involves the use of assumptions, judgments and estimates of future cash flows that represent the Company's best estimate. There was no impairment for goodwill and licenses with indefinite useful lives as of December 31, 2022, 2021 and 2020. The carrying amounts of goodwill and licenses with indefinite useful life by CGU and their carrying amount as of December 31, 2022 and 2021 were as follows: Schedule of assumptions for impairment test Carrying amount CGU Goodwill Licenses with indefinite useful life CGU 2022 2021 2022 2021 2022 2021 IPTAN 17,446 17,446 57,214 57,214 126,024 140,522 IESVAP 27,956 27,956 81,366 81,366 129,305 112,260 CCSI 4,664 4,664 56,737 56,737 53,540 49,030 IESP 73,838 73,838 179,693 179,693 322,968 346,286 FADEP 49,661 49,661 70,606 70,606 153,100 153,791 FASA 58,903 58,903 144,507 144,507 314,967 302,330 IPEMED 87,647 87,647 - - 192,079 126,965 IPEC - - 108,000 108,000 148,067 131,360 UniRedentor 77,662 77,662 121,477 121,477 242,600 246,320 UniSL* 4,420 4,420 273,795 249,387 398,492 305,044 FESAR 71,664 71,664 141,616 141,616 244,084 279,038 FCMPB 110,483 110,483 235,018 235,018 415,453 401,244 ITPAC Garanhuns - - 108,000 108,000 112,628 107,232 Medical Harbour - 4,022 - - - 9,150 Content & Technology for medical education (Pillar 1) 169,975 139,294 - - 279,684 235,300 Practice Management Tools & Electronic Prescription (Pillar 3) 106,774 113,362 - - 216,297 227,909 Clinical Decision Software (Pillar 2) 87,018 87,018 - - 153,526 147,592 Cliquefarma 6,588 - - - 20,045 - Moc 87,777 87,777 190,247 190,247 369,007 356,789 Unigranrio 169,173 130,073 421,538 421,538 854,861 630,185 RXPRO* 29,809 38,446 - - 36,675 46,788 Glic 15,587 - - - 31,022 - Total 1,257,045 1,184,336 2,189,814 2,165,406 4,814,424 4,355,135 * See Note 12 for further details on goodwill changes between 2021 and 2022. Pillar 1: during 2022, Além da Medicina and CardioPapers were added to Content & Technology for medical education Pillar. Also, Medical Harbour joined Pillar 1 in 2022. Medcel has been disclosed as Pillar’s predecessor. All of these entities are internally related and engaged on providing educational tools and technical medical content for physicians throughout their careers. Products originally from each entity are often combined offered to our clients. Pillar 3: During 2022, Cliquefarma was moved by management from pillar “Practice Management Tools & Electronic Prescription” to a separate cash generating unit in connection with an internal restructuring which results in segregation of the CGU. Moc: the cash generating unit is composed by UnifipMoc and ESMC legal entities, due to geographical characteristics and integration of the business, which was approved by the Board of Directors. The main assumptions used by the Company to determine the value in use of the CGUs were: Student enrollment Tuition fees Occupancy rate students effectively enrolled divided by the regulatory capacity in a given period. Regulatory capacity Faculty – Digital content platform users Capital expenditure Discount rates 13.14 15.40 12.10 Perpetuity growth rate – refers to growth rate considered by management on long term periods after the explicit projection period of 5 3 7.3 Significant estimate: impact of possible changes in key assumptions An increase of 25 basis points in management’s estimated discount rate applied to the cash flow projections of each CGU for the year ended December 31, 2022, or a decrease of 25 basis points on estimated EBITDA would have not resulted in significant impacts on these financial statements. Other intangible assets Intangible assets, other than goodwill and licenses with indefinite useful lives, are valued separately for each acquisition and are amortized during each useful life. The useful lives and methods of amortization of other intangibles are reviewed at each financial year end and adjusted prospectively, if appropriate. The estimated useful lives of intangible assets are as follows: Schedule of estimated useful lives of intangible assets Customer relationships – medicine 6 Customer relationships – other courses 4.5 Software license 5 Education content 3 Trademarks 2 30 Developed technology 5 For the years ended December 31, 2022, 2021 and 2020, there were no indicatives that the Company’s intangible assets with finite useful lives might be impaired.

Financial assets and financial

Financial assets and financial liabilities	12 Months Ended
	Dec. 31, 2022
Financial Assets And Financial Liabilities
Financial assets and financial liabilities	13 Financial assets and financial liabilities 13.1 Financial assets Schedule of financial assets Financial assets 2022 2021 At amortized cost Trade receivables 495,399 405,793 Total 495,399 405,793 Current 452,831 378,351 Non-current 42,568 27,442 Financial instruments at amortized cost include trade receivables. 13.2 Financial liabilities Schedule of financial liabilities Financial liabilities 2022 2021 At amortized cost Trade payables 71,482 59,098 Loans and financing 1,882,901 1,374,876 Lease liabilities 769,525 714,085 Accounts payable to selling shareholders 528,678 679,826 Notes payable 62,176 72,726 Advances from customers 133,050 114,585 Total 3,447,812 3,015,196 Current 706,080 581,685 Non-current 2,741,732 2,433,511 13.2.1 Loans and financing Schedule of loans and financing Financial institution Currency Interest rate Maturity 2022 2021 Banco Itaú Unibanco S.A. (a) Brazilian real CDI + 1.90% p.y. 2025 518,134 510,972 FINEP (b) Brazilian real TJLP p.y. 2027 8,418 10,145 Banco Itaú Unibanco S.A. (c) Brazilian real CDI + 1.75% p.y. 2024 32,252 31,199 Softbank (d) Brazilian real 6.5% p.y. 2026 824,258 822,560 Debentures (e) Brazilian real CDI + 1.80 p.y. 2028 499,839 - 1,882,901 1,374,876 Current 145,202 128,720 Non-current 1,737,699 1,246,156 (a) On October 1, 2020, Afya Brazil entered into a loan with Banco Itaú Unibanco S.A. in the amount of R$ 500,000 1.62 On September 28, 2022 Afya signed an amendment with Banco Itau Unibanco S.A in order to extend its debt profile, postponing the original repayments dates from 2022 and 2023 to 2023, 2024 and 2025. Due to such extension, the spread over CDI rate increased from 1.62 1.90 (b) On July 23, 2019, Medcel entered into a loan of R$ 16,153 6,734 4,130 (c) On October 28, 2020, UNIFIPmoc entered into a loan with Banco Itaú Unibanco S.A. in the amount of R$ 30,000 1.75 (d) On April 26, 2021, the Company issued and sold 150,000 0.00005 150,000 821,805 Each Series A perpetual convertible preferred share is entitled to a cash dividend of 6.5% per annum and is convertible, at the holder’s discretion, into the Company’s Class A common shares at an initial conversion price of US$25.35. The Company may require the conversion of any or all of the Series A perpetual convertible preferred shares at any time on or after the three-year anniversary of the original issuance date if certain conditions set forth in the certificate of designation are met (if for 20 out of 30 consecutive trading days prior, Afya’s stock price is equal or above 150% of the conversion rate). The Company may also redeem any or all of the Series A perpetual convertible preferred shares for cash, shares of its common shares or a combination thereof at its election, at any time on or after the seven-year anniversary of the original issuance date as determined in the certificate of designation. On or after the five-year anniversary of the original issuance date, the holders of the Series A convertible perpetual preferred shares shall have the right to redeem all of the outstanding Series A convertible perpetual preferred shares for cash, the Company’s common shares or a combination thereof (at the Company’s election, subject to certain conditions) to be determined in the certificate of designation. Upon the occurrence of a change of control, the holders will have the right to redeem their Series A convertible perpetual preferred shares for cash at a price set forth in the certificate of designation. The Series A convertible perpetual preferred shares will be entitled with the same voting rights of the common shares only when converted into it. The Company determined that the Series A perpetual convertible preferred shares should be classified as financial liability at amortized cost upon their issuance since is redeemable primarily according to the decision of the holder and there is a contractual obligation to deliver assets (cash, shares of its common shares or a combination thereof) that could not be avoided by the Company in an event of redemption. The financial liability is denominated in Brazilian Reais and thus not subject to foreign exchange changes. In addition, as the entire instrument is classified as a liability, the embedded put option to redeem the Series A perpetual convertible preferred shares for cash is an embedded derivative. The embedded derivative will not be treated separately once the exercise price of the option is closely related to the host contract. The initial transaction costs that are directly attributable to the issuance of Series A perpetual convertible preferred shares were measured at fair value together with the financial liability on initial measurement. The transaction costs totaled R$ 13,030 (e) On December 16, 2022, Afya announced the closing of the issuance, through its wholly-owned subsidiary Afya Brazil, of 500,000 1 500.000 100 1.80 This transaction is subject to certain obligations including financial covenants. According to this offering, Afya shall maintain net debt (excluding Softbank transaction and lease liabilities) to adjusted EBITDA ratio below or equal to 3.0 x, at the end of each fiscal year, until maturity date. Adjusted EBITDA considers net income plus (i) income taxes expenses, (ii) net financial result (excluding interest expenses on lease liabilities), (iii) depreciation and amortization expenses (excluding right-of-use depreciation expenses), (iv) share-based compensation expenses, (v) share of income of associate, (vi) interest received and (vii) non-recurring expenses. As of December 31, 2022, the Company is compliant with all obligations set forth in the deed of issuance. The transaction costs that are directly attributable to the issuance of debentures were measured at fair value together with the financial liability on initial measurement. The transaction costs totaled R$ 3,115 13.2.2 Leases The Company has lease contracts for properties. The lease contracts generally have maturities in the lease terms between 5 30 The carrying amounts of right-of-use assets and lease liabilities as of December 31, 2022 and December 31, 2021 and the movements during the years are described below: Schedule of right-of-use assets and lease liabilities Right-of-use assets Lease liabilities As of January 1, 2021 419,074 447,703 Additions 62,689 62,689 Remeasurement 95,962 95,962 Business combinations 139,514 139,514 Depreciation expense (43,237) - Interest expense - 67,212 Payments of lease liabilities - (87,751) Write-off (10,316) (11,244) As of December 31, 2021 663,686 714,085 Additions 42,250 42,250 Remeasurement 58,623 58,623 Depreciation expense (54,684) - Interest expense - 88,571 Payments of lease liabilities - (113,512) Write-off (a) (19,802) (20,492) As of December 31, 2022 690,073 769,525 As of December 31, 2021 Current - 24,955 Non-current 663,686 689,130 As of December 31, 2022 Current - 32,459 Non-current 690,073 737,066 (a) Refers to anticipated termination of real estate leasing contracts. The Company recognized lease expense from short-term leases and low-value assets of R$ 12,153 11,229 2,555 13.2.3 Accounts payable to selling shareholders Schedule of accounts payable to selling shareholders 2022 2021 Acquisition of FASA (a) - 41,581 Acquisition of IPEMED (b) 22,654 30,233 Acquisition of UniRedentor (c) 72,064 85,506 Acquisition of UniSãoLucas (d) 37,301 42,672 Acquisition of FCMPB (e) 111,755 149,175 Acquisition of Medicinae (f) - 3,887 Acquisition of Medical Harbour (g) 4,053 6,801 Acquisition of Cliquefarma (h) - 3,050 Acquisition of Shosp (i) 2,206 2,141 Acquisition of Unigranrio (j) 216,716 249,979 Acquisition of RXPRO (k) 1,781 10,245 Acquisition of Guaranhuns (l) 30,653 54,556 Acquisition of Além da Medicina (m) 11,996 - Acquisition of CardioPapers (n) 7,979 - Acquisition of Glic (o) 9,520 - 528,678 679,826 Current 261,711 239,849 Non-current 266,967 439,977 2022 2021 2020 Opening balance 679,826 518,240 300,237 Cash flows (i) (261,188) (192,681) (134,518) Acquisition of licenses (ii) 24,408 54,000 - Interest 68,064 31,915 13,884 Reversals (iii) (10,353) - - Consideration to be transferred on business combinations - 243,816 343,140 Consideration to be transferred on business combinations (Earn-outs) 27,921 24,536 - Compensation of legal proceedings disbursement - - (4,503) Closing balance 528,678 679,826 518,240 (i) R$ 30,174 (ii) R$ 8,637 1,716 (a) On April 3, 2019, Afya Brazil acquired 90 39,695 29,770 29,770 (b) On May 9, 2019, Afya Brazil acquired 100 45,303 9,061 (c) On January 31, 2020, Afya Brazil acquired 100 100,000 4,503 (d) On May 5, 2020, Afya Brazil acquired 100 60,456 7,816 (e) On November 9, 2020, Afya Brazil acquired 100 188,894 (f) On March 25, 2021, Afya Brazil acquired 100 4,400 1,716 (g) On April 8, 2021, Afya Brazil acquired 100 9,000 4,053 (h) On April 16, 2021, Afya Brazil acquired 100 3,000 (i) On May 13, 2021, Afya Brazil acquired 100 454 1,793 2,206 (j) On August 4, 2021, Afya Brazil acquired 100 618,956 (k) On October 01, 2021, Afya Brazil acquired 100 21,000 1,781 (l) On November 05, 2021, Afya Brazil concluded the acquisition of 100 54,000 54,000 (m) On March 4, 2022, Afya Brazil acquired 100 19,200 11,074 763 (n) On April 5, 2022 100 15,000 7,422 333 (o) On March 23, 2022, Afya Brazil acquired 100 12,000 8,995 13.2.4 Notes payable With the acquisition of UniSL, Afya Brazil assumed notes payable regarding the previous acquisition of a portion of the operations of Universidade Luterana do Brasil (ULBRA) by UniSL in auction by the end of 2018. Two of the UniSL campuses, located in the cities of Ji-Paraná and Porto Velho in the State of Rondônia, were acquired in such transaction. As of December 31, 2022, the notes payable of R$ 62,176 Set out below are the carrying amount of notes payable and the movements during the years ended December 31, 2022 and 2021: Schedule of carrying amount of notes payable and the movements Notes payable As of January 1, 2021 76,181 Payments (*) (11,068) Monetary indexation 7,613 As of December 31, 2021 72,726 Payments (*) (15,008) Monetary indexation 4,458 As of December 31, 2022 62,176 As of December 31, 2021 Current liabilities 14,478 Non-current liabilities 58,248 As of December 31, 2022 Current liabilities 62,176 Non-current liabilities - (*) The amounts have been included on the investing activities of the cash flow statement. 13.3 Fair values The table below is a comparison of the carrying amounts and fair values of the Company’s financial instruments, other than those carrying amounts that are reasonable approximation of fair values: Schedule of fair values of Company’s financial instruments 2022 2021 Carrying amount Fair value Carrying amount Fair value Financial assets Trade receivables (non-current) 42,568 42,568 27,442 27,442 Total 42,568 42,568 27,442 27,442 Financial liabilities Loans and financing 1,882,901 1,934,295 1,374,876 1,387,136 Lease liabilities 769,525 769,525 714,085 714,085 Accounts payable to selling shareholders 528,678 528,678 679,826 679,826 Notes payable 62,176 62,176 72,726 72,726 Total 3,243,280 3,294,674 2,841,513 2,853,773 The Company assessed that the fair values of current trade receivables and other current assets, trade payables, advances from customers and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. The fair value of interest-bearing borrowings and loans are determined by using the DCF method using discount rate that reflects the issuer’s borrowing rate as of the end of the reporting period. The own non-performance risk at December 31, 2022 was assessed to be insignificant. 13.4 Financial instruments risk management objectives and policies The Company’s principal financial liabilities comprise loans and financing, lease liabilities, accounts payable to selling shareholders, notes payable, trade payables and advances from customers. The main purpose of these financial liabilities is to finance the Company’s operations. The Company’s principal financial assets include trade receivables and cash and cash equivalents. The Company is exposed to market risk, credit risk and liquidity risk. The Company monitors market, credit and liquidity risks in line with the objectives in capital management and counts with the support, monitoring and oversight of the Board of Directors in decisions related to capital management and its alignment with the objectives and risks. The Company’s policy is that no trading of derivatives for speculative purposes may be undertaken. The Board of Directors reviews and agrees with policies for managing each of these risks, which are summarized below. 13.4.1 Financial instruments risk management objectives and policies Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The Company’s exposure to market risk is related to interest rate risk and foreign currency risk. The sensitivity analysis in the following sections relate to the position as of December 31, 2022. (i) Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s cash equivalents, loans and financing, accounts payable to selling shareholders and notes payable, with floating interest rates. Sensitivity analysis The following table demonstrates the sensitivity to a reasonably possible change in interest rates on cash equivalents, loans and financing and accounts payable to selling shareholders and notes payable. With all variables held constant, the Company’s income before income taxes is affected through the impact on floating interest rates, as follows: Schedule of sensitivity analysis effects on income statement 2022 Index – % per year Base rate Cash equivalents 1,011,126 99.21% of CDI 136,928 Debentures (499,839) CDI + 1.80% (77,225) Loans and financing (518,134) CDI + 1.90% (80,570) Loans and financing (32,252) CDI + 1.75% (4,966) Loans and financing (8,418) TJLP (620) Accounts payable to selling shareholders (491,143) CDI (67,041) Notes payable (62,176) IPCA (3,600) Net exposure (97,094) Increase in basis points +75 +150 Effect on profit before tax (4,504) (9,010) 2021 Index – % per year Base rate Cash equivalents 636,847 100.38% CDI 5,844 Loans and financing (510,972) CDI + 1,62% (55,032) Loans and financing (31,199) CDI + 1,75% (3,401) Loans and financing (10,145) TJLP (617) Accounts payable to selling shareholders (612,121) CDI (56,009) Accounts payable to selling shareholders (41,581) IPCA + 4,1% (1,708) Notes payable (72,726) IPCA (531) Net exposure (111,454) Increase in basis points +75 +150 Effect on profit before tax (4,814) (9,628) (ii) Foreign currency risk Foreign currency risk is the risk that the fair value or future cash flows of exposure will fluctuate because of changes in foreign exchange rates. The Company’s exposure to the risk of changes in foreign exchange rates relates to cash and cash equivalents denominated in U.S. dollars in the amount of R$ 24,447 23,228 Foreign currency sensitivity The following table demonstrates the sensitivity in the Company’s income before income taxes of a 10 5.2171 1.00 Schedule of currencies used in sensitivity analysis Exposure +10% -10% As of December 31, 2022 Cash equivalents 24,447 2,445 (2,445) 13.4.2 Credit risk Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including cash and cash equivalents. Customer credit risk is managed by the Company based on the established policy, procedures and control relating to customer credit risk management. Outstanding customer receivables are regularly monitored. See Note 7for additional information on the Company’s trade receivables. Credit risk from balances with banks and financial institutions is managed by the Company’s treasury department in accordance with the Company’s policy. Investments of surplus funds are made only with approved counterparties and within limits assigned to each counterparty. The Company’s maximum exposure to credit risk for the components of the statements of financial position on December 31, 2022 and December 31, 2021 is the carrying amounts of its financial assets. 13.4.3 Liquidity risk The Company’s Management has responsibility for monitor liquidity risk. In order to achieve the Company’s objective, Management regularly reviews the risk and maintains appropriate reserves, including bank credit facilities with first tier financial institutions. Management also continuously monitors projected and actual cash flows and the combination of the maturity profiles of the financial assets and liabilities. The main requirements for financial resources used by the Company arise from the need to make payments for suppliers, operating expenses, labor and social obligations, loans and financing and accounts payable to selling shareholders. The tables below summarize the maturity profile of the Company’s financial liabilities based on contractual undiscounted amounts: Schedule of maturity profile of financial liabilities As of December 31, 2022 Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Total Trade payables 71,482 - - - 71,482 Loans and financing 287,741 788,190 1,237,599 - 2,313,530 Lease liabilities 117,506 234,688 219,127 1,139,771 1,711,092 Accounts payable to selling shareholders 282,481 339,281 - - 621,762 Notes payable 62,176 - - - 62,176 Advances from customers 133,050 - - - 133,050 954,436 1,362,159 1,456,726 1,139,771 4,913,092 As of December 31, 2021 Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Total Trade payables 59,098 - - - 59,098 Loans and financing 217,903 585,686 948,503 1,212 1,753,304 Lease liabilities 103,003 211,894 204,744 1,108,555 1,628,196 Accounts payable to selling shareholders 246,059 445,066 88,989 - 780,114 Notes payable 15,644 74,306 - - 89,950 Advances from customers 114,585 - - - 114,585 756,292 1,316,952 1,242,236 1,109,767 4,425,247 13.5 Changes in liabilities arising from financing activities Schedule of changes in liabilities arising from financing activities January 1, 2022 Payments Additions Interest Business combinations Other December 31, 2022 Loans and financing 1,374,876 (118,378) 496,885 127,559 - 1,959 1,882,901 Lease liabilities 714,085 (113,512) 100,873 88,571 - (20,492) 769,525 Dividends payable - (19,736) 19,736 - - - - Total 2,088,961 (251,626) 617,494 216,130 - (18,533) 2,652,426 January 1, 2021 Payments Additions * Interest Business combinations Other December 31, 2021 Loans and financing 617,485 (158,076) 809,539 68,909 36,591 428 1,374,876 Lease liabilities 447,703 (87,751) 158,651 67,212 139,514 (11,244) 714,085 Dividends payable - (18,648) 18,648 - - - - Total 1,065,188 (264,475) 986,838 136,121 176,105 (10,816) 2,088,961 * The additions of loans and financing include proceeds from the SoftBank transaction of R$ 822,569 13,030 January 1, 2020 Payments Additions Interest Foreign exchange movement Business combinations Other December 31, 2020 Loans and financing 60,357 (155,090) 605,041 10,031 21,279 75,815 52 617,485 Lease liabilities 284,515 (55,455) 98,904 44,458 - 76,855 (1,574) 447,703 Dividends payable - (12,984) 12,984 - - - - - Total 344,872 (223,529) 716,929 54,489 21,279 152,670 (1,522) 1,065,188

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Measurement
Fair value measurement	14 Fair value measurement The following table provides the fair value measurement hierarchy of the Company’s assets and liabilities as of December 31, 2022 and December 31, 2021. Schedule of fair value measurement Fair value measurement Total Quoted prices in active markets (Level 1) Significant observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2022 Assets for which fair values are disclosed Trade receivables (non-current) 42,568 - 42,568 - Liabilities for which fair values are disclosed Loans and financing (1,934,295) - (1,934,295) - Lease liabilities (769,525) - (769,525) - Accounts payable to selling shareholders (528,678) - (528,678) - Notes payable (62,176) - (62,176) - December 31, 2021 Assets for which fair values are disclosed Trade receivables (non-current) 27,442 - 27,442 - Liabilities for which fair values are disclosed Loans and financing (1,387,136) - (1,387,136) - Lease liabilities (714,085) - (714,085) - Accounts payable to selling shareholders (679,826) - (679,826) - Notes payable (72,726) - (72,726) - There were no transfers between Levels during the period or year presented.

Capital management

Capital management	12 Months Ended
	Dec. 31, 2022
Capital Management
Capital management	15 Capital management For the purposes of the Company’s capital management, capital considers total equity. The primary objective of the Company’s capital management is to maximize the shareholder value. The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. In order to achieve this overall objective, the Company’s capital management, among other things, aims to ensure that it meets financial covenants that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans or debentures. There have been no breaches of the financial covenants of any loans or debentures in the current and previous periods. No changes were made in the objectives, policies or processes for managing capital during the years ended December 31, 2022 and 2021.

Labor and social obligations

Labor and social obligations	12 Months Ended
	Dec. 31, 2022
Labor And Social Obligations
Labor and social obligations	16 Labor and social obligations a) Variable compensation (bonuses) The Company recorded bonuses related to variable compensation of employees and management in cost of services and general and administrative expenses of R$ 24,248 , R$ 25,587 9,514 b) Afya Limited share-based compensation plans b.1) Stock options plan The stock options plan approved on August 30, 2019, granted to senior executives and other employees of the Company, as a result of the IPO will govern the issuance of equity incentive awards with respect to Company’s Class A common shares. The fair value of the stock options was estimated at the grant date using the Binomial pricing model, taking into account the terms and conditions on which the stock options were granted. The Company accounts for the stock options plan as an equity-settled plan. On July 29, 2020, the board of directors approved a change in the strike price of the current share-based compensation plan. The strike price is now measured in Brazilian Reais (where the Company’s operations are located and valuated) adjusted by CDI rate instead of U.S. dollar adjusted by T-Bond. Furthermore, the first tranche had its vesting period extended from May 2020 to May 2021, including one year lock-up period after the vesting period. This change was assessed as a modification by the Company and was accounted for in accordance with IFRS 2. On July 8, 2022, the People and ESG Committee approved a change in the strike price of the current share-based compensation plan. All the tranches still to be vested had their strike price modified compared to the IPO price in Brazilian Reais (R$ 71.22 As result of those modifications, the expense related to the share-based payment of the Company reflects the cost of the original award at grant date over the vesting period plus the incremental fair value of the repriced options at modification date over the vesting period of the options. The average incremental fair value, as result of the modification, was R$ 3.84 Schedule of model used to determine the fair value of the stock options Modified plan Original plan Strike price at the measurement date R$ 76 R$ 85 126 Dividend yield (%) 0.0 0.0 Expected volatility (%) 48 59 42 69 Risk-free interest rate (%) 13 15 5 13 Expected life of stock options (years) 1 5 1 5 Share price at the measurement date R$ 48 R$ 80 145 Model used Binomial Binomial Weighted average fair value at the measurement date R$ 53.06 R$ 49.22 On May 18, 2022, July 11, 2022 and September 14, 2022, the Company granted 1,234,919 May 2022 July 2022 September 2022 Strike price at the measurement date R$ 70 R$ 52 R$ 52 Dividend yield (%) 0.0 0.0 0.0 Expected volatility (%) 48 60 48 59 48 58 Risk-free interest rate (%) 12 13 13 15 12 Expected life of stock options (years) 1 5 1 5 1 5 Share price at the measurement date R$ 55.54 R$ 48.24 R$ 72.59 Model used Binomial Binomial Binomial Weighted average fair value at the measurement date R$ 19.13 R$ 17.98 R$ 34.86 The following table illustrates the number and movements in stock options during the period: Schedule of share-based compensation plan Weighted average exercise price (in Reais) Number of stock options 2022 2021 2020 Outstanding at January 1 92.33 3,086,728 2,510,983 2,364,214 Granted 53.02 1,234,919 1,170,000 477,220 Exercised - - (442,669) (56,092) Forfeited 107.25 (365,749) (60,000) (274,359) Expired 97.80 (226,611) (91,586) - Outstanding at December 31 79.47 3,729,287 3,086,728 2,510,983 Exercisable 97.65 1,133,774 542,061 - The share-based compensation expense recognized in general and administrative expenses in the statement of income for the year ended December 31, 2022 was R$ 27,242 43,377 32,610 b.2) Restricted Stock Units (RSU) Program On July 8, 2022, the Company approved the new Restricted Stock Units (RSU) program for employees. The participant's right to effectively receive ownership of the restricted shares will be conditioned on the participant's continuance as an employee or director in the business group from the grant date until vesting. The executives will be entitled to these shares in a proportion of 10 20 30 40 In July 2022 and September 2022, 442,546 4,678 48.24 72.59 The Company accounts for the RSU plan as an equity-settled plan, except for the portion of labor and social securities obligations. Total RSU expense recognized in general and administrative expenses in the statement of income for the year ended December 31, 2022 amount R$ 4,032 2,167

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Equity
Equity	17 Equity a) Share capital As of December 31, 2022, the Company’s share capital was R$ 17 17 93,722,831 47,920,068 45,802,763 93,722,831 47,920,068 45,802,763 50 b) Dividends In the year ended December 31, 2022 CCSI and IESVAP approved the payment of dividends of R$ 66,828 47,092 19,736 c) Buy-back program On December 23, 2020, the Company announced that its Board of Directors approved a share buy-back program. Afya may repurchase up to 1,015,844 On October 27, 2021, the Company’s board of directors approved a new share repurchase program. Afya may repurchase up to 1,383,108 On January 27, 2022, the Company’s board of directors approved a new share repurchase program. Afya may repurchase up to 1,874,457 During the year ended December 31, 2022, the Company’s cash outflow was R$ 152,317 213,722 The following table illustrates the number and movements in treasury shares during the year ended December 31, 2022 and 2021 (no treasury shares were repurchased in 2020): Schedule illustrates the number and movements in treasury shares Number of shares Average price (in Brazilian Reais) Outstanding at January 1, 2021 - - Repurchased 2,142,051 119.99 Transferred from exercise of stock options (442,669) 124.26 Transferred from shares contribution (44,455) 111.94 Outstanding at December 31, 2021 1,654,927 92.23 Repurchased 2,131,358 71.46 Outstanding at December 31, 2022 3,786,285 80.54

Earnings per share (EPS)

Earnings per share (EPS)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share
Earnings per share (EPS)	18 Earnings per share (EPS) Basic EPS is calculated by dividing net income attributable to the equity holders of the Company by the weighted average number of common shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to the equity holders of the parent by the weighted average number of common shares outstanding during the period plus the weighted average number of shares that would be issued on conversion of all potential shares with dilutive effects. Diluted earnings per share are computed including stock options granted to key management using the treasury shares method when the effect is dilutive. The Company has the stock option and restricted share unit plans in the category of potentially dilutive shares. Softbank’s series A perpetual convertible preferred shares are antidilutive as of December 31, 2022 and 2021 and are not included on diluted earnings per share. The following table reflects the net income and share data used in the basic and diluted EPS calculations: Schedule of earnings per share 2022 2021 2020 Numerator Net income attributable to equity holders of the parent 373,569 223,326 292,075 Denominator Weighted average number of outstanding shares 90,335,037 93,291,480 92,683,848 Effects of dilution from stock options and restricted share units 329,085 811,818 951,920 Weighted average number of outstanding shares adjusted for the effect of dilution 90,664,122 94,103,298 93,635,768 Basic earnings per share (R$) 4.14 2.39 3.15 Diluted earnings per share (R$) 4.12 2.37 3.12

Revenue

Revenue	12 Months Ended
	Dec. 31, 2022
Revenue [abstract]
Revenue	19 Revenue Schedule of net sales revenue 2022 2021 2020 Tuition fees 2,827,567 2,124,589 1,388,735 Other 213,040 167,441 99,817 Deductions Granted discounts (241,404) (229,254) (89,017) Early payment discounts (92,234) (49,879) (29,299) Returns (45,402) (42,373) (11,437) Taxes (107,004) (74,232) (49,629) PROUNI (225,506) (176,921) (107,979) Revenue from contracts with customers 2,329,057 1,719,371 1,201,191 Timing of revenue recognition of net revenue from contracts with customers Tuition, digital content and app subscription fees - Transferred over time 2,273,578 1,640,889 1,128,558 Other - Transferred at a point in time 55,479 78,482 72,633 The Company`s revenue from contracts with customers are all in Brazil. The Company is not subject to the payment of the social integration program tax (Programa de Integração Social, or PIS) and the social contribution on revenues tax (Contribuição para o Financiamento da Seguridade Social, or COFINS) on the revenue from under graduation degrees under the PROUNI program. The following table presents statements of income for the Company’s operating segments for the years ended December 31, 2022, 2021 and 2020: Schedule of revenue by segment Revenue by segment Undergrad Continuing Education Digital Services Elimination (inter-segment transactions) 2022 Types of services or goods 2,037,889 108,806 189,984 (7,622) 2,329,057 Tuition fees 2,023,128 108,648 - - 2,131,776 Other 14,761 158 189,984 (7,622) 197,281 Timing of revenue recognition 2,037,889 108,806 189,984 (7,622) 2,329,057 Transferred over time 2,024,373 108,806 145,939 (5,540) 2,273,578 Transferred at a point in time 13,516 - 44,045 (2,082) 55,479 Revenue by segment Undergrad Continuing Education Digital Services Elimination (inter-segment transactions) 2021 Types of services or goods 1,498,408 72,983 151,958 (3,978) 1,719,371 Tuition fees 1,486,111 72,983 - - 1,559,094 Other 12,297 - 151,958 (3,978) 160,277 Timing of revenue recognition 1,498,408 72,983 151,958 (3,978) 1,719,371 Transferred over time 1,486,111 72,983 81,795 - 1,640,889 Transferred at a point in time 12,297 - 70,163 (3,978) 78,482 Revenue by segment Undergrad Continuing Education Digital Services Elimination (inter-segment transactions) 2020 Types of services or goods 1,002,461 107,197 93,152 (1,619) 1,201,191 Tuition fees 997,055 107,197 - - 1,104,252 Other 5,406 - 93,152 (1,619) 96,939 Timing of revenue recognition 1,002,461 107,197 93,152 (1,619) 1,201,191 Transferred over time 997,055 107,197 24,306 - 1,128,558 Transferred at a point in time 5,406 - 68,846 (1,619) 72,633

Expenses and costs by nature

Expenses and costs by nature	12 Months Ended
	Dec. 31, 2022
Expenses And Costs By Nature
Expenses and costs by nature	20 Expenses and costs by nature Schedule of expenses by nature 2022 2021 2020 Cost of services (859,552) (652,300) (434,654) General and administrative expenses (798,153) (622,615) (402,855) Total (1,657,705) (1,274,915) (837,509) Payroll (880,664) (677,564) (446,473) Hospital and medical agreements (66,065) (37,449) (37,988) Depreciation and amortization (206,220) (154,220) (108,744) Lease expenses (12,153) (11,229) (2,555) Utilities (17,682) (10,643) (5,892) Maintenance (76,475) (47,141) (20,746) Share-based compensation (31,274) (43,377) (32,610) Tax expenses (10,518) (7,997) (5,326) Pedagogical services (48,084) (47,881) (24,037) Sales and marketing (48,217) (39,506) (18,361) Allowance for doubtful accounts (42,708) (47,819) (32,081) Travel expenses (14,003) (7,542) (4,550) Consulting fees (35,326) (38,818) (31,276) Other (168,316) (103,729) (66,870) Total (1,657,705) (1,274,915) (837,509)

Finance result

Finance result	12 Months Ended
	Dec. 31, 2022
Finance Result
Finance result	21 Finance result Schedule of finance result 2022 2021 2020 Income from financial investments 67,810 35,773 24,479 Changes in fair value of derivative instruments - - 20,739 Interest received 27,197 23,040 11,876 Other 7,035 5,753 5,196 Finance income 102,042 64,566 62,290 Interest expense (200,081) (108,437) (25,543) Interest expense on lease liabilities (88,571) (67,212) (44,458) Financial discounts granted (24,092) (23,193) (8,081) Bank fees (8,623) (7,878) (6,333) Foreign exchange loss, net (852) (17,973) (4,613) IOF taxes (taxes on financial transactions) (178) (3,306) (1,661) Other (27,496) (15,797) (7,580) Finance expenses (349,893) (243,796) (98,269) Finance result (247,851) (179,230) (35,979)

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income taxes	22 Income taxes Income taxes are comprised of taxation over operations in Brazil, related to Corporate Income Tax ("IRPJ") and Social Contribution on Net Profit ("CSLL"). According to Brazilian tax legislation, income taxes and social contribution are assessed and paid by legal entity and not on a consolidated basis. Reconciliation of income taxes expense The following is a reconciliation of income tax expense to profit (loss) for the year, calculated by applying the combined Brazilian statutory rates at 34% for the years ended December 31, 2022, 2021 and 2020: Schedule of reconciliation of income tax expense 2022 2021 2020 Income before income taxes 428,433 273,462 335,054 Combined statutory income taxes rate - % 34% 34% 34% Income taxes at statutory rates (145,667) (92,977) (113,918) Reconciliation adjustments: Tax effect on loss from an entity not subject to taxation (32,859) (37,794) (8,474) PROUNI - Fiscal Incentive (a) 270,062 194,830 120,851 Unrecognized deferred tax assets (117,377) (86,233) (41,319) Presumed profit income tax regime effect (b) (1,549) (7,066) (2,640) Permanent adjustments (12,226) (6,232) 2,567 Other 3,939 4,293 15,866 Income taxes expense – current (35,677) (31,179) (27,067) Effective rate 8.33% 11.40% 8.08% (a) The Company adhered to PROUNI, established by Law 11,096 / 2005, which is a federal program that exempt companies of paying income taxes and social contribution. (b) Brazilian tax law establishes that companies that generate gross revenues of up to R$ 78,000 in the prior fiscal year may calculate income taxes as a percentage of gross revenue, using the presumed profit income tax regime. The effect of the presumed profit of certain subsidiaries represents the difference between the taxation based on this method and the amount that would be due based on the statutory rate applied to the taxable profit of the subsidiaries. Deferred income taxes As of December 31, 2022, the Company had accumulated unrecognized deferred income tax assets on temporary differences and tax losses in the amount of R$ 778,080 432,226

Insurance contracts and conting

Insurance contracts and contingencies	12 Months Ended
	Dec. 31, 2022
Insurance Contracts And Contingencies
Insurance contracts and contingencies	23 Insurance contracts and contingencies a) Insurance contracts The Company and its subsidiaries have a risk management program with the purpose of delimiting the risks, seeking in the market coverage compatible with its size and operations. b) Legal proceedings and contingencies The provisions related to labor, civil and taxes proceedings whose likelihood of loss is assessed as probable are as follows: Schedule of legal proceedings and contingencies Labor Civil Taxes (i) Total Balances as of December 31, 2019 2,501 2,768 - 5,269 Business combinations 2,741 2,348 27,487 32,576 Additions 562 10,869 7,853 19,284 Reversals (1,285) (2,705) - (3,990) Balances as of December 31, 2020 4,519 13,280 35,340 53,139 Business combinations 16,597 6,017 57,638 80,252 Additions * 5,418 5,101 14,225 24,744 Reversals (1,044) (1,470) (7,334) (9,848) Balances as of December 31, 2021 25,490 22,928 99,869 148,287 Additions 2,300 7,911 63,698 73,909 Reversals (5,306) (6,175) (14,861) (26,342) Balances as of December 31, 2022 22,484 24,664 148,706 195,854 * The amount of R$ 4,232 (i) During the year ended December 31, 2022, R$ 48,333 The principal labor proceedings to which we are a party were filed by former employees or service providers seeking enforcement of labor rights allegedly not provided by us. The judicial proceedings relate to employment bonds (judicial proceedings filed by former service providers), overtime, premiums for hazardous workplace conditions, statutory severance, fines for severance payment delays, and compensation for workplace-related accidents. The civil claims to which we are a party generally relate to consumer claims, including those related to student complaints. The tax claims to which the Company is party are mostly tax foreclosures filed by Brazilian federal and municipal tax authorities. There are other civil, labor, taxes and social security proceedings assessed by Management and its legal counsels as possible risk of loss, for which no provisions are recognized, as follows: Schedule of social security proceedings assessed by Management 2022 2021 Labor 13,914 5,098 Civil 59,603 56,501 Taxes and social security 4,931 4,459 Total 78,448 66,058 The Company has judicial deposits, related to taxes, civil and labor proceedings, recorded in other assets (non-current) in the amount of R$ 12,693 18,825 Under the terms of the Share Purchase and Sale Agreements ("Agreements") between the Company and the selling shareholders of certain subsidiaries acquired, the Company assesses that the selling shareholders are exclusively responsible for any provisions (including labor, tax and civil), which are or will be the subject of a claim by any third party, arising from the act or fact occurred, by action or omission, prior to or on the closing dates of the acquisitions. Accordingly, and considering that the provisions for legal proceedings recorded by the Company that result from causes arising from events occurring prior to the closing dates of the acquisitions, any liability for the amounts to be disbursed, in case of their effective materialization in loss, belongs exclusively to the selling shareholders. In this context, the Agreements state that the Company and its subsidiaries are indemnified and therefore exempt from any liability related to said contingent liabilities and, therefore, the provision amounts related to such contingencies are presented in the non-current liabilities and the correspondent amount of R$ 145,300 135,355

Non-cash transactions

Non-cash transactions	12 Months Ended
	Dec. 31, 2022
Non-cash Transactions
Non-cash transactions	24 Non-cash transactions During the years ended December 31, 2022, 2021 and 2020, the Company carried out non-cash transactions which are not reflected in the statement of cash flows. The main non-cash transactions are as follows: Schedule of non-cash transactions 2022 2021 2020 Issuance of shares for acquisition of Pebmed - - 17,531 Issuance of shares for acquisition of iClinic - 71,500 - Issuance of shares for acquisition of Cliquefarma - 3,000 - Issuance of shares for acquisition of RXPRO - 5,112 - Provision for legal proceedings with corresponding indemnification assets 48,333 4,232 9,940 Additions and remeasurements of right-of-use assets and lease liabilities 100,873 158,651 98,904

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent events	25 Subsequent events Acquisition of UNIT Alagoas and FITS Jaboatão dos Guararapes On January 2, 2023, Afya Brazil announced the closing of the acquisition of 100 The aggregate purchase price was R$ 825,000 575,000 250,000 150,000 50,000 50,000 There is a contingent payment related to 84 additional seats subject to approval. If the Ministry of Education approves those seats until December 31, 2024, it will result in a potential additional payment of R$ 1,250 The acquisition date fair value of each major class of consideration, including the allocation of the purchase price has not been completed by the Company as of the issuance date of these financial statements. Transaction costs to date amounted to R$ 11,860

Significant accounting polici_2

Significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Business combinations and goodwill	a) Business combinations and goodwill Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree. For each business combination, the Company elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets. Acquisition-related costs are expensed as incurred and included in general and administrative expenses. When the Company acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as of the acquisition date. Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed). If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, the Company re-assesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognized at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then the gain is recognized in the consolidated statement of income. After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company’s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquire are assigned to those units. Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.
Current versus non-current classification	b) Current versus non-current classification The Company presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is: · Expected to be realized or intended to be sold or consumed in the normal operating cycle; · Held primarily for the purpose of trading; · Expected to be realized within twelve months after the reporting period; or · Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current. A liability is current when: · It is expected to be settled in the normal operating cycle; · It is held primarily for the purpose of trading; · It is due to be settled within twelve months after the reporting period; or · There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The Company classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities.
Fair value measurement	c) Fair value measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: (i) in the principal market for the asset or liability; or (ii) in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: · Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities. · Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. · Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable. For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. At each reporting date, the Company analyzes the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Company’s accounting policies. For this analysis, the Company verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents. The Company also compares the change in the fair value of each asset and liability with relevant external sources to determine whether the change is reasonable. For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.
Financial instruments – initial recognition and measurement	d) Financial instruments – initial recognition and measurement A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. i) Financial assets Initial recognition and measurement The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Company’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, are measured at the transaction price determined under IFRS 15. In order for a financial asset to be classified and measured at amortized cost or fair value through OCI (Other Comprehensive Income), it needs to give rise to cash flows that are “solely payments of principal and interest (SPPI)” on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. The Company’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset. Subsequent measurement For purposes of subsequent measurement, financial assets are classified as: financial assets at amortized cost or financial assets at fair value through profit or loss. There are no financial assets designated as fair value through OCI. Financial assets at amortized cost The Company measures financial assets at amortized cost if both of the following conditions are met: • The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in the statement of income when the asset is derecognized, modified or impaired. Financial assets at fair value through profit or loss Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified and measured at fair value through profit or loss, irrespective of the business model. Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of income. This category includes derivative instruments. Derecognition A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company’s statement of financial position) when: • The rights to receive cash flows from the asset have expired; or • The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ‘pass-through’ arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay. Impairment of financial assets Further disclosures relating to impairment of financial assets are also provided in the following notes: • Significant accounting estimates and assumptions – Note 3 • Trade receivables – Note 7 The Company recognizes an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms. For trade receivables, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognizes an allowance for credit losses based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. The Company considers a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before considering any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows. ii) Financial liabilities Initial recognition and measurement Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company’s financial liabilities include trade payables, loans and financing, notes payable, lease liabilities, advances from costumers and accounts payable to selling shareholders. Subsequent measurement The measurement of financial liabilities depends on their classification, as described below: Financial liabilities at fair value through profit or loss Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes, when applicable, derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Gains or losses on liabilities held for trading are recognized in the statement of income. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. Loans and borrowings After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the statement of income when the liabilities are derecognized as well as through the EIR amortization process. Amortized cost is calculated by considering any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance expenses in the statement of income. Derecognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of income. Offsetting of financial instruments Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.
Cash and cash equivalents	e) Cash and cash equivalents Cash and cash equivalents in the statement of financial position comprise cash at banks and on hand, and short-term financial investments with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term financial investments, as they are considered an integral part of the Company’s cash management.
Restricted cash	f) Restricted cash Restricted cash in the statement of financial position comprise of financial investments in investment funds that serve as collateral for loan agreements and other commitments.
Inventories	g) Inventories Inventories are valued at the lower of cost and net realizable value. The costs of inventories are based on the average cost method and include costs incurred in the purchase of inventories and other costs incurred in bringing them to their current location and condition. Costs of purchased inventory are determined after deducting any discounts and recoverable taxes.
Property and equipment	h) Property and equipment Property and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Subsequent expenditures are capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows: Schedule of estimated useful lives of the assets Building 25 Machinery and equipment 10 Vehicles 4 Furniture and fixtures 10 IT equipment 5 Library books 10 Laboratories and clinics 10 Leasehold improvements 5 20 An item of property and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefit is expected from its use or disposal. Any gain or loss arising on the derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of income when the asset is derecognized. The residual values, useful lives and methods of depreciation of property and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.
Leases	i) Leases As from January 1, 2019, the determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the contract. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset (or assets) and the arrangement conveys a right to use the asset (or assets), even if that asset is (or those assets are) not explicitly specified in an arrangement. Company as a lessee The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of use assets are subject to impairment. Lease liabilities At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets The Company applies the short-term lease recognition exemption to its short-term leases of properties (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered of low value. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.
Intangible assets	j) Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles are not capitalized and the related expenditure is reflected in the statement of income in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in the statement of income in the expense category that is consistent with the function of the intangible assets. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. An intangible asset is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of income.
Impairment of non-financial assets	k) Impairment of non-financial assets The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset’s recoverable amount. An asset’s recoverable amount is the higher of an asset’s or CGU’s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are considered. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators. The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company’s CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years, considering the companies activities and maturation period of its graduate and undergraduate courses. A long-term growth rate is calculated and applied to project future cash flows after the last projected year. For impairment testing, goodwill acquired through business combinations and licenses with indefinite useful lives are allocated to their respective CGUs. The Company has defined each of its operating subsidiaries as a CGU, except for digital services segment, which combines subsidiaries of (i) “Content & Technology for medical education”; (ii) “Clinical Decision Software”; and (iii) “Practice Management Tools & Electronic Prescription”, where the subsidiaries were combined as one CGU following the business strategic pillars. Whenever applicable, impairment losses of continuing operations are recognized in the statement of income in expense categories consistent with the function of the impaired asset. For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset’s or CGU’s recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset’s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of income. Goodwill is tested for impairment annually as at December 31 and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognized. Impairment losses relating to goodwill cannot be reversed in future periods. Intangible assets with indefinite useful lives are tested for impairment annually as at December 31 at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.
Investments	l) Investments Investments in associates are initially recognized at consideration transferred and adjusted thereafter for the equity method, being increased or reduced from its interest in the investee's income after the acquisition date. An associate is an entity over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.
Accounts payable to selling shareholders	m) Accounts payable to selling shareholders These amounts represent liabilities related to the acquisitions made by the Company which are not yet due. Accounts payable to selling shareholders are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.
Provisions	n) Provisions Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of income, net of any reimbursement, when applicable.
Dividends payable	o) Dividends payable The Company recognizes a liability to pay a dividend when the distribution is authorized and the distribution is no longer at the discretion of the Company. The distribution is authorized when it is required to pay a minimum dividend of the net income for the year in accordance with the Brazilian Corporate Law (applicable for Afya Brazil) and the Company’s By-Laws or is approved by the shareholders. A corresponding amount is recognized directly in equity.
Labor and social obligations	p) Labor and social obligations Labor and social obligations are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.
Share-based payments	q) Share-based payments Certain key executives of the Company receive remuneration in the form of share-based payments, which includes Stock Options and Restricted Stock Units (“RSUs”), whereby the executives render services as consideration for equity instruments (equity-settled transactions). The expense of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. That expense is recognized in general and administrative expenses, together with a corresponding increase in equity, over the period in which the service and, where applicable, the performance conditions are fulfilled (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of income for a period represents the movement in cumulative expense recognized as at the beginning and end of that period. Service and non-market performance conditions are not considered when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Company’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions. No expense is recognized for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. Where awards include a market or non-vesting condition, the transactions are treated as vested irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied. When the terms of an equity-settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original vesting terms of the award are met. An additional expense, measured as at the date of modification, is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee. Where an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through the statement of income. The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.
Revenue from contracts with customers	r) Revenue from contracts with customers Revenue recognition transferred over time The Company's revenue consists primarily of tuition fees charged for medical courses. The Company also generates revenue from tuition fees for other undergraduate courses, student fees, certain education-related activities, digital education content and subscription of digital services. Revenues are recognized when services are rendered to the customer and the performance obligation is satisfied. Revenue from tuitions, digital education content and electronic medical records are recognized over time when services are rendered to the customer and the Company satisfies its performance obligation under the contract at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services. Revenues from tuitions are recognized net of scholarships and other discounts, refunds and taxes. Other revenues are recognized at a point in time when the service is rendered to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for the service. Other revenues are presented net of the corresponding discounts, returns and taxes. Revenue recognition transferred at point in time Revenue from sale of printed books, e-books, healthcare payments, online platforms and marketing for pharmaceutical industry are recognized at the point in time when control of the asset or services is transferred to the customer, generally on delivery of the goods at the customer’s location and permission to access the digital content. The Company considers whether there are other promises in the contract that are separate performance obligations to which a portion of the transaction price needs to be allocated. In determining the transaction price for the printed books and e-books, the Company considers the effects of variable consideration, financing component, noncash consideration, and consideration payable to the customer to be not significant. The Company has concluded that it is the principal in its revenue arrangements. The Company assesses collectability on a portfolio basis prior to recording revenue. Generally, students cannot re-enroll for the next academic session without satisfactory resolution of any past-due amounts. If a student withdraws from an institution, the Company's obligation to issue a refund depends on the refund policy at that institution and the timing of the student's withdrawal. Generally, the refund obligations are reduced over the course of the academic term. Trade receivables Trade receivables represent the Company’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in Financial instruments – initial recognition and subsequent measurement. Advances from customers Advances from customers (a contract liability) are the obligation to transfer services to a customer for which the Company has received consideration (or an amount of consideration is due) from the customer, as a result of pre-paid tuition, digital education content and mobile app subscription for digital medical content received from customers and is recognized separately in current liabilities, when the payment is received. Advances from customers are recognized as revenue when the Company performs all obligations related to the contract, generally in the following month.
Taxes	s) Taxes The Company’s subsidiaries in the undergrad segment joined the PROUNI ( Programa Universidade para Todos – • Income taxes and social contribution • PIS and COFINS The regulation of PROUNI defines that the revenue from traditional and technological graduation activities is exempt from PIS and COFINS. For income from other teaching activities, PIS and COFINS are charged at rates of 0.65 3.00 1.65 7.6 Current income taxes Current income taxes were calculated based on the criteria established by the Normative Instruction of the Brazilian Internal Revenue Service, specifically regarding the PROUNI program, which allows exemption of these taxes from traditional and technological graduation activities. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.
Treasury shares	t) Treasury shares Own equity instruments that are reacquired (treasury shares) are recognized at cost and deducted from equity. No gain or loss is recognized in profit or loss on the purchase, sale, issue or cancellation of the Company’s own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognized in the share premium. 2.4 Changes in accounting policies and disclosures New standards, interpretations and amendments adopted by the Company The following amendments apply for the first time in 2022, but there are no significant impacts on the financial statements of the Company: Schedule of changes in accounting policies and disclosures Amendments / standards Description Period First adopted Impact Onerous Contracts – Costs of Fulfilling a Contract – Amendments to IAS 37 Specify that when assessing whether a contract is onerous or loss-making, an entity needs to include costs that relate directly to a contract to provide goods or services including both incremental costs (e.g., the costs of direct labour and materials) and an allocation of costs directly related to contract activities (e.g., depreciation of equipment used to fulfil the contract and costs of contract management and supervision). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. 1 January 2022 These amendments have no significant impact on the Company’s consolidated financial statements. Reference to the Conceptual Framework – Amendments to IFRS 3 The amendments add an exception to the recognition principle of IFRS 3 Business Combinations to avoid the issue of potential ‘day 2’ gains or losses arising for liabilities and contingent liabilities that would be within the scope of IAS 37 Provisions, Contingent Liabilities and Contingent Assets or IFRIC 21 Levies, if incurred separately. The exception requires entities to apply the criteria in IAS 37 or IFRIC 21, respectively, instead of the Conceptual Framework, to determine whether a present obligation exists at the acquisition date. The amendments also add a new paragraph to IFRS 3 to clarify that contingent assets do not qualify for recognition at the acquisition date. 1 January 2022 These amendments had no impact on the Company’s consolidated financial statements. Property, Plant and Equipment: Proceeds before Intended Use – Amendments to IAS 16 Leases The amendment prohibits entities from deducting from the cost of an item of property, plant and equipment, any proceeds of the sale of items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling such items, and the costs of producing those items, in profit or loss. 1 January 2022 These amendments had no impact on the Company’s consolidated financial statements. The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company’s financial statements are presented below. The Group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. Amendments / standards Description Period First adopted Impact Amendments to IAS 1: Classification of Liabilities as Current or Non-current The amendments clarify: i) what is meant by a right to defer settlement; ii) that a right to defer must exist at the end of the reporting period; iii) that classification is unaffected by the likelihood that an entity will exercise its deferral right; iv) that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification The amendments must be applied retrospectively. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements. Definition of Accounting Estimates - Amendments to IAS 8 The IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates’. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments when effective apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements. Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 The IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their ‘significant’ accounting policies with a requirement to disclose their ‘material’ accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. Since the amendments to the Practice Statement 2 provide non-mandatory guidance on the application of the definition of material to accounting policy information, an effective date for these amendments is not necessary. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements. Deferred Tax related to Assets and Liabilities arising from a Single Transaction - Amendments to IAS 12 The Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognised for all deductible and taxable temporary differences associated with leases and decommissioning obligations. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements.

Significant accounting polici_3

Significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Schedule of Company’s subsidiaries and associate	Schedule of Company’s subsidiaries and associate Direct and indirect interest Name Principal activities Location Investment type December 31, 2022 December 31, 2021 Afya Participações S.A. (“Afya Brazil”) Holding Nova Lima - MG Subsidiary 100 100 Instituto Tocantinense Presidente Antônio Carlos Porto S.A. – (“ITPAC Porto”) Undergraduate degree programs Porto Nacional - TO Subsidiary 100 100 Instituto Tocantinense Presidente Antônio Carlos S.A. – (“ITPAC Araguaina”) Undergraduate degree programs Araguaína - TO Subsidiary 100 100 União Educacional do Vale do Aço S.A. – (“UNIVAÇO”) Medicine undergraduate degree program Ipatinga - MG Subsidiary 100 100 IPTAN - Instituto de Ensino Superior Presidente Tancredo de Almeida Neves S.A. (“IPTAN”) Undergraduate degree programs São João Del Rei - MG Subsidiary 100 100 Instituto de Educação Superior do Vale do Parnaíba S.A. (“IESVAP”) Undergraduate degree programs Parnaíba - PI Subsidiary 80 80 Centro de Ciências em Saúde de Itajubá S.A. (“CCSI”) Medicine undergraduate degree program Itajubá - MG Subsidiary 60 60 Instituto de Ensino Superior do Piauí S.A. (”IESP”) Undergraduate and graduate degree programs Teresina - PI Subsidiary 100 100 Centro Integrado de Saúde de Teresina (“CIS”) Outpatient care Teresina - PI Subsidiary 100 100 FADEP - Faculdade Educacional de Pato Branco Ltda. (“FADEP”) Undergraduate degree programs Pato Branco - PR Subsidiary 100 100 Medcel Editora e Eventos S.A. (“Medcel”) Medical education content São Paulo - SP Subsidiary 100 100 Instituto Educacional Santo Agostinho S.A. (“FASA”) Undergraduate degree programs Montes Claros - MG Subsidiary 100 100 ESMC Educação Superior Ltda. (“ESMC”) Undergraduate degree programs Montes Claros - MG Subsidiary 100 100 Instituto de Pesquisa e Ensino Médico do Estado de Minas Gerais Ltda. (“IPEMED”) Graduate Belo Horizonte - MG Subsidiary 100 100 Instituto Paraense de Educação e Cultura Ltda (“IPEC”) Medicine degree programs Marabá - PA Subsidiary 100 100 Sociedade Universitária Redentor S.A. (“UniRedentor”) Undergraduate and graduate degree programs Itaperuna - RJ Subsidiary 100 100 Centro Universitário São Lucas Ltda. (“UniSL”) Undergraduate degree programs Porto Velho - RO Subsidiary 100 100 Peb Med Instituição de Pesquisa Médica e Serviços Ltda (“PebMed”) Content and clinical tools and online platform Rio de Janeiro - RJ Subsidiary 100 100 Faculdade de Ensino Superior da Amazônia Reunida – (“FESAR”) Undergraduate degree programs Redenção – PA Subsidiary 100 100 Centro Superior de Ciências da Saúde S/S Ltda. (“FCMPB”) Medicine degree programs João Pessoa – PB Subsidiary 100 100 MedPhone Tecnologia em Saúde Ltda. (“MedPhone”) Content and clinical tools and online platform Recife – PE Subsidiary - 100 iClinic Desenvolvimento de Software Ltda (“iClinic”) Electronic Medical Record, Clinical Management System Ribeirão Preto - SP Subsidiary 100 100 Medicinae Solutions S.A. (“Medicinae”) Healthcare payments and financial services Rio de Janeiro – RJ Subsidiary 100 100 Medical Harbour Aparelhos Médico Hospitalares e Serviços em Tecnologia Ltda. (“Medical Harbour”) Educational health and medical imaging Florianópolis – SC Subsidiary 100 100 Cliquefarma Drogarias Online Ltda.(“Cliquefarma”) Online platform São Paulo – SP Subsidiary 100 100 Shosp Tecnologia da Informação Ltda. (“Shosp”) Electronic Medical Record, Clinical Management System Rio de Janeiro – RJ Subsidiary 100 100 Sociedade Padrão de Educação Superior Ltda. (“UnifipMoc”) Undergraduate degree programs Montes Claros - MG Subsidiary 100 100 Nucleo de Atenção à Saúde e de Práticas Profissionalizantes (“NASPP) Outpatient care Montes Claros - MG Subsidiary 100 100 Companhia Nilza Cordeiro Herdy de Educação e Cultura. (“Unigranrio”) Undergraduate and graduate degree programs Duque de Caxias - RJ Subsidiary 100 100 Policlínica e Centro de Estética Duque de Caxias Ltda. (“Policlínica”) Outpatient care Duque de Caxias - RJ Subsidiary 100 100 Sociedade Educacional de Palhoça S/A Ltda. (“SOCIESP”) Basic Education Palhoça - SC Subsidiary 100 100 Instituto de Ensino Superior de Palhoça S/S Ltda. (“IESP PALHOÇA”) Undergraduate degree programs Palhoça - SC Subsidiary 100 100 RX PRO Soluções de Tecnologia Ltda. (“RX PRO”) Marketing for pharmaceutical industry São Paulo – SP Subsidiary 100 100 RX PRO LOG Transporte e Logística Ltda. (“RX PRO LOG”) Marketing for pharmaceutical industry São Paulo – SP Subsidiary 100 100 BMV Atividades Médicas Ltda. (“Além da Medicina”) Medical education content São Paulo – SP Subsidiary 100 - Cardiopapers Soluções Digitais Ltda (“CardioPapers”) Medical education content Recife – PE Subsidiary 100 - Quasar Telemedicina Desenvolvimento de Sistemas Computacionais Ltda. (“Glic”) Patient physician relationship Barueri – SP Subsidiary 100 - União Educacional do Planalto Central S.A. (“UEPC”) Undergraduate degree programs Brasília - DF Associate 30 30 * See Note 5 for further details of the business combinations during 2022. ** Medphone was merged by Afya Participações in October 2022.
Schedule of estimated useful lives of the assets	Schedule of estimated useful lives of the assets Building 25 Machinery and equipment 10 Vehicles 4 Furniture and fixtures 10 IT equipment 5 Library books 10 Laboratories and clinics 10 Leasehold improvements 5 20
Schedule of changes in accounting policies and disclosures	Schedule of changes in accounting policies and disclosures Amendments / standards Description Period First adopted Impact Onerous Contracts – Costs of Fulfilling a Contract – Amendments to IAS 37 Specify that when assessing whether a contract is onerous or loss-making, an entity needs to include costs that relate directly to a contract to provide goods or services including both incremental costs (e.g., the costs of direct labour and materials) and an allocation of costs directly related to contract activities (e.g., depreciation of equipment used to fulfil the contract and costs of contract management and supervision). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. 1 January 2022 These amendments have no significant impact on the Company’s consolidated financial statements. Reference to the Conceptual Framework – Amendments to IFRS 3 The amendments add an exception to the recognition principle of IFRS 3 Business Combinations to avoid the issue of potential ‘day 2’ gains or losses arising for liabilities and contingent liabilities that would be within the scope of IAS 37 Provisions, Contingent Liabilities and Contingent Assets or IFRIC 21 Levies, if incurred separately. The exception requires entities to apply the criteria in IAS 37 or IFRIC 21, respectively, instead of the Conceptual Framework, to determine whether a present obligation exists at the acquisition date. The amendments also add a new paragraph to IFRS 3 to clarify that contingent assets do not qualify for recognition at the acquisition date. 1 January 2022 These amendments had no impact on the Company’s consolidated financial statements. Property, Plant and Equipment: Proceeds before Intended Use – Amendments to IAS 16 Leases The amendment prohibits entities from deducting from the cost of an item of property, plant and equipment, any proceeds of the sale of items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling such items, and the costs of producing those items, in profit or loss. 1 January 2022 These amendments had no impact on the Company’s consolidated financial statements. The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company’s financial statements are presented below. The Group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. Amendments / standards Description Period First adopted Impact Amendments to IAS 1: Classification of Liabilities as Current or Non-current The amendments clarify: i) what is meant by a right to defer settlement; ii) that a right to defer must exist at the end of the reporting period; iii) that classification is unaffected by the likelihood that an entity will exercise its deferral right; iv) that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification The amendments must be applied retrospectively. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements. Definition of Accounting Estimates - Amendments to IAS 8 The IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates’. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments when effective apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements. Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2 The IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their ‘significant’ accounting policies with a requirement to disclose their ‘material’ accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. Since the amendments to the Practice Statement 2 provide non-mandatory guidance on the application of the definition of material to accounting policy information, an effective date for these amendments is not necessary. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements. Deferred Tax related to Assets and Liabilities arising from a Single Transaction - Amendments to IAS 12 The Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognised for all deductible and taxable temporary differences associated with leases and decommissioning obligations. 1 January 2023 These amendments are not expected to have a significant impact on the Company’s financial statements.

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Information
Schedule of assets and liabilities information for the company's operating segments	Schedule of assets and liabilities information for the company's operating segments Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2022 Total assets 6,775,829 149,254 275,564 7,200,647 (1,108) 7,199,539 Current assets 1,461,802 61,673 115,290 1,638,765 (1,108) 1,637,657 Non-current assets 5,314,027 87,581 160,274 5,561,882 - 5,561,882 Total liabilities and equity 6,775,829 149,254 275,564 7,200,647 (1,108) 7,199,539 Current liabilities 711,896 57,605 137,296 906,797 (1,108) 905,689 Non-current liabilities 2,938,960 63,990 40,742 3,043,692 - 3,043,692 Equity 3,124,973 27,659 97,526 3,250,158 - 3,250,158 Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2022 Other disclosures Investments in associate 53,907 - - 53,907 - 53,907 Capital expenditures (*) 247,634 8,827 61,694 318,155 - 318,155 (*) Some of the capital expenditures are considered non-cash transactions (refer to note 24). Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2021 Total assets 6,072,135 105,629 272,122 6,449,886 (2,480) 6,447,406 Current assets 1,048,869 42,737 117,726 1,209,332 (2,480) 1,206,852 Non-current assets 5,023,266 62,892 154,396 5,240,554 - 5,240,554 Total liabilities and equity 6,072,135 105,629 272,122 6,449,886 (2,480) 6,447,406 Current liabilities 645,657 32,300 91,029 768,986 (2,480) 766,506 Non-current liabilities 2,551,175 47,705 82,002 2,680,882 - 2,680,882 Equity 2,875,303 25,624 99,091 3,000,018 - 3,000,018 Undergrad Continuing Education Digital Services Total reportable segments Adjustments and eliminations Total As of December 31, 2021 Other disclosures Investments in associate 48,477 - - 48,477 - 48,477 As of December 31, 2021 Capital expenditures (*) 220,202 25,682 56,095 301,979 - 301,979 (*) Some of the capital expenditures are considered non-cash transactions (refer to note 24).
Schedule of operating income for each operating segment	Schedule of operating income for each operating segment December 31, 2022 Undergrad Continuing Education Digital Services Total reportable segments Elimination (inter-segment transactions) Total External customer 2,037,889 108,806 182,362 2,329,057 - 2,329,057 Inter-segment - - 7,622 7,622 (7,622) - Revenue 2,037,889 108,806 189,984 2,336,679 (7,622) 2,329,057 Cost of services (763,185) (56,554) (47,435) (867,174) 7,622 (859,552) Gross profit 1,274,704 52,252 142,549 1,469,505 - 1,469,505 General and administrative expenses (798,153) Other expenses, net (7,252) Operating income 664,100 Finance income 102,042 Finance expenses (349,893) Share of income of associate 12,184 Income before income taxes 428,433 Income taxes expenses (35,677) Net income 392,756 December 31, 2021 Undergrad Continuing Education Digital Services Total reportable segments Elimination (inter-segment transactions) Total External customer 1,498,408 72,983 147,980 1,719,371 - 1,719,371 Inter-segment - - 3,978 3,978 (3,978) - Revenue 1,498,408 72,983 151,958 1,723,349 (3,978) 1,719,371 Cost of services (554,995) (50,773) (50,510) (656,278) 3,978 (652,300) Gross profit 943,413 22,210 101,448 1,067,071 - 1,067,071 General and administrative expenses - - - - - (622,615) Other expenses, net - - - - - (3,561) Operating income - - - - - 440,895 Finance income - - - - - 64,566 Finance expenses - - - - - (243,796) Share of income of associate - - - - - 11,797 Income before income taxes - - - - - 273,462 Income taxes expenses - - - - - (31,179) Net income - - - - - 242,283 December 31, 2020 Undergrad Continuing Education Digital Services Total reportable segments Elimination (inter-segment transactions) Total External customer 1,002,461 107,197 91,533 1,201,191 - 1,201,191 Inter-segment - - 1,619 1,619 (1,619) - Revenue 1,002,461 107,197 93,152 1,202,810 (1,619) 1,201,191 Cost of services (381,964) (40,000) (14,309) (436,273) 1,619 (434,654) Gross profit 620,497 67,197 78,843 766,537 - 766,537 General and administrative expenses - - - - - (402,855) Other expenses, net - - - - - (347) Operating income - - - - - 363,335 Finance income - - - - - 62,290 Finance expenses - - - - - (98,269) Share of income of associate - - - - - 7,698 Income before income taxes - - - - - 335,054 Income taxes expenses - - - - - (27,067) Net income - - - - - 307,987

Business combinations (Tables)

Business combinations (Tables)	12 Months Ended
	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Schedule of fair values of the identifiable assets acquired and liabilities assumed	Schedule of fair values of the identifiable assets acquired and liabilities assumed Assets Além da Medicina CardioPapers Glic Cash and cash and equivalents 298 3,648 151 Trade receivables 1,705 1,350 94 Other assets 266 1 36 Property and equipment 37 43 - Intangible assets 20,299 28,655 15,395 22,605 33,697 15,676 Liabilities Trade payables 705 1,703 1 Labor and social obligations 79 60 - Taxes and contributions payable 1,182 352 91 Advances from customers 6,185 3,893 - Other liabilities - - 574 8,151 6,008 666 Total identifiable net assets at fair value 14,454 27,689 15,010 Goodwill arising on acquisition 12,335 14,324 15,587 Purchase consideration transferred 26,789 42,013 30,597 Cash paid 14,952 34,924 21,602 Contingent consideration 11,074 7,422 8,995 Consideration to be transferred (Price adjustment) 763 (333) - Analysis of cash flows on acquisition: Transaction costs of the acquisition (included in cash flows from operating activities) 227 274 222 Cash paid net of cash acquired with the subsidiary (included in cash flows from investing activities) 14,654 31,276 21,451 Net of cash flow on acquisition 14,881 31,550 21,673
Schedule of acquisition of glic	Schedule of acquisition of glic Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Schedule of preliminary fair values of the identifiable assets acquired and liabilities acquired	Schedule of preliminary fair values of the identifiable assets acquired and liabilities acquired Assets iClinic Medicinae Medical Harbour Cliquefarma Shosp Unifipmoc Unigranrio (i) RXPRO (ii) Cash and cash and equivalents 1,659 201 47 1,009 397 6,140 34,755 91 Restrict cash 6,050 - - - - - - - Trade receivables 1,201 - 159 501 - 34,309 26,622 1,211 Inventories - - - - - - 352 246 Recoverable taxes 72 15 - - 1 1,295 738 112 Other assets 20 - 2 - - 702 12,159 366 Right-of-use assets 88 - - - - 52,079 87,265 82 Property and equipment 473 17 34 - 5 24,277 40,775 42 Indemnification assets 1,252 - - - - 7,331 71,669 - Intangible assets 84,987 4,518 7,359 14,991 4,856 227,534 510,356 6,330 95,802 4,751 7,601 16,501 5,259 353,667 784,691 8,480 Liabilities Trade payables 619 - 6 8 1 985 6,197 1,060 Loans and financing - - 299 580 - 30,179 5,533 - Labor and social obligations 1,414 159 4 102 89 5,306 22,854 62 Taxes and contributions payable 77 4 1 307 123 758 94,025 100 Provision for legal proceedings 1,252 - - - - 7,331 71,669 - Leases liabilities 88 - - - - 52,079 87,265 82 Advances from customers 400 - 35 3 167 10,745 3,387 - Other liabilities - - - - - 5,739 4,878 - 3,850 163 345 1,000 380 113,122 295,808 1,304 Total identifiable net assets at fair value 91,952 4,588 7,256 15,501 4,879 240,545 488,883 7,176 Goodwill arising on acquisition 99,168 4,584 4,022 6,588 3,022 87,777 130,073 38,446 Purchase consideration transferred 191,120 9,172 11,278 22,089 7,901 328,322 618,956 45,622 Cash paid 119,620 5,600 5,000 16,166 5,855 328,322 375,670 30,263 Contingent consideration - 3,572 6,278 2,923 1,592 - - 10,171 Consideration to be transferred - - - - 454 - 243,286 76 Paid in shares 71,500 - - 3,000 - - - 5,112 Analysis of cash flows on acquisition: Transaction costs of the acquisition (included in cash flows from operating activities) 856 117 144 336 188 177 10,990 264 Cash paid net of cash acquired with the subsidiary (included in cash flows from investing activities) 117,961 5,399 4,953 15,157 5,458 322,182 340,915 30,172 Net of cash flow on acquisition 118,817 5,516 5,097 15,493 5,646 322,359 351,905 30,436 (*) There are 40 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$50,000. (**) There are 82 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$90,200.
Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Schedule Of Acquisition Of AlemDa Medicina	Schedule Of Acquisition Of AlemDa Medicina Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Educational content Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Cardio Paper [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition cardiopapers	Schedule of acquisition cardiopapers Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Educational content Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset. Copyrights Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
I Clinic [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of Uniredentor	Schedule of acquisition of Uniredentor Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Cliquefarma [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of UniSL	Schedule of acquisition of UniSL Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Schedule of acquisition of FESAR	Schedule of acquisition of FESAR Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Harbour [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of PEBMED	Schedule of acquisition of PEBMED Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
P E B M E D [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of Medphone	Schedule of acquisition of Medphone Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
U N I F I P Moc [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of FCMPB	Schedule of acquisition of FCMPB Intangible assets acquired Valuation technique Licenses With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
U N I G R A N R I O [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of Unigranrio	Schedule of acquisition of Unigranrio Intangible assets acquired Valuation technique Licenses With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
P X P R O [Member]
IfrsStatementLineItems [Line Items]
Schedule of acquisition of RXPRO	Schedule of acquisition of RXPRO Intangible assets acquired Valuation technique Trademark Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value. Customer relationships Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets. Developed technology intangible assets Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2022
Cash and cash equivalents [abstract]
Schedule of cash and cash equivalents	Schedule of cash and cash equivalents 2022 2021 Cash and bank deposits 57,509 88,487 Cash equivalents 1,035,573 660,075 Cash and cash equivalents 1,093,082 748,562

Trade receivables (Tables)

Trade receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Trade Receivables
Schedule of trade accounts receivable	Schedule of trade accounts receivable 2022 2021 Tuition fees 356,074 279,915 Educational content (a) 50,913 69,227 FIES 62,325 61,342 Educational credits (b) 27,535 5,375 Mobile app subscription (c) 27,675 20,946 Others 14,923 14,001 539,445 450,806 (-) Allowance for doubtful accounts (44,046) (45,013) 495,399 405,793 Current 452,831 378,351 Non-current 42,568 27,442 (a) Related to trade receivables from sales of printed books, e-books and medical courses through digital platform from Medcel, Além da Medicina and CardioPapers. (b) Related to trade receivables from special financing programs and balances outstanding from previous acquisitions. (c) Related to trade receivables from mobile applications subscriptions for digital medical content.
Schedule of aging of trade accounts receivable	Schedule of aging of trade accounts receivable 2022 2021 Neither past due nor impaired 261,025 184,382 Past due 1 to 30 days 56,280 68,932 31 to 90 days 90,734 69,299 91 to 180 days 80,522 55,764 More than 180 days 50,884 72,429 539,445 450,806
Schedule of allowance for doubtful accounts	Schedule of allowance for doubtful accounts 2022 2021 2020 Balances at the beginning of the period (45,013) (32,980) (14,763) Additions (42,708) (47,819) (32,081) Write-offs 43,675 35,786 13,864 Balances at the end of the period (44,046) (45,013) (32,980)

Related parties (Tables)

Related parties (Tables)	12 Months Ended
	Dec. 31, 2022
Related Parties
Schedule of balances and transactions with related parties	Schedule of balances and transactions with related parties 2022 2021 Assets Trade receivables (a) 917 692 Other assets (b) 1,975 - Total 2,892 692 Current 2,892 692 Non-current - - Liabilities Accounts payable to selling shareholders (c) 30,653 54,556 Total 30,653 54,556 Current 30,653 27,278 Non-current - 27,278 2022 2021 2020 Other income UEPC (a) 477 752 104 477 752 104 Lease RVL Esteves Gestão Imobiliária S.A. 20,394 15,336 11,288 UNIVAÇO Patrimonial Ltda. 3,409 3,210 2,915 IESVAP Patrimonial Ltda. 4,920 4,560 3,470 28,723 23,106 17,673 (a) Refers to sales of educational content from Medcel to UEPC; (b) Refers to amounts to be reimbursed from Bertelsmann SE& Co. KGaA regarding the transaction on which the control of Afya was acquired; (c) Refers to amounts to be payable to our shareholder Nicolau Carvalho Esteves regarding the agreement to which Afya Brazil acquired the right to develop ITPAC Garanhuns medical school, a greenfield unit. The amount represents 50% of the transaction, due in two equal annual installments, adjusted by the CDI rate.
Schedule of key management personnel compensation included in the Company’s consolidated statement of income	Schedule of key management personnel compensation included in the Company’s consolidated statement of income 2022 2021 2020 Short-term employee benefits 13,564 11,933 9,629 Share-based compensation plan 13,116 20,251 23,989 26,680 32,184 33,618

Other assets (Tables)

Other assets (Tables)	12 Months Ended
	Dec. 31, 2022
Other Assets
Schedule of Other Assets	Schedule of Other Assets 2022 2021 Indemnification assets (a) 145,300 135,355 Judicial deposits 12,693 18,825 Prepaid expenses 18,441 10,110 Other FIES receivables 26,440 21,450 Other 40,627 37,099 Total 243,501 222,839 Current 51,745 42,533 Non-current 191,756 180,306 (a) Under the terms of the Share Purchase and Sale Agreements ("Agreements") between the Company and the selling shareholders of certain subsidiaries acquired, the Company assesses that the selling shareholders are exclusively responsible for any provisions (including labor, tax and civil), which are or will be the subject of a claim by any third party, arising from the act or fact occurred, by action or omission, prior to or on the closing dates of the acquisitions.

Investment in associate (Tables

Investment in associate (Tables)	12 Months Ended
	Dec. 31, 2022
Investment In Associate
Schedule of investments	Schedule of investments 2022 2021 Current assets 32,651 33,976 Non-current assets 122,378 109,805 Current liabilities (22,840) (35,049) Non-current liabilities (96,442) (91,086) Equity 35,747 17,646 Company’s share in equity – 30% 10,724 5,294 Goodwill 43,183 43,183 Carrying amount of the investment 53,907 48,477 2022 2021 2020 Net revenue 138,584 127,618 113,965 Cost of services (57,421) (57,935) (55,926) General and administrative expenses (34,991) (24,025) (27,341) Finance results (4,103) (4,585) (4,882) Income before income taxesz 42,069 41,073 25,816 Income taxes expenses (1,456) (1,748) (252) Net income for the period 40,613 39,325 25,564 Company’s share of income for the period 12,184 11,797 7,698 2022 2021 2020 Opening balance 48,477 51,410 45,634 Dividends received (6,754) (11,770) - Dividends receivable (included in Other assets) - (2,960) (1,922) Share of income 12,184 11,797 7,698 Closing balance 53,907 48,477 51,410

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property And Equipment
Schedule of detailed information about property, plant and equipment	Schedule of detailed information about property, plant and equipment Cost Building Machinery and equipment Lands Vehicles Furniture and fixtures IT equipment Library books Laboratories and clinics Leasehold improvements Construction in progress Total As of January 1, 2020 - 44,329 7,005 707 21,438 15,994 18,139 1,049 30,911 36,731 176,303 Additions - 13,806 672 - 4,550 9,657 1,012 - 54,748 5,387 89,832 Business combinations 6,771 8,973 5,724 508 3,061 2,493 2,473 - 12,787 5,090 47,880 Transfer 19,148 1,395 - - 82 367 - (1,049) 23,559 (43,502) - As of December 31, 2020 25,919 68,503 13,401 1,215 29,131 28,511 21,624 - 122,005 3,706 314,015 Additions 1,384 10,268 5,451 111 21,075 19,511 3,392 - 4,720 59,957 125,869 Business combinations - 12,810 - 346 16,684 10,138 5,142 - 17,425 3,078 65,623 Write-off * 62 (14,213) - (205) 2,862 (4,985) (86) - (550) (417) (17,532) Transfer 25,068 3 - - 82 9 - - 9,376 (34,538) - As of December 31, 2021 52,433 77,371 18,852 1,467 69,834 53,184 30,072 - 152,976 31,786 487,975 Additions 527 36,486 - 968 26,047 15,766 645 - 2,667 85,026 168,132 Business combinations - 45 - - - 35 - - - - 80 Write-off * 13 (8,159) - (933) 500 (6,992) - - - (78) (15,649) Transfer 38,884 (5,353) - (449) (5,669) 6,600 6,645 - (9,797) (30,046) 815 As of December 31, 2022 91,857 100,390 18,852 1,053 90,712 68,593 37,362 - 145,846 86,688 641,353 Depreciation As of January 1, 2020 - (13,793) - (59) (5,890) (6,537) (8,663) (386) (1,655) - (36,983) Depreciation - (5,065) - (112) (2,199) (4,314) (2,154) (78) (2,729) - (16,651) Transfer - (464) - - - - - 464 - - - As of December 31, 2020 - (19,322) - (171) (8,089) (10,851) (10,817) - (4,384) - (53,634) Depreciation (1,673) (7,215) - (196) (5,601) (7,529) (3,416) - (4,831) - (30,461) Write-off * - 10,146 - 147 1,194 3,458 633 - 350 - 15,928 As of December 31, 2021 (1,673) (16,391) - (220) (12,496) (14,922) (13,600) - (8,865) - (68,167) Depreciation (3,472) (11,166) - (284) (7,725) (10,140) (3,415) - (8,849) - (45,051) Write-off * - 5,474 - 791 153 7,350 67 - 117 - 13,952 Transfer (606) 1,453 - 1 9,719 (4,125) (5,940) - (502) - - As of December 31, 2022 (5,751) (20,630) - 288 (10,349) (21,837) (22,888) - (18,099) - (99,266) Net book value As of December 31, 2022 86,106 79,760 18,852 1,341 80,363 46,756 14,474 - 127,747 86,688 542,087 As of December 31, 2021 50,760 60,980 18,852 1,247 57,338 38,262 16,472 - 144,111 31,786 419,808 * Refers to items written-off as result of lack of expectation of future use, in connection with the Company’s physical inventory procedures.

Intangible assets and goodwill

Intangible assets and goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible assets and goodwill [abstract]
Schedule of intangible assets	Schedule of intangible assets Goodwill Licenses with indefinite useful life (i) Trademark Customer relationships Software Education content Developed technology Educational platform Software in progress Other Total Cost As of January 1, 2020 459,409 703,772 32,111 125,413 9,389 17,305 - 12,191 2,050 - 1,361,640 Additions - - - - 4,175 - - 15,227 247 19,649 Disposals - - - - (460) - - - - (460) Business combinations 351,247 747,498 42,903 158,126 3,117 - 355 484 - 1,303,730 As of December 31, 2020 810,656 1,451,270 75,014 283,539 16,221 17,305 355 27,902 2,297 - 2,684,559 Additions (iv) - 108,000 - 684 3,044 - 996 39,686 23,700 - 176,110 Write-off * - - - - 1,020 - - (2,743) (417) - (2,140) Business combinations 373,680 606,136 58,355 147,054 1,474 - 33,046 11,599 3,267 - 1,234,611 As of December 31, 2021 1,184,336 2,165,406 133,369 431,277 21,759 17,305 34,397 76,444 28,847 - 4,093,140 Additions (ii) (i) 39,100 24,408 - 80 1,423 11,231 32,879 14,761 26,141 - 150,023 Write-off - - (22) - (381) (7) - (9) (28) - (447) Remeasurement (iii) (8,637) - - - - - - - - - (8,637) Transfer - - (2,472) 530 20,466 38,433 17,953 (35,499) (40,226) - (815) Business combinations 42,246 - 51,185 3,929 33 2,627 5,520 - - 1,055 106,595 As of December 31, 2022 1,257,045 2,189,814 182,060 435,816 43,300 69,589 90,749 55,697 14,734 1,055 4,339,859 Amortization As of January 1, 2020 - - (1,150) (37,872) (4,536) (4,876) - (868) - (49,302) Amortization - - (2,352) (47,960) (2,180) (2,816) (32) (7,367) - (62,707) Disposals - - - - 460 - - - - 460 As of December 31, 2020 - - (3,502) (85,832) (6,256) (7,692) (32) (8,235) - - (111,549) Amortization - - (5,027) (56,438) (5,844) (8,980) (625) (3,608) - - (80,522) Write-off - - - - (599) - - 365 - - (234) As of December 31, 2021 - - (8,529) (142,270) (12,699) (16,672) (657) (11,478) - - (192,305) Amortization - - (6,426) (70,093) (4,943) (9,634) (9,436) (5,874) - (79) (106,485) Write-off - - - - 365 57 - - - - 422 Transfer - - - - (313) - 313 - - - As of December 31, 2022 - - (14,955) (212,363) (17,277) (26,562) (10,093) (17,039) - (79) (298,368) Net book value As of December 31, 2022 1,257,045 2,189,814 167,105 223,453 26,023 43,027 80,656 38,658 14,734 976 4,041,491 As of December 31, 2021 1,184,336 2,165,406 124,840 289,007 9,060 633 33,740 64,966 28,847 - 3,900,835 * Refers to intangible assets written-off as result of lack of expectation of future use. (i) On March 18, 2022, Afya announced that MEC authorized the increase of 28 seats of Centro Universitário São Lucas, in Ji-Parana located in the state of Rondônia. The earn-out related to the seats approval is R$800 per seat, adjusted by the CDI rate from the closing until the payment date, of which 50% was paid in April 2022 and the remaining amount is payable in cash in two equal installments through 2024. (ii) During the measurement period, the goodwill for the acquisition of Unigranrio was adjusted by R$39,100 (R$130,073 initial goodwill) as a result of an increase of liabilities regarding tax contingencies. (iii) During the measurement period, R$8,637 of goodwill (R$38,446 initial goodwill) arising from the acquisition of RXPRO was reduced, in connection with management’s view of remote likelihood of RXPRO achieving the revenue goals stablished at the terms of the earn-out. (iv) On November 05, 2021 Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") authorized the operation of 120 medical school seats in Garanhuns, for which our shareholder Nicolau Carvalho Esteves entered into an agreement with Afya Brazil pursuant to which he assigned to Afya Brazil the right to develop the ITPAC Garanhuns greenfield unit, a medical school in the city of Garanhuns, State of Pernambuco. Management assessed the aspects of such transaction and concluded that the transaction does not fall under the definition of business, but an acquisition of license with indefinite useful life recognized in intangible assets. Total purchase price was R$108,000 of which 50% was paid in cash on the transaction closing date and 50% in two equal annual installments, adjusted by the CDI rate.
Schedule of assumptions for impairment test	Schedule of assumptions for impairment test Carrying amount CGU Goodwill Licenses with indefinite useful life CGU 2022 2021 2022 2021 2022 2021 IPTAN 17,446 17,446 57,214 57,214 126,024 140,522 IESVAP 27,956 27,956 81,366 81,366 129,305 112,260 CCSI 4,664 4,664 56,737 56,737 53,540 49,030 IESP 73,838 73,838 179,693 179,693 322,968 346,286 FADEP 49,661 49,661 70,606 70,606 153,100 153,791 FASA 58,903 58,903 144,507 144,507 314,967 302,330 IPEMED 87,647 87,647 - - 192,079 126,965 IPEC - - 108,000 108,000 148,067 131,360 UniRedentor 77,662 77,662 121,477 121,477 242,600 246,320 UniSL* 4,420 4,420 273,795 249,387 398,492 305,044 FESAR 71,664 71,664 141,616 141,616 244,084 279,038 FCMPB 110,483 110,483 235,018 235,018 415,453 401,244 ITPAC Garanhuns - - 108,000 108,000 112,628 107,232 Medical Harbour - 4,022 - - - 9,150 Content & Technology for medical education (Pillar 1) 169,975 139,294 - - 279,684 235,300 Practice Management Tools & Electronic Prescription (Pillar 3) 106,774 113,362 - - 216,297 227,909 Clinical Decision Software (Pillar 2) 87,018 87,018 - - 153,526 147,592 Cliquefarma 6,588 - - - 20,045 - Moc 87,777 87,777 190,247 190,247 369,007 356,789 Unigranrio 169,173 130,073 421,538 421,538 854,861 630,185 RXPRO* 29,809 38,446 - - 36,675 46,788 Glic 15,587 - - - 31,022 - Total 1,257,045 1,184,336 2,189,814 2,165,406 4,814,424 4,355,135 * See Note 12 for further details on goodwill changes between 2021 and 2022.
Schedule of estimated useful lives of intangible assets	Schedule of estimated useful lives of intangible assets Customer relationships – medicine 6 Customer relationships – other courses 4.5 Software license 5 Education content 3 Trademarks 2 30 Developed technology 5

Financial assets and financia_2

Financial assets and financial liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Assets And Financial Liabilities
Schedule of financial assets	Schedule of financial assets Financial assets 2022 2021 At amortized cost Trade receivables 495,399 405,793 Total 495,399 405,793 Current 452,831 378,351 Non-current 42,568 27,442
Schedule of financial liabilities	Schedule of financial liabilities Financial liabilities 2022 2021 At amortized cost Trade payables 71,482 59,098 Loans and financing 1,882,901 1,374,876 Lease liabilities 769,525 714,085 Accounts payable to selling shareholders 528,678 679,826 Notes payable 62,176 72,726 Advances from customers 133,050 114,585 Total 3,447,812 3,015,196 Current 706,080 581,685 Non-current 2,741,732 2,433,511
Schedule of loans and financing	Schedule of loans and financing Financial institution Currency Interest rate Maturity 2022 2021 Banco Itaú Unibanco S.A. (a) Brazilian real CDI + 1.90% p.y. 2025 518,134 510,972 FINEP (b) Brazilian real TJLP p.y. 2027 8,418 10,145 Banco Itaú Unibanco S.A. (c) Brazilian real CDI + 1.75% p.y. 2024 32,252 31,199 Softbank (d) Brazilian real 6.5% p.y. 2026 824,258 822,560 Debentures (e) Brazilian real CDI + 1.80 p.y. 2028 499,839 - 1,882,901 1,374,876 Current 145,202 128,720 Non-current 1,737,699 1,246,156 (a) On October 1, 2020, Afya Brazil entered into a loan with Banco Itaú Unibanco S.A. in the amount of R$ 500,000 1.62 On September 28, 2022 Afya signed an amendment with Banco Itau Unibanco S.A in order to extend its debt profile, postponing the original repayments dates from 2022 and 2023 to 2023, 2024 and 2025. Due to such extension, the spread over CDI rate increased from 1.62 1.90 (b) On July 23, 2019, Medcel entered into a loan of R$ 16,153 6,734 4,130 (c) On October 28, 2020, UNIFIPmoc entered into a loan with Banco Itaú Unibanco S.A. in the amount of R$ 30,000 1.75 (d) On April 26, 2021, the Company issued and sold 150,000 0.00005 150,000 821,805
Schedule of right-of-use assets and lease liabilities	Schedule of right-of-use assets and lease liabilities Right-of-use assets Lease liabilities As of January 1, 2021 419,074 447,703 Additions 62,689 62,689 Remeasurement 95,962 95,962 Business combinations 139,514 139,514 Depreciation expense (43,237) - Interest expense - 67,212 Payments of lease liabilities - (87,751) Write-off (10,316) (11,244) As of December 31, 2021 663,686 714,085 Additions 42,250 42,250 Remeasurement 58,623 58,623 Depreciation expense (54,684) - Interest expense - 88,571 Payments of lease liabilities - (113,512) Write-off (a) (19,802) (20,492) As of December 31, 2022 690,073 769,525 As of December 31, 2021 Current - 24,955 Non-current 663,686 689,130 As of December 31, 2022 Current - 32,459 Non-current 690,073 737,066 (a) Refers to anticipated termination of real estate leasing contracts.
Schedule of accounts payable to selling shareholders	Schedule of accounts payable to selling shareholders 2022 2021 Acquisition of FASA (a) - 41,581 Acquisition of IPEMED (b) 22,654 30,233 Acquisition of UniRedentor (c) 72,064 85,506 Acquisition of UniSãoLucas (d) 37,301 42,672 Acquisition of FCMPB (e) 111,755 149,175 Acquisition of Medicinae (f) - 3,887 Acquisition of Medical Harbour (g) 4,053 6,801 Acquisition of Cliquefarma (h) - 3,050 Acquisition of Shosp (i) 2,206 2,141 Acquisition of Unigranrio (j) 216,716 249,979 Acquisition of RXPRO (k) 1,781 10,245 Acquisition of Guaranhuns (l) 30,653 54,556 Acquisition of Além da Medicina (m) 11,996 - Acquisition of CardioPapers (n) 7,979 - Acquisition of Glic (o) 9,520 - 528,678 679,826 Current 261,711 239,849 Non-current 266,967 439,977 2022 2021 2020 Opening balance 679,826 518,240 300,237 Cash flows (i) (261,188) (192,681) (134,518) Acquisition of licenses (ii) 24,408 54,000 - Interest 68,064 31,915 13,884 Reversals (iii) (10,353) - - Consideration to be transferred on business combinations - 243,816 343,140 Consideration to be transferred on business combinations (Earn-outs) 27,921 24,536 - Compensation of legal proceedings disbursement - - (4,503) Closing balance 528,678 679,826 518,240 (i) R$ 30,174 (ii) R$ 8,637 1,716 (a) On April 3, 2019, Afya Brazil acquired 90 39,695 29,770 29,770 (b) On May 9, 2019, Afya Brazil acquired 100 45,303 9,061 (c) On January 31, 2020, Afya Brazil acquired 100 100,000 4,503 (d) On May 5, 2020, Afya Brazil acquired 100 60,456 7,816 (e) On November 9, 2020, Afya Brazil acquired 100 188,894 (f) On March 25, 2021, Afya Brazil acquired 100 4,400 1,716 (g) On April 8, 2021, Afya Brazil acquired 100 9,000 4,053 (h) On April 16, 2021, Afya Brazil acquired 100 3,000 (i) On May 13, 2021, Afya Brazil acquired 100 454 1,793 2,206 (j) On August 4, 2021, Afya Brazil acquired 100 618,956 (k) On October 01, 2021, Afya Brazil acquired 100 21,000 1,781 (l) On November 05, 2021, Afya Brazil concluded the acquisition of 100 54,000 54,000 (m) On March 4, 2022, Afya Brazil acquired 100 19,200 11,074 763 (n) On April 5, 2022 100 15,000 7,422 333 (o) On March 23, 2022, Afya Brazil acquired 100 12,000 8,995
Schedule of carrying amount of notes payable and the movements	Schedule of carrying amount of notes payable and the movements Notes payable As of January 1, 2021 76,181 Payments (*) (11,068) Monetary indexation 7,613 As of December 31, 2021 72,726 Payments (*) (15,008) Monetary indexation 4,458 As of December 31, 2022 62,176 As of December 31, 2021 Current liabilities 14,478 Non-current liabilities 58,248 As of December 31, 2022 Current liabilities 62,176 Non-current liabilities - (*) The amounts have been included on the investing activities of the cash flow statement.
Schedule of fair values of Company’s financial instruments	Schedule of fair values of Company’s financial instruments 2022 2021 Carrying amount Fair value Carrying amount Fair value Financial assets Trade receivables (non-current) 42,568 42,568 27,442 27,442 Total 42,568 42,568 27,442 27,442 Financial liabilities Loans and financing 1,882,901 1,934,295 1,374,876 1,387,136 Lease liabilities 769,525 769,525 714,085 714,085 Accounts payable to selling shareholders 528,678 528,678 679,826 679,826 Notes payable 62,176 62,176 72,726 72,726 Total 3,243,280 3,294,674 2,841,513 2,853,773
Schedule of sensitivity analysis effects on income statement	Schedule of sensitivity analysis effects on income statement 2022 Index – % per year Base rate Cash equivalents 1,011,126 99.21% of CDI 136,928 Debentures (499,839) CDI + 1.80% (77,225) Loans and financing (518,134) CDI + 1.90% (80,570) Loans and financing (32,252) CDI + 1.75% (4,966) Loans and financing (8,418) TJLP (620) Accounts payable to selling shareholders (491,143) CDI (67,041) Notes payable (62,176) IPCA (3,600) Net exposure (97,094) Increase in basis points +75 +150 Effect on profit before tax (4,504) (9,010) 2021 Index – % per year Base rate Cash equivalents 636,847 100.38% CDI 5,844 Loans and financing (510,972) CDI + 1,62% (55,032) Loans and financing (31,199) CDI + 1,75% (3,401) Loans and financing (10,145) TJLP (617) Accounts payable to selling shareholders (612,121) CDI (56,009) Accounts payable to selling shareholders (41,581) IPCA + 4,1% (1,708) Notes payable (72,726) IPCA (531) Net exposure (111,454) Increase in basis points +75 +150 Effect on profit before tax (4,814) (9,628)
Schedule of currencies used in sensitivity analysis	Schedule of currencies used in sensitivity analysis Exposure +10% -10% As of December 31, 2022 Cash equivalents 24,447 2,445 (2,445)
Schedule of maturity profile of financial liabilities	Schedule of maturity profile of financial liabilities As of December 31, 2022 Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Total Trade payables 71,482 - - - 71,482 Loans and financing 287,741 788,190 1,237,599 - 2,313,530 Lease liabilities 117,506 234,688 219,127 1,139,771 1,711,092 Accounts payable to selling shareholders 282,481 339,281 - - 621,762 Notes payable 62,176 - - - 62,176 Advances from customers 133,050 - - - 133,050 954,436 1,362,159 1,456,726 1,139,771 4,913,092 As of December 31, 2021 Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Total Trade payables 59,098 - - - 59,098 Loans and financing 217,903 585,686 948,503 1,212 1,753,304 Lease liabilities 103,003 211,894 204,744 1,108,555 1,628,196 Accounts payable to selling shareholders 246,059 445,066 88,989 - 780,114 Notes payable 15,644 74,306 - - 89,950 Advances from customers 114,585 - - - 114,585 756,292 1,316,952 1,242,236 1,109,767 4,425,247
Schedule of changes in liabilities arising from financing activities	Schedule of changes in liabilities arising from financing activities January 1, 2022 Payments Additions Interest Business combinations Other December 31, 2022 Loans and financing 1,374,876 (118,378) 496,885 127,559 - 1,959 1,882,901 Lease liabilities 714,085 (113,512) 100,873 88,571 - (20,492) 769,525 Dividends payable - (19,736) 19,736 - - - - Total 2,088,961 (251,626) 617,494 216,130 - (18,533) 2,652,426 January 1, 2021 Payments Additions * Interest Business combinations Other December 31, 2021 Loans and financing 617,485 (158,076) 809,539 68,909 36,591 428 1,374,876 Lease liabilities 447,703 (87,751) 158,651 67,212 139,514 (11,244) 714,085 Dividends payable - (18,648) 18,648 - - - - Total 1,065,188 (264,475) 986,838 136,121 176,105 (10,816) 2,088,961 * The additions of loans and financing include proceeds from the SoftBank transaction of R$ 822,569 13,030 January 1, 2020 Payments Additions Interest Foreign exchange movement Business combinations Other December 31, 2020 Loans and financing 60,357 (155,090) 605,041 10,031 21,279 75,815 52 617,485 Lease liabilities 284,515 (55,455) 98,904 44,458 - 76,855 (1,574) 447,703 Dividends payable - (12,984) 12,984 - - - - - Total 344,872 (223,529) 716,929 54,489 21,279 152,670 (1,522) 1,065,188

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Measurement
Schedule of fair value measurement	Schedule of fair value measurement Fair value measurement Total Quoted prices in active markets (Level 1) Significant observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2022 Assets for which fair values are disclosed Trade receivables (non-current) 42,568 - 42,568 - Liabilities for which fair values are disclosed Loans and financing (1,934,295) - (1,934,295) - Lease liabilities (769,525) - (769,525) - Accounts payable to selling shareholders (528,678) - (528,678) - Notes payable (62,176) - (62,176) - December 31, 2021 Assets for which fair values are disclosed Trade receivables (non-current) 27,442 - 27,442 - Liabilities for which fair values are disclosed Loans and financing (1,387,136) - (1,387,136) - Lease liabilities (714,085) - (714,085) - Accounts payable to selling shareholders (679,826) - (679,826) - Notes payable (72,726) - (72,726) -

Labor and social obligations (T

Labor and social obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Labor And Social Obligations
Schedule of model used to determine the fair value of the stock options	Schedule of model used to determine the fair value of the stock options Modified plan Original plan Strike price at the measurement date R$ 76 R$ 85 126 Dividend yield (%) 0.0 0.0 Expected volatility (%) 48 59 42 69 Risk-free interest rate (%) 13 15 5 13 Expected life of stock options (years) 1 5 1 5 Share price at the measurement date R$ 48 R$ 80 145 Model used Binomial Binomial Weighted average fair value at the measurement date R$ 53.06 R$ 49.22 On May 18, 2022, July 11, 2022 and September 14, 2022, the Company granted 1,234,919 May 2022 July 2022 September 2022 Strike price at the measurement date R$ 70 R$ 52 R$ 52 Dividend yield (%) 0.0 0.0 0.0 Expected volatility (%) 48 60 48 59 48 58 Risk-free interest rate (%) 12 13 13 15 12 Expected life of stock options (years) 1 5 1 5 1 5 Share price at the measurement date R$ 55.54 R$ 48.24 R$ 72.59 Model used Binomial Binomial Binomial Weighted average fair value at the measurement date R$ 19.13 R$ 17.98 R$ 34.86
Schedule of share-based compensation plan	Schedule of share-based compensation plan Weighted average exercise price (in Reais) Number of stock options 2022 2021 2020 Outstanding at January 1 92.33 3,086,728 2,510,983 2,364,214 Granted 53.02 1,234,919 1,170,000 477,220 Exercised - - (442,669) (56,092) Forfeited 107.25 (365,749) (60,000) (274,359) Expired 97.80 (226,611) (91,586) - Outstanding at December 31 79.47 3,729,287 3,086,728 2,510,983 Exercisable 97.65 1,133,774 542,061 -

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity
Schedule illustrates the number and movements in treasury shares	Schedule illustrates the number and movements in treasury shares Number of shares Average price (in Brazilian Reais) Outstanding at January 1, 2021 - - Repurchased 2,142,051 119.99 Transferred from exercise of stock options (442,669) 124.26 Transferred from shares contribution (44,455) 111.94 Outstanding at December 31, 2021 1,654,927 92.23 Repurchased 2,131,358 71.46 Outstanding at December 31, 2022 3,786,285 80.54

Earnings per share (EPS) (Table

Earnings per share (EPS) (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share
Schedule of earnings per share	Schedule of earnings per share 2022 2021 2020 Numerator Net income attributable to equity holders of the parent 373,569 223,326 292,075 Denominator Weighted average number of outstanding shares 90,335,037 93,291,480 92,683,848 Effects of dilution from stock options and restricted share units 329,085 811,818 951,920 Weighted average number of outstanding shares adjusted for the effect of dilution 90,664,122 94,103,298 93,635,768 Basic earnings per share (R$) 4.14 2.39 3.15 Diluted earnings per share (R$) 4.12 2.37 3.12

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue [abstract]
Schedule of net sales revenue	Schedule of net sales revenue 2022 2021 2020 Tuition fees 2,827,567 2,124,589 1,388,735 Other 213,040 167,441 99,817 Deductions Granted discounts (241,404) (229,254) (89,017) Early payment discounts (92,234) (49,879) (29,299) Returns (45,402) (42,373) (11,437) Taxes (107,004) (74,232) (49,629) PROUNI (225,506) (176,921) (107,979) Revenue from contracts with customers 2,329,057 1,719,371 1,201,191 Timing of revenue recognition of net revenue from contracts with customers Tuition, digital content and app subscription fees - Transferred over time 2,273,578 1,640,889 1,128,558 Other - Transferred at a point in time 55,479 78,482 72,633
Schedule of revenue by segment	Schedule of revenue by segment Revenue by segment Undergrad Continuing Education Digital Services Elimination (inter-segment transactions) 2022 Types of services or goods 2,037,889 108,806 189,984 (7,622) 2,329,057 Tuition fees 2,023,128 108,648 - - 2,131,776 Other 14,761 158 189,984 (7,622) 197,281 Timing of revenue recognition 2,037,889 108,806 189,984 (7,622) 2,329,057 Transferred over time 2,024,373 108,806 145,939 (5,540) 2,273,578 Transferred at a point in time 13,516 - 44,045 (2,082) 55,479 Revenue by segment Undergrad Continuing Education Digital Services Elimination (inter-segment transactions) 2021 Types of services or goods 1,498,408 72,983 151,958 (3,978) 1,719,371 Tuition fees 1,486,111 72,983 - - 1,559,094 Other 12,297 - 151,958 (3,978) 160,277 Timing of revenue recognition 1,498,408 72,983 151,958 (3,978) 1,719,371 Transferred over time 1,486,111 72,983 81,795 - 1,640,889 Transferred at a point in time 12,297 - 70,163 (3,978) 78,482 Revenue by segment Undergrad Continuing Education Digital Services Elimination (inter-segment transactions) 2020 Types of services or goods 1,002,461 107,197 93,152 (1,619) 1,201,191 Tuition fees 997,055 107,197 - - 1,104,252 Other 5,406 - 93,152 (1,619) 96,939 Timing of revenue recognition 1,002,461 107,197 93,152 (1,619) 1,201,191 Transferred over time 997,055 107,197 24,306 - 1,128,558 Transferred at a point in time 5,406 - 68,846 (1,619) 72,633

Expenses and costs by nature (T

Expenses and costs by nature (Tables)	12 Months Ended
	Dec. 31, 2022
Expenses And Costs By Nature
Schedule of expenses by nature	Schedule of expenses by nature 2022 2021 2020 Cost of services (859,552) (652,300) (434,654) General and administrative expenses (798,153) (622,615) (402,855) Total (1,657,705) (1,274,915) (837,509) Payroll (880,664) (677,564) (446,473) Hospital and medical agreements (66,065) (37,449) (37,988) Depreciation and amortization (206,220) (154,220) (108,744) Lease expenses (12,153) (11,229) (2,555) Utilities (17,682) (10,643) (5,892) Maintenance (76,475) (47,141) (20,746) Share-based compensation (31,274) (43,377) (32,610) Tax expenses (10,518) (7,997) (5,326) Pedagogical services (48,084) (47,881) (24,037) Sales and marketing (48,217) (39,506) (18,361) Allowance for doubtful accounts (42,708) (47,819) (32,081) Travel expenses (14,003) (7,542) (4,550) Consulting fees (35,326) (38,818) (31,276) Other (168,316) (103,729) (66,870) Total (1,657,705) (1,274,915) (837,509)

Finance result (Tables)

Finance result (Tables)	12 Months Ended
	Dec. 31, 2022
Finance Result
Schedule of finance result	Schedule of finance result 2022 2021 2020 Income from financial investments 67,810 35,773 24,479 Changes in fair value of derivative instruments - - 20,739 Interest received 27,197 23,040 11,876 Other 7,035 5,753 5,196 Finance income 102,042 64,566 62,290 Interest expense (200,081) (108,437) (25,543) Interest expense on lease liabilities (88,571) (67,212) (44,458) Financial discounts granted (24,092) (23,193) (8,081) Bank fees (8,623) (7,878) (6,333) Foreign exchange loss, net (852) (17,973) (4,613) IOF taxes (taxes on financial transactions) (178) (3,306) (1,661) Other (27,496) (15,797) (7,580) Finance expenses (349,893) (243,796) (98,269) Finance result (247,851) (179,230) (35,979)

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of reconciliation of income tax expense	Schedule of reconciliation of income tax expense 2022 2021 2020 Income before income taxes 428,433 273,462 335,054 Combined statutory income taxes rate - % 34% 34% 34% Income taxes at statutory rates (145,667) (92,977) (113,918) Reconciliation adjustments: Tax effect on loss from an entity not subject to taxation (32,859) (37,794) (8,474) PROUNI - Fiscal Incentive (a) 270,062 194,830 120,851 Unrecognized deferred tax assets (117,377) (86,233) (41,319) Presumed profit income tax regime effect (b) (1,549) (7,066) (2,640) Permanent adjustments (12,226) (6,232) 2,567 Other 3,939 4,293 15,866 Income taxes expense – current (35,677) (31,179) (27,067) Effective rate 8.33% 11.40% 8.08%

Insurance contracts and conti_2

Insurance contracts and contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Insurance Contracts And Contingencies
Schedule of legal proceedings and contingencies	Schedule of legal proceedings and contingencies Labor Civil Taxes (i) Total Balances as of December 31, 2019 2,501 2,768 - 5,269 Business combinations 2,741 2,348 27,487 32,576 Additions 562 10,869 7,853 19,284 Reversals (1,285) (2,705) - (3,990) Balances as of December 31, 2020 4,519 13,280 35,340 53,139 Business combinations 16,597 6,017 57,638 80,252 Additions * 5,418 5,101 14,225 24,744 Reversals (1,044) (1,470) (7,334) (9,848) Balances as of December 31, 2021 25,490 22,928 99,869 148,287 Additions 2,300 7,911 63,698 73,909 Reversals (5,306) (6,175) (14,861) (26,342) Balances as of December 31, 2022 22,484 24,664 148,706 195,854 * The amount of R$ 4,232 (i) During the year ended December 31, 2022, R$ 48,333
Schedule of social security proceedings assessed by Management	Schedule of social security proceedings assessed by Management 2022 2021 Labor 13,914 5,098 Civil 59,603 56,501 Taxes and social security 4,931 4,459 Total 78,448 66,058

Non-cash transactions (Tables)

Non-cash transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Non-cash Transactions
Schedule of non-cash transactions	Schedule of non-cash transactions 2022 2021 2020 Issuance of shares for acquisition of Pebmed - - 17,531 Issuance of shares for acquisition of iClinic - 71,500 - Issuance of shares for acquisition of Cliquefarma - 3,000 - Issuance of shares for acquisition of RXPRO - 5,112 - Provision for legal proceedings with corresponding indemnification assets 48,333 4,232 9,940 Additions and remeasurements of right-of-use assets and lease liabilities 100,873 158,651 98,904

Corporate information (Details

Corporate information (Details Narrative) R$ / shares in Units, $ / shares in Units, $ in Thousands						1 Months Ended	12 Months Ended
	May 05, 2022 R$ / shares shares	Mar. 10, 2020 BRL (R$) shares	Mar. 10, 2020 USD ($) shares	Feb. 06, 2020 BRL (R$) shares	Feb. 06, 2020 USD ($) $ / shares shares	Mar. 18, 2022 R$ / shares	Dec. 31, 2022 BRL (R$)	Dec. 31, 2021 BRL (R$)	Apr. 26, 2021 R$ / shares
IfrsStatementLineItems [Line Items]
Earn out related charges per share | R$ / shares						R$ 800
Purchase prices per share | R$ / shares									R$ 0.00005
Net of discounts							R$ 9926000	R$ 33081000
Bertelsmann [Member]
IfrsStatementLineItems [Line Items]
Own percentage							57.50%	33%
Voting interest							31%	18%
Class A Common Shares [Member]
IfrsStatementLineItems [Line Items]
Proceeds from issue of shares		R$ 294312
Class A Common Shares [Member] | United States of America, Dollars
IfrsStatementLineItems [Line Items]
Proceeds from issue of shares | $			$ 68,060
Ordinary shares [member] | Bertelsmann [Member]
IfrsStatementLineItems [Line Items]
Acquired shares | shares	6,000,000
Purchase prices per share | R$ / shares	R$ 26.90
Initial Public Offering [Member] | Class A Common Shares [Member]
IfrsStatementLineItems [Line Items]
Number of additional common shares issued | shares				3,019,928	3,019,928
Initial Public Offering [Member] | Class A Common Shares [Member] | Shareholders [Member]
IfrsStatementLineItems [Line Items]
Number of additional common shares issued | shares				9,406,812	9,406,812
Additional shares gross proceeds				R$ 358286
Net proceeds of additional shares				339,648
Other offering expenses				R$ 18638
Initial Public Offering [Member] | Class A Common Shares [Member] | Shareholders [Member] | United States of America, Dollars
IfrsStatementLineItems [Line Items]
Additional offering price | $ / shares					$ 27.50
Additional shares gross proceeds | $					$ 83,048
Net proceeds of additional shares | $					78,846
Other offering expenses | $					$ 4,202
Initial Public Offering [Member] | Class A Common Shares [Member] | Underwriters [Member]
IfrsStatementLineItems [Line Items]
Additional shares gross proceeds		30,884
Net proceeds of additional shares		29,819
Other offering expenses		R$ 1066
Initial Public Offering [Member] | Class A Common Shares [Member] | Underwriters [Member] | United States of America, Dollars
IfrsStatementLineItems [Line Items]
Number of additional common shares issued | shares		240,552	240,552
Additional shares gross proceeds | $			$ 6,615
Net proceeds of additional shares		R$ 6387000
Other offering expenses		R$ 228000

Significant accounting polici_4

Significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Afya Participacoes S A [Member]
IfrsStatementLineItems [Line Items]
Name	Afya Participações S.A. (“Afya Brazil”)
Principal activities	Holding
Location	Nova Lima - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%
Instituto Tocantinense Presidente Antonio Carlos Porto S A Itpac Porto Nacional [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto Tocantinense Presidente Antônio Carlos Porto S.A. – (“ITPAC Porto”)
Principal activities	Undergraduate degree programs
Location	Porto Nacional - TO
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Instituto Tocantinense Presidente Antonio Carlos S A I T P A C Araguaina [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto Tocantinense Presidente Antônio Carlos S.A. – (“ITPAC Araguaina”)
Principal activities	Undergraduate degree programs
Location	Araguaína - TO
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Uniao Educacional Do Vale Do Aco S A U N I V A C O [Member]
IfrsStatementLineItems [Line Items]
Name	União Educacional do Vale do Aço S.A. – (“UNIVAÇO”)
Principal activities	Medicine undergraduate degree program
Location	Ipatinga - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
I P T A N Instituto De Ensino Superior Presidente Trancredo De Almeida Neves S A [Member]
IfrsStatementLineItems [Line Items]
Name	IPTAN - Instituto de Ensino Superior Presidente Tancredo de Almeida Neves S.A. (“IPTAN”)
Principal activities	Undergraduate degree programs
Location	São João Del Rei - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Instituto De Educacao Superior Do Vale Do Parnaiba S A [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto de Educação Superior do Vale do Parnaíba S.A. (“IESVAP”)
Principal activities	Undergraduate degree programs
Location	Parnaíba - PI
Investment type	Subsidiary
Direct and indirect interest of subsidiary	80%	80%
Centro De Ciencias Em Saude De Itajuba S A [Member]
IfrsStatementLineItems [Line Items]
Name	Centro de Ciências em Saúde de Itajubá S.A. (“CCSI”)
Principal activities	Medicine undergraduate degree program
Location	Itajubá - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	60%	60%
Instituto De Ensino Superior Do Piaui S A [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto de Ensino Superior do Piauí S.A. (”IESP”)
Principal activities	Undergraduate and graduate degree programs
Location	Teresina - PI
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Centro Integrado De Saude De Teresina C I S [Member]
IfrsStatementLineItems [Line Items]
Name	Centro Integrado de Saúde de Teresina (“CIS”)
Principal activities	Outpatient care
Location	Teresina - PI
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
F A D E P Faculdade Educacional De Pato Branco Ltda [Member]
IfrsStatementLineItems [Line Items]
Name	FADEP - Faculdade Educacional de Pato Branco Ltda. (“FADEP”)
Principal activities	Undergraduate degree programs
Location	Pato Branco - PR
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Medcel Editora E Eventos S A Medcel [Member]
IfrsStatementLineItems [Line Items]
Name	Medcel Editora e Eventos S.A. (“Medcel”)
Principal activities	Medical education content
Location	São Paulo - SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Instituto Educacional Santo Agostinho S A [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto Educacional Santo Agostinho S.A. (“FASA”)
Principal activities	Undergraduate degree programs
Location	Montes Claros - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%	90%
E S M C Educacao Superior Ltda E S M C [Member]
IfrsStatementLineItems [Line Items]
Name	ESMC Educação Superior Ltda. (“ESMC”)
Principal activities	Undergraduate degree programs
Location	Montes Claros - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Institutode Pesquisae Ensino Medicodo Estadode Minas Gerais Ltda [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto de Pesquisa e Ensino Médico do Estado de Minas Gerais Ltda. (“IPEMED”)
Principal activities	Graduate
Location	Belo Horizonte - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%	100%
Instituto Paraensede Educacaoe Cultura Ltda [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto Paraense de Educação e Cultura Ltda (“IPEC”)
Principal activities	Medicine degree programs
Location	Marabá - PA
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Sociedade Universitaria Redentor S A Uni Redentor [Member]
IfrsStatementLineItems [Line Items]
Name	Sociedade Universitária Redentor S.A. (“UniRedentor”)
Principal activities	Undergraduate and graduate degree programs
Location	Itaperuna - RJ
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Centro Universitario Sao Lucas Ltda Uni S L [Member]
IfrsStatementLineItems [Line Items]
Name	Centro Universitário São Lucas Ltda. (“UniSL”)
Principal activities	Undergraduate degree programs
Location	Porto Velho - RO
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Peb Med Instituicao De Pesquisa Medica E Servicos Ltda Peb Med [Member]
IfrsStatementLineItems [Line Items]
Name	Peb Med Instituição de Pesquisa Médica e Serviços Ltda (“PebMed”)
Principal activities	Content and clinical tools and online platform
Location	Rio de Janeiro - RJ
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Faculdade De Ensino Superior Da Amazonia Reunida F E S A R [Member]
IfrsStatementLineItems [Line Items]
Name	Faculdade de Ensino Superior da Amazônia Reunida – (“FESAR”)
Principal activities	Undergraduate degree programs
Location	Redenção – PA
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Centro Superior de Ciencias da Saude S/S Ltda (FCMPB) [member]
IfrsStatementLineItems [Line Items]
Name	Centro Superior de Ciências da Saúde S/S Ltda. (“FCMPB”)
Principal activities	Medicine degree programs
Location	João Pessoa – PB
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Med Phone Tecnologia Em Saude Ltda Med Phone [Member]
IfrsStatementLineItems [Line Items]
Name	MedPhone Tecnologia em Saúde Ltda. (“MedPhone”)
Principal activities	Content and clinical tools and online platform
Location	Recife – PE
Investment type	Subsidiary
Direct and indirect interest of subsidiary		100%
I Clinic Desenvolvimento De Software Ltdai Clinic [Member]
IfrsStatementLineItems [Line Items]
Name	iClinic Desenvolvimento de Software Ltda (“iClinic”)
Principal activities	Electronic Medical Record, Clinical Management System
Location	Ribeirão Preto - SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Medicinae Solutions S A Medicinae [Member]
IfrsStatementLineItems [Line Items]
Name	Medicinae Solutions S.A. (“Medicinae”)
Principal activities	Healthcare payments and financial services
Location	Rio de Janeiro – RJ
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Medical Harbour Aparelhos Medico Hospitalares E Servicos Em Tecnologia Ltda Medical Harbour [Member]
IfrsStatementLineItems [Line Items]
Name	Medical Harbour Aparelhos Médico Hospitalares e Serviços em Tecnologia Ltda. (“Medical Harbour”)
Principal activities	Educational health and medical imaging
Location	Florianópolis – SC
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Cliquefarma Drogarias Online Ltda Cliquefarma [Member]
IfrsStatementLineItems [Line Items]
Name	Cliquefarma Drogarias Online Ltda.(“Cliquefarma”)
Principal activities	Online platform
Location	São Paulo – SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Shosp Tecnologia Da Informacao Ltda Shosp [Member]
IfrsStatementLineItems [Line Items]
Name	Shosp Tecnologia da Informação Ltda. (“Shosp”)
Principal activities	Electronic Medical Record, Clinical Management System
Location	Rio de Janeiro – RJ
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Sociedade Padrao De Educacao Superior Ltda Unifip Moc [Member]
IfrsStatementLineItems [Line Items]
Name	Sociedade Padrão de Educação Superior Ltda. (“UnifipMoc”)
Principal activities	Undergraduate degree programs
Location	Montes Claros - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Nucleo De Atencao A Saude E De Praticas Profissionalizantes N A S P P [Member]
IfrsStatementLineItems [Line Items]
Name	Nucleo de Atenção à Saúde e de Práticas Profissionalizantes (“NASPP)
Principal activities	Outpatient care
Location	Montes Claros - MG
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Companhia Nilza Cordeiro Herdy De Educacaoe Cultura Unigranrio [Member]
IfrsStatementLineItems [Line Items]
Name	Companhia Nilza Cordeiro Herdy de Educação e Cultura. (“Unigranrio”)
Principal activities	Undergraduate and graduate degree programs
Location	Duque de Caxias - RJ
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Policlinica E Centro De Estetica Duque De Caxias Ltda Policlinica [Member]
IfrsStatementLineItems [Line Items]
Name	Policlínica e Centro de Estética Duque de Caxias Ltda. (“Policlínica”)
Principal activities	Outpatient care
Location	Duque de Caxias - RJ
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Sociedade Educacional De Palhoca S A Ltda S O C I E S P [Member]
IfrsStatementLineItems [Line Items]
Name	Sociedade Educacional de Palhoça S/A Ltda. (“SOCIESP”)
Principal activities	Basic Education
Location	Palhoça - SC
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
Instituto De Ensino Superior De Palhoca S S Ltda I E S P P A L H O C A [Member]
IfrsStatementLineItems [Line Items]
Name	Instituto de Ensino Superior de Palhoça S/S Ltda. (“IESP PALHOÇA”)
Principal activities	Undergraduate degree programs
Location	Palhoça - SC
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
R X P R O Solucoes De Tecnologia Ltda R X P R O [Member]
IfrsStatementLineItems [Line Items]
Name	RX PRO Soluções de Tecnologia Ltda. (“RX PRO”)
Principal activities	Marketing for pharmaceutical industry
Location	São Paulo – SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
R X P R O L O G Transporte E Logistica Ltda R X P R O L O G [Member]
IfrsStatementLineItems [Line Items]
Name	RX PRO LOG Transporte e Logística Ltda. (“RX PRO LOG”)
Principal activities	Marketing for pharmaceutical industry
Location	São Paulo – SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%	100%
B M V Atividades Medicas Ltda Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Name	BMV Atividades Médicas Ltda. (“Além da Medicina”)
Principal activities	Medical education content
Location	São Paulo – SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%
Cardiopapers Solucoes Digitais Ltda Cardio Papers [Member]
IfrsStatementLineItems [Line Items]
Name	Cardiopapers Soluções Digitais Ltda (“CardioPapers”)
Principal activities	Medical education content
Location	Recife – PE
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%
Quasar Telemedicina Desenvolvimento De Sistemas Computacionais Ltda Glic [Member]
IfrsStatementLineItems [Line Items]
Name	Quasar Telemedicina Desenvolvimento de Sistemas Computacionais Ltda. (“Glic”)
Principal activities	Patient physician relationship
Location	Barueri – SP
Investment type	Subsidiary
Direct and indirect interest of subsidiary	100%
Uniao Educacional Do Planalto Central S A [Member]
IfrsStatementLineItems [Line Items]
Name	União Educacional do Planalto Central S.A. (“UEPC”)
Principal activities	Undergraduate degree programs
Location	Brasília - DF
Investment type	Associate
Direct and indirect interest of subsidiary	30%	30%

Significant accounting polici_5

Significant accounting policies (Details 1)	12 Months Ended
	Dec. 31, 2022
Buildings [member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	25 years
Machinery And Equipments [Member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	10 years
Vehicles [member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	4 years
Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	10 years
It Equipment [Member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	5 years
Library Books [Member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	10 years
Laboratories And Clinics [Member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	10 years
Leasehold improvements [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	5 years
Leasehold improvements [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Useful lives of assets	20 years

Significant accounting polici_6

Significant accounting policies (Details 2)	12 Months Ended
	Dec. 31, 2022
A S 37 [Member]
IfrsStatementLineItems [Line Items]
Standard	Onerous Contracts – Costs of Fulfilling a Contract – Amendments to IAS 37
Description	Specify that when assessing whether a contract is onerous or loss-making, an entity needs to include costs that relate directly to a contract to provide goods or services including both incremental costs (e.g., the costs of direct labour and materials) and an allocation of costs directly related to contract activities (e.g., depreciation of equipment used to fulfil the contract and costs of contract management and supervision). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract.
Period First adopted	1 January 2022
Impact	These amendments have no significant impact on the Company’s consolidated financial statements.
I F R S 3 [Member]
IfrsStatementLineItems [Line Items]
Standard	Reference to the Conceptual Framework – Amendments to IFRS 3
Description	The amendments add an exception to the recognition principle of IFRS 3 Business Combinations to avoid the issue of potential ‘day 2’ gains or losses arising for liabilities and contingent liabilities that would be within the scope of IAS 37 Provisions, Contingent Liabilities and Contingent Assets or IFRIC 21 Levies, if incurred separately. The exception requires entities to apply the criteria in IAS 37 or IFRIC 21, respectively, instead of the Conceptual Framework, to determine whether a present obligation exists at the acquisition date. The amendments also add a new paragraph to IFRS 3 to clarify that contingent assets do not qualify for
Period First adopted	1 January 2022
Impact	These amendments had no impact on the Company’s consolidated financial statements.
I A S 16 [Member]
IfrsStatementLineItems [Line Items]
Standard	Property, Plant and Equipment: Proceeds before Intended Use – Amendments to IAS 16 Leases
Description	The amendment prohibits entities from deducting from the cost of an item of property, plant and equipment, any proceeds of the sale of items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling such items, and the costs of producing those items, in profit or loss.
Period First adopted	1 January 2022
Impact	These amendments had no impact on the Company’s consolidated financial statements.
I A S 1 [Member]
IfrsStatementLineItems [Line Items]
Standard	Amendments to IAS 1: Classification of Liabilities as Current or Non-current
Description	The amendments clarify: i) what is meant by a right to defer settlement; ii) that a right to defer must exist at the end of the reporting period; iii) that classification is unaffected by the likelihood that an entity will exercise its deferral right; iv) that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification
Period First adopted	1 January 2023
Impact	These amendments are not expected to have a significant impact on the Company’s financial statements.
I A S 8 [Member]
IfrsStatementLineItems [Line Items]
Standard	Definition of Accounting Estimates -  Amendments to IAS 8
Description	The IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates’. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates.
Period First adopted	1 January 2023
Impact	These amendments are not expected to have a significant impact on the Company’s financial statements.
I F R S Practice Statement 2 [Member]
IfrsStatementLineItems [Line Items]
Standard	Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2
Description	The IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that
Period First adopted	1 January 2023
Impact	These amendments are not expected to have a significant impact on the Company’s financial statements.
I A S 12 [Member]
IfrsStatementLineItems [Line Items]
Standard	Deferred Tax related to Assets and Liabilities arising from a Single Transaction - Amendments to IAS 12
Description	The Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences.
Period First adopted	1 January 2023
Impact	These amendments are not expected to have a significant impact on the Company’s financial statements.

Significant accounting polici_7

Significant accounting policies (Details Narrative)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Tax rate	34%	34%	34%
Program of social integration ("pis") [member] | Teaching Activities [Member]
IfrsStatementLineItems [Line Items]
Tax rate	0.65%
Program of social integration ("pis") [member] | Non-teaching activities [member]
IfrsStatementLineItems [Line Items]
Tax rate	1.65%
Contribution for the financing of social security ("COFINS") [member] | Teaching Activities [Member]
IfrsStatementLineItems [Line Items]
Tax rate	3%
Contribution for the financing of social security ("COFINS") [member] | Non-teaching activities [member]
IfrsStatementLineItems [Line Items]
Tax rate	7.60%

Segment information (Details)

Segment information (Details) - BRL (R$) R$ in Thousands	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Total assets	R$ 7199539		R$ 6447406
Current assets	1,637,657		1,206,852
Non-current assets	5,561,882		5,240,554
Total liabilities and equity	7,199,539		6,447,406
Current liabilities	905,689		766,506
Non-current liabilities	3,043,692		2,680,882
Equity	3,250,158		3,000,018		R$ 2833780	R$ 2113726
Operating segments [member]
IfrsStatementLineItems [Line Items]
Total assets	7,199,539		6,447,406
Current assets	1,637,657		1,206,852
Non-current assets	5,561,882		5,240,554
Total liabilities and equity	7,199,539		6,447,406
Current liabilities	905,689		766,506
Non-current liabilities	3,043,692		2,680,882
Equity	3,250,158		3,000,018
Investments in associate	53,907		48,477
Capital expenditures	318,155	[1]	301,979	[2]
Operating segments [member] | Undergrad [Member]
IfrsStatementLineItems [Line Items]
Total assets	6,775,829		6,072,135
Current assets	1,461,802		1,048,869
Non-current assets	5,314,027		5,023,266
Total liabilities and equity	6,775,829		6,072,135
Current liabilities	711,896		645,657
Non-current liabilities	2,938,960		2,551,175
Equity	3,124,973		2,875,303
Investments in associate	53,907		48,477
Capital expenditures	247,634	[1]	220,202	[2]
Operating segments [member] | Continuing Education [Member]
IfrsStatementLineItems [Line Items]
Total assets	149,254		105,629
Current assets	61,673		42,737
Non-current assets	87,581		62,892
Total liabilities and equity	149,254		105,629
Current liabilities	57,605		32,300
Non-current liabilities	63,990		47,705
Equity	27,659		25,624
Investments in associate
Capital expenditures	8,827	[1]	25,682	[2]
Operating segments [member] | Digital Services [Member]
IfrsStatementLineItems [Line Items]
Total assets	275,564		272,122
Current assets	115,290		117,726
Non-current assets	160,274		154,396
Total liabilities and equity	275,564		272,122
Current liabilities	137,296		91,029
Non-current liabilities	40,742		82,002
Equity	97,526		99,091
Investments in associate
Capital expenditures	61,694	[1]	56,095	[2]
Operating segments [member] | Total Reportable Segments [Member]
IfrsStatementLineItems [Line Items]
Total assets	7,200,647		6,449,886
Current assets	1,638,765		1,209,332
Non-current assets	5,561,882		5,240,554
Total liabilities and equity	7,200,647		6,449,886
Current liabilities	906,797		768,986
Non-current liabilities	3,043,692		2,680,882
Equity	3,250,158		3,000,018
Investments in associate	53,907		48,477
Capital expenditures	318,155	[1]	301,979	[2]
Operating segments [member] | Adjustments And Eliminations [Member]
IfrsStatementLineItems [Line Items]
Total assets	(1,108)		(2,480)
Current assets	(1,108)		(2,480)
Non-current assets
Total liabilities and equity	(1,108)		(2,480)
Current liabilities	(1,108)		(2,480)
Non-current liabilities
Equity
Investments in associate
Capital expenditures		[1]		[2]
[1]Some of the capital expenditures are considered non-cash transactions (refer to note 24).[2]Some of the capital expenditures are considered non-cash transactions (refer to note 24).

Segment information (Details 1)

Segment information (Details 1) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Net revenue	R$ 2329057	R$ 1719371	R$ 1201191
Cost of services	859,552	652,300	434,654
Gross profit	1,469,505	1,067,071	766,537
General and administrative expenses	798,153	622,615	402,855
Operating income	664,100	440,895	363,335
Finance income	102,042	64,566	62,290
Income before income taxes	428,433	273,462	335,054
Income taxes expenses	35,677	31,179	27,067
Net income	392,756	242,283	307,987
Operating segments [member]
IfrsStatementLineItems [Line Items]
External customer	2,329,057	1,719,371	1,201,191
Inter-segment
Net revenue	2,329,057	1,719,371	1,201,191
Cost of services	(859,552)	(652,300)	(434,654)
Gross profit	1,469,505	1,067,071	766,537
General and administrative expenses	(798,153)	(622,615)	(402,855)
Other expenses, net	(7,252)	(3,561)	(347)
Operating income	664,100	440,895	363,335
Finance income	102,042	64,566	62,290
Finance expenses	(349,893)	(243,796)	(98,269)
Share of income of associate	12,184	11,797	7,698
Income before income taxes	428,433	273,462	335,054
Income taxes expenses	(35,677)	(31,179)	(27,067)
Net income	392,756	242,283	307,987
Operating segments [member] | Undergrad [Member]
IfrsStatementLineItems [Line Items]
External customer	2,037,889	1,498,408	1,002,461
Inter-segment
Net revenue	2,037,889	1,498,408	1,002,461
Cost of services	(763,185)	(554,995)	(381,964)
Gross profit	1,274,704	943,413	620,497
General and administrative expenses
Other expenses, net
Operating income
Finance income
Finance expenses
Share of income of associate
Income before income taxes
Income taxes expenses
Net income
Operating segments [member] | Continuing Education [Member]
IfrsStatementLineItems [Line Items]
External customer	108,806	72,983	107,197
Inter-segment
Net revenue	108,806	72,983	107,197
Cost of services	(56,554)	(50,773)	(40,000)
Gross profit	52,252	22,210	67,197
General and administrative expenses
Other expenses, net
Operating income
Finance income
Finance expenses
Share of income of associate
Income before income taxes
Income taxes expenses
Net income
Operating segments [member] | Digital Services [Member]
IfrsStatementLineItems [Line Items]
External customer	182,362	147,980	91,533
Inter-segment	7,622	3,978	1,619
Net revenue	189,984	151,958	93,152
Cost of services	(47,435)	(50,510)	(14,309)
Gross profit	142,549	101,448	78,843
General and administrative expenses
Other expenses, net
Operating income
Finance income
Finance expenses
Share of income of associate
Income before income taxes
Income taxes expenses
Net income
Operating segments [member] | Total Reportable Segments [Member]
IfrsStatementLineItems [Line Items]
External customer	2,329,057	1,719,371	1,201,191
Inter-segment	7,622	3,978	1,619
Net revenue	2,336,679	1,723,349	1,202,810
Cost of services	(867,174)	(656,278)	(436,273)
Gross profit	1,469,505	1,067,071	766,537
General and administrative expenses
Other expenses, net
Operating income
Finance income
Finance expenses
Share of income of associate
Income before income taxes
Income taxes expenses
Net income
Operating segments [member] | Adjustments And Eliminations [Member]
IfrsStatementLineItems [Line Items]
External customer
Inter-segment	(7,622)	(3,978)	(1,619)
Net revenue	(7,622)	(3,978)	(1,619)
Cost of services	7,622	3,978	1,619
Gross profit
General and administrative expenses
Other expenses, net
Operating income
Finance income
Finance expenses
Share of income of associate
Income before income taxes
Income taxes expenses
Net income

Business combinations (Details)

Business combinations (Details) - BRL (R$) R$ in Thousands					12 Months Ended
		May 23, 2022	Apr. 05, 2022	Mar. 04, 2022	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Indemnification assets recognised as of acquisition date	[1]				R$ 145300	R$ 135355
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination					R$ 13030
Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents				R$ 298
Restricted Cash				1,705
Other Assets As Of Acquisition Date				266
Property, plant and equipment recognised as of acquisition date				37
Identifiable intangible assets recognised as of acquisition date				20,299
Total				22,605
Trade and other payables recognised as of acquisition date				705
Labor And Social Obligations As Of Acquisition Date				79
Taxes Payable As Of Acquisition Date				1,182
Advances From Customers As Of Acquisition Date				6,185
Other Liabilities As Of Acquisition Date
Total				8,151
Indemnification assets recognised as of acquisition date				14,454
Goodwill recognised as of acquisition date				12,335
Consideration transferred, acquisition-date fair value				26,789
Cash transferred				14,952
Contingent consideration recognised as of acquisition date				11,074
Consideration To Be Transferred				763
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination				227
Cash and cash equivalents in subsidiary or businesses acquired or disposed				14,654
Net of cash flow on acquisition				R$ 14881
Cardio Papers [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents			R$ 3648
Restricted Cash			1,350
Other Assets As Of Acquisition Date			1
Property, plant and equipment recognised as of acquisition date			43
Identifiable intangible assets recognised as of acquisition date			28,655
Total			33,697
Trade and other payables recognised as of acquisition date			1,703
Labor And Social Obligations As Of Acquisition Date			60
Taxes Payable As Of Acquisition Date			352
Advances From Customers As Of Acquisition Date			3,893
Other Liabilities As Of Acquisition Date
Total			6,008
Indemnification assets recognised as of acquisition date			27,689
Goodwill recognised as of acquisition date			14,324
Consideration transferred, acquisition-date fair value			42,013
Cash transferred			34,924
Contingent consideration recognised as of acquisition date			7,422
Consideration To Be Transferred			(333)
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination			274
Cash and cash equivalents in subsidiary or businesses acquired or disposed			31,276
Net of cash flow on acquisition			R$ 31550
Glic [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents		R$ 151
Restricted Cash		94
Other Assets As Of Acquisition Date		36
Property, plant and equipment recognised as of acquisition date
Identifiable intangible assets recognised as of acquisition date		15,395
Total		15,676
Trade and other payables recognised as of acquisition date		1
Labor And Social Obligations As Of Acquisition Date
Taxes Payable As Of Acquisition Date		91
Advances From Customers As Of Acquisition Date
Other Liabilities As Of Acquisition Date		574
Total		666
Indemnification assets recognised as of acquisition date		15,010
Goodwill recognised as of acquisition date		15,587
Consideration transferred, acquisition-date fair value		30,597
Cash transferred		21,602
Contingent consideration recognised as of acquisition date		8,995
Consideration To Be Transferred
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination		222
Cash and cash equivalents in subsidiary or businesses acquired or disposed		21,451
Net of cash flow on acquisition		R$ 21673
[1]Under the terms of the Share Purchase and Sale Agreements ("Agreements") between the Company and the selling shareholders of certain subsidiaries acquired, the Company assesses that the selling shareholders are exclusively responsible for any provisions (including labor, tax and civil), which are or will be the subject of a claim by any third party, arising from the act or fact occurred, by action or omission, prior to or on the closing dates of the acquisitions.

Business combinations (Details

Business combinations (Details 1)	Apr. 05, 2022	Mar. 04, 2022	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique									Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Brand names [member] | Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Valuation technique		Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.						Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Customer-related intangible assets [member] | Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Valuation technique		Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Educational Content [Member] | Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Valuation technique		Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Technology-based intangible assets [member] | Alem Da Medicina [Member]
IfrsStatementLineItems [Line Items]
Valuation technique		Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detail_2

Business combinations (Details 2)	Apr. 05, 2022	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique				Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Brand names [member] | Cardio Papers [Member]
IfrsStatementLineItems [Line Items]
Valuation technique	Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Educational Content [Member] | Cardio Papers [Member]
IfrsStatementLineItems [Line Items]
Valuation technique	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Copyrights [Member] | Cardio Papers [Member]
IfrsStatementLineItems [Line Items]
Valuation technique	Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.

Business combinations (Detail_3

Business combinations (Details 3)	May 23, 2022	Apr. 05, 2022	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique									Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Brand names [member] | Glic [Member]
IfrsStatementLineItems [Line Items]
Valuation technique	Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.					Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Customer-related intangible assets [member] | Glic [Member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
Technology-based intangible assets [member] | Glic [Member]
IfrsStatementLineItems [Line Items]
Valuation technique	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detail_4

Business combinations (Details 4) - BRL (R$) R$ in Thousands								12 Months Ended
		Nov. 09, 2020	Nov. 05, 2020	Nov. 03, 2020	Jul. 20, 2020	May 05, 2020	Jan. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Indemnification assets recognised as of acquisition date	[1]							R$ 145300	R$ 135355
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination								13,030
I Clinic [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents		R$ 1659
Restricted Cash		6,050
Trade Receivales		1,201
Inventories
Recoverable Taxes As Of Acquisition Date		72
Other Assets As Of Acquisition Date		20
Right Of Use Assets As Of Acquisition Date		88
Property, plant and equipment recognised as of acquisition date		473
Imdemnification Assets		1,252
Identifiable intangible assets recognised as of acquisition date		84,987
Total		95,802
Trade and other payables recognised as of acquisition date		619
Borrowings recognised as of acquisition date
Labor And Social Obligations As Of Acquisition Date		1,414
Taxes Payable As Of Acquisition Date		77
Provision For Legal Proceedings As Of Acquisition Date		1,252
Lease Liabilities As Of Acquisition Date		88
Advances From Customers As Of Acquisition Date		400
Other Liabilities As Of Acquisition Date
Total		3,850
Indemnification assets recognised as of acquisition date		91,952
Goodwill recognised as of acquisition date		99,168
Consideration transferred, acquisition-date fair value		191,120
Cash transferred		119,620
Contingent consideration recognised as of acquisition date
Consideration To Be Transferred
Paid In Shares		71,500
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination		856
Cash and cash equivalents in subsidiary or businesses acquired or disposed		117,961
Net of cash flow on acquisition		118,817
Medicinae [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents		201
Restricted Cash
Trade Receivales
Inventories
Recoverable Taxes As Of Acquisition Date		15
Other Assets As Of Acquisition Date
Right Of Use Assets As Of Acquisition Date
Property, plant and equipment recognised as of acquisition date		17
Imdemnification Assets
Identifiable intangible assets recognised as of acquisition date		4,518
Total		4,751
Trade and other payables recognised as of acquisition date
Borrowings recognised as of acquisition date
Labor And Social Obligations As Of Acquisition Date		159
Taxes Payable As Of Acquisition Date		4
Provision For Legal Proceedings As Of Acquisition Date
Lease Liabilities As Of Acquisition Date
Advances From Customers As Of Acquisition Date
Other Liabilities As Of Acquisition Date
Total		163
Indemnification assets recognised as of acquisition date		4,588
Goodwill recognised as of acquisition date		4,584
Consideration transferred, acquisition-date fair value		9,172
Cash transferred		5,600
Contingent consideration recognised as of acquisition date		3,572						1,716
Consideration To Be Transferred
Paid In Shares
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination		117
Cash and cash equivalents in subsidiary or businesses acquired or disposed		5,399
Net of cash flow on acquisition		5,516
Medical Harbour [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents		47
Restricted Cash
Trade Receivales		159
Inventories
Recoverable Taxes As Of Acquisition Date
Other Assets As Of Acquisition Date		2
Right Of Use Assets As Of Acquisition Date
Property, plant and equipment recognised as of acquisition date		34
Imdemnification Assets
Identifiable intangible assets recognised as of acquisition date		7,359
Total		7,601
Trade and other payables recognised as of acquisition date		6
Borrowings recognised as of acquisition date		299
Labor And Social Obligations As Of Acquisition Date		4
Taxes Payable As Of Acquisition Date		1
Provision For Legal Proceedings As Of Acquisition Date
Lease Liabilities As Of Acquisition Date
Advances From Customers As Of Acquisition Date		35
Other Liabilities As Of Acquisition Date
Total		345
Indemnification assets recognised as of acquisition date		7,256
Goodwill recognised as of acquisition date		4,022
Consideration transferred, acquisition-date fair value		11,278
Cash transferred		5,000
Contingent consideration recognised as of acquisition date		6,278
Consideration To Be Transferred
Paid In Shares
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination		144		R$ 188			R$ 264
Cash and cash equivalents in subsidiary or businesses acquired or disposed		4,953		5,458
Net of cash flow on acquisition		R$ 5097		5,646
Cliquefarma [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents			R$ 1009
Restricted Cash
Trade Receivales			501
Inventories
Recoverable Taxes As Of Acquisition Date
Other Assets As Of Acquisition Date
Right Of Use Assets As Of Acquisition Date
Property, plant and equipment recognised as of acquisition date
Imdemnification Assets
Identifiable intangible assets recognised as of acquisition date			14,991
Total			16,501
Trade and other payables recognised as of acquisition date			8
Borrowings recognised as of acquisition date			580
Labor And Social Obligations As Of Acquisition Date			102
Taxes Payable As Of Acquisition Date			307
Provision For Legal Proceedings As Of Acquisition Date
Lease Liabilities As Of Acquisition Date
Advances From Customers As Of Acquisition Date			3
Other Liabilities As Of Acquisition Date
Total			1,000
Indemnification assets recognised as of acquisition date			15,501
Goodwill recognised as of acquisition date			6,588
Consideration transferred, acquisition-date fair value			22,089
Cash transferred			16,166
Contingent consideration recognised as of acquisition date			2,923
Consideration To Be Transferred
Paid In Shares			3,000
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination			336
Cash and cash equivalents in subsidiary or businesses acquired or disposed			15,157
Net of cash flow on acquisition			R$ 15493
Shosp [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents				397
Restricted Cash
Trade Receivales
Inventories
Recoverable Taxes As Of Acquisition Date				1
Other Assets As Of Acquisition Date
Right Of Use Assets As Of Acquisition Date
Property, plant and equipment recognised as of acquisition date				5
Imdemnification Assets
Identifiable intangible assets recognised as of acquisition date				4,856
Total				5,259
Trade and other payables recognised as of acquisition date				1
Borrowings recognised as of acquisition date
Labor And Social Obligations As Of Acquisition Date				89
Taxes Payable As Of Acquisition Date				123
Provision For Legal Proceedings As Of Acquisition Date
Lease Liabilities As Of Acquisition Date
Advances From Customers As Of Acquisition Date				167
Other Liabilities As Of Acquisition Date
Total				380
Indemnification assets recognised as of acquisition date				4,879
Goodwill recognised as of acquisition date				3,022
Consideration transferred, acquisition-date fair value				7,901
Cash transferred				5,855
Contingent consideration recognised as of acquisition date				1,592
Consideration To Be Transferred				454
Paid In Shares
Sociedade Universitaria Fipmoc S A [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents					R$ 6140
Restricted Cash
Trade Receivales					34,309
Inventories
Recoverable Taxes As Of Acquisition Date					1,295
Other Assets As Of Acquisition Date					702
Right Of Use Assets As Of Acquisition Date					52,079
Property, plant and equipment recognised as of acquisition date					24,277
Imdemnification Assets					7,331
Identifiable intangible assets recognised as of acquisition date					227,534
Total					353,667
Trade and other payables recognised as of acquisition date					985
Borrowings recognised as of acquisition date					30,179
Labor And Social Obligations As Of Acquisition Date					5,306
Taxes Payable As Of Acquisition Date					758
Provision For Legal Proceedings As Of Acquisition Date					7,331
Lease Liabilities As Of Acquisition Date					52,079
Advances From Customers As Of Acquisition Date					10,745
Other Liabilities As Of Acquisition Date					5,739
Total					113,122
Indemnification assets recognised as of acquisition date					240,545
Goodwill recognised as of acquisition date					87,777
Consideration transferred, acquisition-date fair value					328,322
Cash transferred					328,322
Contingent consideration recognised as of acquisition date	[2]
Consideration To Be Transferred
Paid In Shares
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination					177
Cash and cash equivalents in subsidiary or businesses acquired or disposed					322,182
Net of cash flow on acquisition					R$ 322359
Sociedade Universitaria Granario S A [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents						R$ 34755
Restricted Cash
Trade Receivales						26,622
Inventories						352
Recoverable Taxes As Of Acquisition Date						738
Other Assets As Of Acquisition Date						12,159
Right Of Use Assets As Of Acquisition Date						87,265
Property, plant and equipment recognised as of acquisition date						40,775
Imdemnification Assets						71,669
Identifiable intangible assets recognised as of acquisition date						510,356
Total						784,691
Trade and other payables recognised as of acquisition date						6,197
Borrowings recognised as of acquisition date						5,533
Labor And Social Obligations As Of Acquisition Date						22,854
Taxes Payable As Of Acquisition Date						94,025
Provision For Legal Proceedings As Of Acquisition Date						71,669
Lease Liabilities As Of Acquisition Date						87,265
Advances From Customers As Of Acquisition Date						3,387
Other Liabilities As Of Acquisition Date						4,878
Total						295,808
Indemnification assets recognised as of acquisition date						488,883
Goodwill recognised as of acquisition date						130,073
Consideration transferred, acquisition-date fair value						618,956
Cash transferred						375,670
Contingent consideration recognised as of acquisition date	[3]
Consideration To Be Transferred						243,286
Paid In Shares
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination						10,990
Cash and cash equivalents in subsidiary or businesses acquired or disposed						340,915
Net of cash flow on acquisition						R$ 351905
R X P R O [Member]
IfrsStatementLineItems [Line Items]
Cash and cash and equivalents							91
Restricted Cash
Trade Receivales							1,211
Inventories							246
Recoverable Taxes As Of Acquisition Date							112
Other Assets As Of Acquisition Date							366
Right Of Use Assets As Of Acquisition Date							82
Property, plant and equipment recognised as of acquisition date							42
Imdemnification Assets
Identifiable intangible assets recognised as of acquisition date							6,330
Total							8,480
Trade and other payables recognised as of acquisition date							1,060
Borrowings recognised as of acquisition date
Labor And Social Obligations As Of Acquisition Date							62
Taxes Payable As Of Acquisition Date							100
Provision For Legal Proceedings As Of Acquisition Date
Lease Liabilities As Of Acquisition Date							82
Advances From Customers As Of Acquisition Date
Other Liabilities As Of Acquisition Date
Total							1,304
Indemnification assets recognised as of acquisition date							7,176
Goodwill recognised as of acquisition date							38,446
Consideration transferred, acquisition-date fair value							45,622
Cash transferred							30,263
Contingent consideration recognised as of acquisition date							10,171	R$ 8637
Consideration To Be Transferred							76
Paid In Shares							5,112
Cash and cash equivalents in subsidiary or businesses acquired or disposed							30,172
Net of cash flow on acquisition							R$ 30436
[1]Under the terms of the Share Purchase and Sale Agreements ("Agreements") between the Company and the selling shareholders of certain subsidiaries acquired, the Company assesses that the selling shareholders are exclusively responsible for any provisions (including labor, tax and civil), which are or will be the subject of a claim by any third party, arising from the act or fact occurred, by action or omission, prior to or on the closing dates of the acquisitions.[2]There are 40 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$50,000.[3]There are 82 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$90,200.

Business combinations (Detail_5

Business combinations (Details 5)	Apr. 05, 2022	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique								Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.					Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detail_6

Business combinations (Details 6)	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique					Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detail_7

Business combinations (Details 7)	Apr. 05, 2022	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique								Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.					Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detail_8

Business combinations (Details 8)	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique					Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detail_9

Business combinations (Details 9)	Apr. 05, 2022	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique								Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.					Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detai_10

Business combinations (Details 10)	Apr. 05, 2022	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Licences [member]
IfrsStatementLineItems [Line Items]
Valuation technique		With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.

Business combinations (Detai_11

Business combinations (Details 11)	Apr. 05, 2022	Nov. 09, 2020	Nov. 03, 2020	Aug. 04, 2020	Jul. 20, 2020
Licences [member]
IfrsStatementLineItems [Line Items]
Description of valuation techniques and significant inputs used to measure non-controlling interest in acquiree measured at fair value		With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Description of valuation techniques and significant inputs used to measure non-controlling interest in acquiree measured at fair value	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.		Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Sociedade Universitaria Granario S A [Member] | Licences [member]
IfrsStatementLineItems [Line Items]
Description of valuation techniques and significant inputs used to measure non-controlling interest in acquiree measured at fair value				With-and-without method The with-and-without method consists of estimating the fair value of an asset by the difference between the value of this asset in two scenarios: a scenario considering the existence of the asset in question and another considering its non-existence.
Sociedade Universitaria Granario S A [Member] | Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Description of valuation techniques and significant inputs used to measure non-controlling interest in acquiree measured at fair value				Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.

Business combinations (Detai_12

Business combinations (Details 12)	Apr. 05, 2022	Oct. 02, 2021	Apr. 16, 2021	Mar. 25, 2021	Mar. 13, 2021	Jan. 21, 2021	Nov. 09, 2020	Nov. 03, 2020	Jul. 20, 2020
Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique									Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.						Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.	Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.	Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.			Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.
R X P R O [Member] | Brand names [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Relief from royalty This methodology is based on the market remuneration of the use license granted to third parties. The value of the asset is restated by the savings of royalties that the owner would have to own the asset. It is necessary to determine a royalty rate that reflects the appropriate remuneration of the asset. The royalty payments, net of taxes, are discounted to present value.
R X P R O [Member] | Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Multi-period excess earnings method The method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cash flows related to contributory assets.
R X P R O [Member] | Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Valuation technique		Replacement cost This methodology is based on the estimated cost of replacing the referred asset with a new one (acquisition or reconstruction), adjusted to reflect the losses in value resulting from the physical deterioration and the functional and economic obsolescence of that asset.

Business combinations (Detai_13

Business combinations (Details Narrative) - BRL (R$) R$ in Thousands

12 Months Ended

May 23, 2022

Apr. 05, 2022

Mar. 04, 2022

Mar. 04, 2022

Oct. 02, 2021

Aug. 04, 2021

Jun. 02, 2021

May 13, 2021

Apr. 16, 2021

Apr. 08, 2021

Mar. 25, 2021

Jan. 21, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Aug. 04, 2022

Jun. 01, 2021

IfrsStatementLineItems [Line Items]

Transaction costs

R$ 13030

Net revenue

2,329,057

R$ 1719371

R$ 1201191

Income loss before income taxes

428,433

R$ 273462

R$ 335054

Alem Da Medicina [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

100%

Description of acquiree

The aggregate purchase price of R$26,789 is comprised by: i) R$14,952 paid in cash on the transaction closing date; ii) an earn-out (“contingent consideration”) of up of R$ 19,200 is payable in connection with revenue target achievements for 2023 and 2024; and iii) price adjustment related to net debt of R$763 in favor of selling shareholders. The contingent consideration of R$11,074 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 227

Net revenue

12,859

Income loss before income taxes

R$ 1448

Increase in revenue

2,529

Increase in income before income taxes

867

Cardio Papers [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$42,013 is comprised by: i) R$34,924 paid in cash on the transaction closing date; ii) an earn-out (“contingent consideration”) of up of R$15,000 is payable in connection with revenue target achievements for 2023 and 2024 and other goals; and iii) price adjustment related to net debt of R$333 in favor of Afya Brazil. The contingent consideration of R$7,422 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 274

Net revenue

9,934

Income loss before income taxes

2,352

Increase in revenue

2,117

Decrease in income before income taxes

R$ 2041

Glic [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$30,597 is comprised by: i) R$21,602 paid in cash on the transaction closing date and ii) an earn-out (“contingent consideration”) of up of R$12,000 is payable in connection with revenue target achievements for 2023 and 2024 and product development goals. The contingent consideration of R$8,995 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 222

Net revenue

389

Income loss before income taxes

R$ 1539

Increase in revenue

173

Decrease in income before income taxes

700

I Clinic [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$191,120 is comprised of: (i) 62.6% was paid in cash, and (ii) 37.4% was settled with Afya's shares on the transaction closing date.

Transaction costs

R$ 856

Net revenue

16,456

Income loss before income taxes

R$ 8250

Increase in revenue

1,158

Increase in income before income taxes

1,320

Medicinae [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$9,172 is comprised by: i) R$ 5,600 of which 100% was paid in cash on the transaction closing date; and ii) an earn-out (“contingent consideration”) of up of R$ 4,400 is payable in connection with product development goals for 2021 and revenue achievements for 2022. The contingent consideration of R$3,572 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 117

Net revenue

359

Income loss before income taxes

R$ 1518

Increase in revenue

105

Decrease in income before income taxes

113

Harbour [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$11,278 is comprised by: i) R$ 5,000 of which 100% was paid in cash on the transaction closing date; and ii) an earn-out (“contingent consideration”) of up to R$ 9,000 is payable in connection with product development goals for 2021 and 2022 and revenue achievements for 2023. The contingent consideration of R$6,278 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 144

Net revenue

1,945

Income loss before income taxes

127

Increase in revenue

1,435

Increase in income before income taxes

926

Revenue of acquiree since acquisition date

R$ 484

Revenue of combined entity as if combination occurred at beginning of period

268

Cliquefarma [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$ 22,089 is comprised by: (i) R$ 16,166 paid in cash; (ii) R$3,000 settled with Afya's shares on the transaction closing date; and (iii) an earn-out (“contingent consideration”) of R$ 3,000 is payable in relation to product development. The contingent consideration of R$2,923 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 336

Net revenue

3,268

Income loss before income taxes

1,752

Shosp [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$7,901 is comprised by: i) R$ 5,855 was paid in cash; ii) R$ 454 of consideration to be transferred; and iii) an earn-out (“contingent consideration”) of up to R$ 1,793 is payable in relation to product development. The contingent consideration of R$1,592 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 188

Net revenue

1,376

Income loss before income taxes

R$ 448

Increase in revenue

306

Decrease in income before income taxes

82

U N I F I P Moc [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price is R$ 328,322 and the total amount was paid in cash. There are 40 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$ 50,000. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and thus the contingent consideration was not measured at acquisition date. Should the additional seats be approved it will result in additional licenses, which will be measured accordingly if and when approved.

Transaction costs

R$ 177

Net revenue

69,887

Income loss before income taxes

R$ 19458

Increase in revenue

46,150

Increase in income before income taxes

12,847

U N I G R A N [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate original purchase price of R$ 626,116 of which 60% was paid in cash on the transaction closing date, and 40% is payable in cash in four equal installments through 2022 to 2025, adjusted by the CDI rate, was adjusted by R$7,160, because of the actual net debt, to R$618,956. There are 82 additional seats still pending approval which, if approved by MEC, will result in a potential additional payment of up to R$90,200. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and thus the contingent consideration was not measured at acquisition date. Should the additional seats be approved it will result in additional licenses, which will be measured accordingly if and when approved.

Transaction costs

R$ 10990

Net revenue

123,369

Income loss before income taxes

R$ 33450

Increase in revenue

150,456

Increase in income before income taxes

22,191

P X P R O [Member]

IfrsStatementLineItems [Line Items]

Percentage of voting equity interests acquired

100%

Description of acquiree

The aggregate purchase price of R$45,622 is comprised by: i) R$ 30,263 was paid in cash; ii) R$ 76 to be paid as price adjustment, iii) R$5,112 settled with Afya's treasury shares on the transaction closing date; and (iv) an earn-out (“contingent consideration”) of R$ 21,000 is payable in relation to revenue achievements. The contingent consideration of R$10,171 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.

Transaction costs

R$ 264

Net revenue

907

Income loss before income taxes

R$ 984

Increase in revenue

3,155

Increase in income before income taxes

R$ 325

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents [abstract]
Cash and bank deposits	R$ 57509	R$ 88487
Cash equivalents	1,035,573	660,075
Cash and cash equivalents	R$ 1093082	R$ 748562	R$ 1045042	R$ 943209

Cash and cash equivalents (De_2

Cash and cash equivalents (Details Narrative) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Cash equivalents (a)	R$ 1035573	R$ 660075
U S D [Member]
IfrsStatementLineItems [Line Items]
Cash equivalents (a)	R$ 24447	R$ 23228
Bank Certificates Of Deposit [Member]
IfrsStatementLineItems [Line Items]
Percentage of average interest	99.21%
Interbank Certificates Of Deposit [Member]
IfrsStatementLineItems [Line Items]
Percentage of average interest		100.38%

Trade receivables (Details)

Trade receivables (Details) - BRL (R$) R$ in Thousands		Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Trade receivables, gross		R$ 539445	R$ 450806
(-) Allowance for doubtful accounts		(44,046)	(45,013)
Trade receivables, net		495,399	405,793
Current		452,831	378,351
Non-current		42,568	27,442
Tuition Fees [Member]
IfrsStatementLineItems [Line Items]
Trade receivables, gross		356,074	279,915
Educational Content [Member]
IfrsStatementLineItems [Line Items]
Trade receivables, gross	[1]	50,913	69,227
F I E S [Member]
IfrsStatementLineItems [Line Items]
Trade receivables, gross		62,325	61,342
Educational Credits [Member]
IfrsStatementLineItems [Line Items]
Trade receivables, gross	[2]	27,535	5,375
Mobile App Subscription [Member]
IfrsStatementLineItems [Line Items]
Trade receivables, gross	[3]	27,675	20,946
Others [Member]
IfrsStatementLineItems [Line Items]
Trade receivables, gross		R$ 14923	R$ 14001
[1]Related to trade receivables from sales of printed books, e-books and medical courses through digital platform from Medcel, Além da Medicina and CardioPapers.[2]Related to trade receivables from special financing programs and balances outstanding from previous acquisitions.[3]Related to trade receivables from mobile applications subscriptions for digital medical content.

Trade receivables (Details 1)

Trade receivables (Details 1) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Trade receivable	R$ 539445	R$ 450806
Current [member]
IfrsStatementLineItems [Line Items]
Trade receivable	56,280	68,932
Later Than One Months And Not Later Than Three Months [Member]
IfrsStatementLineItems [Line Items]
Trade receivable	90,734	69,299
Later than three months and not later than six months [member]
IfrsStatementLineItems [Line Items]
Trade receivable	80,522	55,764
Later Than One Eighty [Member]
IfrsStatementLineItems [Line Items]
Trade receivable	50,884	72,429
Financial assets neither past due nor impaired [member]
IfrsStatementLineItems [Line Items]
Trade receivable	R$ 261025	R$ 184382

Trade receivables (Details 2)

Trade receivables (Details 2) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Trade Receivables
Balances at the beginning of the period	R$ 45013	R$ 32980	R$ 14763
Additions	(42,708)	(47,819)	(32,081)
Write-offs	43,675	35,786	13,864
Balances at the end of the period	R$ 44046	R$ 45013	R$ 32980

Related parties (Details)

Related parties (Details) - BRL (R$) R$ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Trade receivables	[1]	R$ 917	R$ 692
Other assets	[2]	1,975
Total		2,892	692
Current		2,892	692
Non-current
Accounts Payable To Selling Shareholders	[3]	30,653	54,556
Total		30,653	54,556
Current		30,653	27,278
Non-current			27,278
Other income		477	752	R$ 104
Lease		28,723	23,106	17,673
U E P C [Member]
IfrsStatementLineItems [Line Items]
Other income		477	752	104
R V L Esteves Gestao Imobiliaria S A [Member]
IfrsStatementLineItems [Line Items]
Lease		20,394	15,336	11,288
U N I V A C O Patrimonial Ltda [Member]
IfrsStatementLineItems [Line Items]
Lease		3,409	3,210	2,915
I E S V A P Patrimonial Ltda [Member]
IfrsStatementLineItems [Line Items]
Lease		R$ 4920	R$ 4560	R$ 3470
[1]Refers to sales of educational content from Medcel to UEPC;[2]Refers to amounts to be reimbursed from Bertelsmann SE& Co. KGaA regarding the transaction on which the control of Afya was acquired;[3]Refers to amounts to be payable to our shareholder Nicolau Carvalho Esteves regarding the agreement to which Afya Brazil acquired the right to develop ITPAC Garanhuns medical school, a greenfield unit. The amount represents 50% of the transaction, due in two equal annual installments, adjusted by the CDI rate.

Related parties (Details 1)

Related parties (Details 1) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Parties
Short-term employee benefits	R$ 13564	R$ 11933	R$ 9629
Share-based compensation plans	13,116	20,251	23,989
Total	R$ 26680	R$ 32184	R$ 33618

Related parties (Details Narrat

Related parties (Details Narrative) - Lease Agreements 1 [Member] - BRL (R$) R$ in Thousands					12 Months Ended
	Aug. 02, 2021	Sep. 06, 2018	Sep. 06, 2018	Apr. 25, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Lease term			20 years		20 years
Renewal term					20 years
R V L Esteves Gestao Imobiliaria S A [Member]
IfrsStatementLineItems [Line Items]
Lease expenses	R$ 40				R$ 20394	R$ 15336	R$ 11288
U N I V A C O Patrimonial Ltda [Member]
IfrsStatementLineItems [Line Items]
Percentage of revenue					6.50%
Renewal term					20 years
Lease expenses					R$ 3409	3,210	2,915
I E S V A P Patrimonial Ltda [Member]
IfrsStatementLineItems [Line Items]
Lease term				20 years
Percentage of revenue				7.50%
Renewal term				20 years
Lease expenses					R$ 4920	R$ 4560	R$ 3470
Description of lease term				The lease agreement is for an amount equal to 7.5% of the monthly revenue of IESVAP until maturation.
Instituto Tocantinense Presidente Antonio Carlos S.A. (ITPAC ) [Member] | R V L Esteves Gestao Imobiliaria S A [Member]
IfrsStatementLineItems [Line Items]
Percentage of revenue		7.50%
Instituto De Ensino Superior Presidente Trancredo De Almeida Neves S.A. (IPTAN) [Member] | R V L Esteves Gestao Imobiliaria S A [Member]
IfrsStatementLineItems [Line Items]
Description of lease term	(i) up to June 2022, R$40; (ii) from July 2022 until December 2028, 6.5% of the monthly revenue of ITPAC

Other assets (Details)

Other assets (Details) - BRL (R$) R$ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Other Assets
Indemnification assets	[1]	R$ 145300	R$ 135355
Judicial deposits		12,693	18,825
Prepaid expenses		18,441	10,110
Other FIES receivables		26,440	21,450
Other		40,627	37,099
Total		243,501	222,839
Current		51,745	42,533
Non-current		R$ 191756	R$ 180306
[1]Under the terms of the Share Purchase and Sale Agreements ("Agreements") between the Company and the selling shareholders of certain subsidiaries acquired, the Company assesses that the selling shareholders are exclusively responsible for any provisions (including labor, tax and civil), which are or will be the subject of a claim by any third party, arising from the act or fact occurred, by action or omission, prior to or on the closing dates of the acquisitions.

Investment in associate (Detail

Investment in associate (Details) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Current assets	R$ 1637657	R$ 1206852
Non-current assets	5,561,882	5,240,554
Current liabilities	905,689	766,506
Non-current liabilities	(3,043,692)	(2,680,882)
Net revenue	2,329,057	1,719,371	R$ 1201191
Cost of services	859,552	652,300	434,654
General and administrative expenses	(798,153)	(622,615)	(402,855)
Finance results	(102,042)	(64,566)	(62,290)
Income before income taxesz	428,433	273,462	335,054
Income taxes expenses	35,677	31,179	27,067
Net income for the period	392,756	242,283	307,987
Dividends receivable (included in Other assets)	(6,754)	(11,770)
Associates [member]
IfrsStatementLineItems [Line Items]
Current assets	32,651	33,976
Non-current assets	122,378	109,805
Current liabilities	(22,840)	(35,049)
Non-current liabilities	(96,442)	(91,086)
Equity	35,747	17,646
Company’s share in equity – 30%	10,724	5,294
Goodwill	43,183	43,183
Carrying amount of the investment	53,907	48,477
Net revenue	138,584	127,618	113,965
Cost of services	(57,421)	(57,935)	(55,926)
General and administrative expenses	34,991	24,025	27,341
Finance results	(4,103)	(4,585)	(4,882)
Income before income taxesz	42,069	41,073	25,816
Income taxes expenses	(1,456)	(1,748)	(252)
Net income for the period	40,613	39,325	25,564
Company’s share of income for the period	12,184	11,797	7,698
Opening balance	48,477	51,410	45,634
Dividends received	(6,754)	(11,770)
Dividends receivable (included in Other assets)		(2,960)	(1,922)
Share of income	12,184	11,797	7,698
Closing balance	R$ 53907	R$ 48477	R$ 51410

Property and equipment (Details

Property and equipment (Details) - BRL (R$) R$ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
As of December 31, 2021		R$ 419808
Transfer
As of December 31, 2022		542,087	R$ 419808
As of December 31, 2021		542,087	419,808
Buildings [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		50,760
Transfer		(606)
As of December 31, 2022		86,106	50,760
As of December 31, 2021		86,106	50,760
Machinery And Equipments [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		60,980
Transfer		1,453		(464)
As of December 31, 2022		79,760	60,980
As of December 31, 2021		79,760	60,980
Land [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		18,852
Transfer
As of December 31, 2022		18,852	18,852
As of December 31, 2021		18,852	18,852
Vehicles [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		1,247
Transfer		1
As of December 31, 2022		1,341	1,247
As of December 31, 2021		1,341	1,247
Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		57,338
Transfer		9,719
As of December 31, 2022		80,363	57,338
As of December 31, 2021		80,363	57,338
It Equipment [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		38,262
Transfer		(4,125)
As of December 31, 2022		46,756	38,262
As of December 31, 2021		46,756	38,262
Library Books [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		16,472
Transfer		(5,940)
As of December 31, 2022		14,474	16,472
As of December 31, 2021		14,474	16,472
Laboratories And Clinics [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021
Transfer				464
As of December 31, 2022
As of December 31, 2021
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		144,111
Transfer		(502)
As of December 31, 2022		127,747	144,111
As of December 31, 2021		127,747	144,111
Construction in progress [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		31,786
Transfer
As of December 31, 2022		86,688	31,786
As of December 31, 2021		86,688	31,786
Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		487,975	314,015	176,303
Additions		168,132	125,869	89,832
Business combinations		80	65,623	47,880
Transfer		815
Write-off	[1]	(15,649)	(17,532)
As of December 31, 2022		641,353	487,975	314,015
As of December 31, 2021		641,353	487,975	314,015
Gross carrying amount [member] | Buildings [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		52,433	25,919
Additions		527	1,384
Business combinations				6,771
Transfer		38,884	25,068	19,148
Write-off	[1]	13	62
As of December 31, 2022		91,857	52,433	25,919
As of December 31, 2021		91,857	52,433	25,919
Gross carrying amount [member] | Machinery And Equipments [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		77,371	68,503	44,329
Additions		36,486	10,268	13,806
Business combinations		45	12,810	8,973
Transfer		(5,353)	3	1,395
Write-off	[1]	(8,159)	(14,213)
As of December 31, 2022		100,390	77,371	68,503
As of December 31, 2021		100,390	77,371	68,503
Gross carrying amount [member] | Land [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		18,852	13,401	7,005
Additions			5,451	672
Business combinations				5,724
Transfer
Write-off	[1]
As of December 31, 2022		18,852	18,852	13,401
As of December 31, 2021		18,852	18,852	13,401
Gross carrying amount [member] | Vehicles [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		1,467	1,215	707
Additions		968	111
Business combinations			346	508
Transfer		(449)
Write-off	[1]	(933)	(205)
As of December 31, 2022		1,053	1,467	1,215
As of December 31, 2021		1,053	1,467	1,215
Gross carrying amount [member] | Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		69,834	29,131	21,438
Additions		26,047	21,075	4,550
Business combinations			16,684	3,061
Transfer		(5,669)	82	82
Write-off	[1]	500	2,862
As of December 31, 2022		90,712	69,834	29,131
As of December 31, 2021		90,712	69,834	29,131
Gross carrying amount [member] | It Equipment [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		53,184	28,511	15,994
Additions		15,766	19,511	9,657
Business combinations		35	10,138	2,493
Transfer		6,600	9	367
Write-off	[1]	(6,992)	(4,985)
As of December 31, 2022		68,593	53,184	28,511
As of December 31, 2021		68,593	53,184	28,511
Gross carrying amount [member] | Library Books [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		30,072	21,624	18,139
Additions		645	3,392	1,012
Business combinations			5,142	2,473
Transfer		6,645
Write-off	[1]		(86)
As of December 31, 2022		37,362	30,072	21,624
As of December 31, 2021		37,362	30,072	21,624
Gross carrying amount [member] | Laboratories And Clinics [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021				1,049
Additions
Business combinations
Transfer				(1,049)
Write-off	[1]
As of December 31, 2022
As of December 31, 2021
Gross carrying amount [member] | Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		152,976	122,005	30,911
Additions		2,667	4,720	54,748
Business combinations			17,425	12,787
Transfer		(9,797)	9,376	23,559
Write-off	[1]		(550)
As of December 31, 2022		145,846	152,976	122,005
As of December 31, 2021		145,846	152,976	122,005
Gross carrying amount [member] | Construction in progress [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		31,786	3,706	36,731
Additions		85,026	59,957	5,387
Business combinations			3,078	5,090
Transfer		(30,046)	(34,538)	(43,502)
Write-off	[1]	(78)	(417)
As of December 31, 2022		86,688	31,786	3,706
As of December 31, 2021		86,688	31,786	3,706
Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(68,167)	(53,634)	(36,983)
Write-off	[1]	13,952	15,928
As of December 31, 2022		(99,266)	(68,167)	(53,634)
Depreciation		(45,051)	(30,461)	(16,651)
As of December 31, 2021		(99,266)	(68,167)	(53,634)
Accumulated depreciation and amortisation [member] | Buildings [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(1,673)
Write-off	[1]
As of December 31, 2022		(5,751)	(1,673)
Depreciation		(3,472)	(1,673)
As of December 31, 2021		(5,751)	(1,673)
Accumulated depreciation and amortisation [member] | Machinery And Equipments [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(16,391)	(19,322)	(13,793)
Write-off	[1]	5,474	10,146
As of December 31, 2022		(20,630)	(16,391)	(19,322)
Depreciation		(11,166)	(7,215)	(5,065)
As of December 31, 2021		(20,630)	(16,391)	(19,322)
Accumulated depreciation and amortisation [member] | Land [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021
Write-off	[1]
As of December 31, 2022
Depreciation
As of December 31, 2021
Accumulated depreciation and amortisation [member] | Vehicles [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(220)	(171)	(59)
Write-off	[1]	791	147
As of December 31, 2022		288	(220)	(171)
Depreciation		(284)	(196)	(112)
As of December 31, 2021		288	(220)	(171)
Accumulated depreciation and amortisation [member] | Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(12,496)	(8,089)	(5,890)
Write-off	[1]	153	1,194
As of December 31, 2022		(10,349)	(12,496)	(8,089)
Depreciation		(7,725)	(5,601)	(2,199)
As of December 31, 2021		(10,349)	(12,496)	(8,089)
Accumulated depreciation and amortisation [member] | It Equipment [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(14,922)	(10,851)	(6,537)
Write-off	[1]	7,350	3,458
As of December 31, 2022		(21,837)	(14,922)	(10,851)
Depreciation		(10,140)	(7,529)	(4,314)
As of December 31, 2021		(21,837)	(14,922)	(10,851)
Accumulated depreciation and amortisation [member] | Library Books [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(13,600)	(10,817)	(8,663)
Write-off	[1]	67	633
As of December 31, 2022		(22,888)	(13,600)	(10,817)
Depreciation		(3,415)	(3,416)	(2,154)
As of December 31, 2021		(22,888)	(13,600)	(10,817)
Accumulated depreciation and amortisation [member] | Laboratories And Clinics [Member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021				(386)
Write-off	[1]
As of December 31, 2022
Depreciation				(78)
As of December 31, 2021
Accumulated depreciation and amortisation [member] | Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021		(8,865)	(4,384)	(1,655)
Write-off	[1]	117	350
As of December 31, 2022		(18,099)	(8,865)	(4,384)
Depreciation		(8,849)	(4,831)	(2,729)
As of December 31, 2021		(18,099)	(8,865)	(4,384)
Accumulated depreciation and amortisation [member] | Construction in progress [member]
IfrsStatementLineItems [Line Items]
As of December 31, 2021
Write-off	[1]
As of December 31, 2022
Depreciation
As of December 31, 2021
[1]Refers to items written-off as result of lack of expectation of future use, in connection with the Company’s physical inventory procedures.

Intangible assets and goodwil_2

Intangible assets and goodwill (Details) - BRL (R$) R$ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		R$ 3900835
Write-off		25		R$ 2374
Intangible assets and goodwill, balance at end		4,041,491		3,900,835
Intangible assets and goodwill		4,041,491		3,900,835
Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		4,093,140		2,684,559		1,361,640
Additions		150,023	[1],[2]	176,110	[3]	19,649
Disposals						(460)
Business combinations		106,595		1,234,611		1,303,730
Write-off		(447)		(2,140)	[4]
Remesurement	[5]	(8,637)
Transfer amount		(815)
Intangible assets and goodwill, balance at end		4,339,859		4,093,140		2,684,559
Intangible assets and goodwill		4,339,859		4,093,140		2,684,559
Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(192,305)		(111,549)		(49,302)
Disposals						460
Write-off		422		(234)
Intangible assets and goodwill, balance at end		(298,368)		(192,305)		(111,549)
Amortization		(106,485)		(80,522)		(62,707)
Intangible assets and goodwill		(298,368)		(192,305)		(111,549)
Goodwill [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		1,184,336
Intangible assets and goodwill, balance at end		1,257,045		1,184,336
Intangible assets and goodwill		1,257,045		1,184,336
Goodwill [member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		1,184,336		810,656		459,409
Additions	[1],[2]	39,100
Business combinations		42,246		373,680		351,247
Remesurement	[5]	(8,637)
Intangible assets and goodwill, balance at end		1,257,045		1,184,336		810,656
Intangible assets and goodwill		1,257,045		1,184,336		810,656
Goodwill [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning
Intangible assets and goodwill, balance at end
Amortization
Intangible assets and goodwill
Licences [member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning	[2]	2,165,406		1,451,270		703,772
Additions	[2]	24,408	[1]	108,000	[3]
Business combinations	[2]			606,136		747,498
Intangible assets and goodwill, balance at end	[2]	2,189,814		2,165,406		1,451,270
Intangible assets and goodwill	[2]	2,189,814		2,165,406		1,451,270
Licences [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning	[2]
Intangible assets and goodwill, balance at end	[2]
Amortization	[2]
Intangible assets and goodwill	[2]
Brand names [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		167,105		124,840
Intangible assets and goodwill, balance at end				167,105		124,840
Intangible assets and goodwill				167,105		124,840
Brand names [member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		133,369		75,014		32,111
Business combinations		51,185		58,355		42,903
Write-off				(22)
Transfer amount				(2,472)
Intangible assets and goodwill, balance at end		182,060		133,369		75,014
Intangible assets and goodwill		182,060		133,369		75,014
Brand names [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(8,529)		(3,502)		(1,150)
Intangible assets and goodwill, balance at end		(14,955)		(8,529)		(3,502)
Amortization		(6,426)		(5,027)		(2,352)
Intangible assets and goodwill		(14,955)		(8,529)		(3,502)
Customer-related intangible assets [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		289,007
Intangible assets and goodwill, balance at end		223,453		289,007
Intangible assets and goodwill		223,453		289,007
Customer-related intangible assets [member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		431,277		283,539		125,413
Additions		80	[1],[2]	684	[3]
Business combinations		3,929		147,054		158,126
Transfer amount		530
Intangible assets and goodwill, balance at end		435,816		431,277		283,539
Intangible assets and goodwill		435,816		431,277		283,539
Customer-related intangible assets [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(142,270)		(85,832)		(37,872)
Intangible assets and goodwill, balance at end		(212,363)		(142,270)		(85,832)
Amortization		(70,093)		(56,438)		(47,960)
Intangible assets and goodwill		(212,363)		(142,270)		(85,832)
Computer software [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		9,060
Intangible assets and goodwill, balance at end		26,023		9,060
Intangible assets and goodwill		26,023		9,060
Computer software [member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		21,759		16,221		9,389
Additions		1,423	[1],[2]	3,044	[3]	4,175
Disposals						(460)
Business combinations		33		1,474		3,117
Write-off		(381)		1,020	[4]
Transfer amount		20,466
Intangible assets and goodwill, balance at end		43,300		21,759		16,221
Intangible assets and goodwill		43,300		21,759		16,221
Computer software [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(12,699)		(6,256)		(4,536)
Disposals						460
Write-off		365		(599)
Intangible assets and goodwill, balance at end		(17,277)		(12,699)		(6,256)
Amortization		(4,943)		(5,844)		(2,180)
Intangible assets and goodwill		(17,277)		(12,699)		(6,256)
Education Content [Member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		633
Intangible assets and goodwill, balance at end		43,027		633
Intangible assets and goodwill		43,027		633
Education Content [Member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		17,305		17,305		17,305
Additions	[1],[2]	11,231
Business combinations		2,627
Write-off		(7)
Transfer amount		38,433
Intangible assets and goodwill, balance at end		69,589		17,305		17,305
Intangible assets and goodwill		69,589		17,305		17,305
Education Content [Member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(16,672)		(7,692)		(4,876)
Write-off		57
Transfer amount		(313)
Intangible assets and goodwill, balance at end		(26,562)		(16,672)		(7,692)
Amortization		(9,634)		(8,980)		(2,816)
Intangible assets and goodwill		(26,562)		(16,672)		(7,692)
Educational Platform [Member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		64,966
Intangible assets and goodwill, balance at end		38,658		64,966
Intangible assets and goodwill		38,658		64,966
Educational Platform [Member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		76,444		27,902		12,191
Additions		14,761	[1],[2]	39,686	[3]	15,227
Business combinations				11,599		484
Write-off		(9)		(2,743)	[4]
Transfer amount		(35,499)
Intangible assets and goodwill, balance at end		55,697		76,444		27,902
Intangible assets and goodwill		55,697		76,444		27,902
Educational Platform [Member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(11,478)		(8,235)		(868)
Write-off				365
Transfer amount		313
Intangible assets and goodwill, balance at end		(17,039)		(11,478)		(8,235)
Amortization		(5,874)		(3,608)		(7,367)
Intangible assets and goodwill		(17,039)		(11,478)		(8,235)
Software In Progress [Member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		28,847
Intangible assets and goodwill, balance at end		14,734		28,847
Intangible assets and goodwill		14,734		28,847
Software In Progress [Member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		28,847		2,297		2,050
Additions		26,141	[1],[2]	23,700	[3]	247
Business combinations				3,267
Write-off		(28)		(417)	[4]
Transfer amount		(40,226)
Intangible assets and goodwill, balance at end		14,734		28,847		2,297
Intangible assets and goodwill		14,734		28,847		2,297
Software In Progress [Member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning
Intangible assets and goodwill, balance at end
Amortization
Intangible assets and goodwill
Developed Technology Intangible Assets [Member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Business combinations		5,520		33,046		355
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		33,740
Intangible assets and goodwill, balance at end		80,656		33,740
Intangible assets and goodwill		80,656		33,740
Technology-based intangible assets [member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		34,397		355
Additions		32,879	[1],[2]	996	[3]
Transfer amount		17,953
Intangible assets and goodwill, balance at end		90,749		34,397		355
Intangible assets and goodwill		90,749		34,397		355
Technology-based intangible assets [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning		(657)		(32)
Intangible assets and goodwill, balance at end		(10,093)		(657)		(32)
Amortization		(9,436)		(625)		(32)
Intangible assets and goodwill		(10,093)		(657)		(32)
Other [Member] | Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Business combinations		1,055
Intangible assets and goodwill, balance at end		1,055
Intangible assets and goodwill		1,055
Others [Member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at end		976
Intangible assets and goodwill		976
Others [Member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Intangible assets and goodwill, balance at beginnning
Intangible assets and goodwill, balance at end		(79)
Amortization		(79)
Intangible assets and goodwill		R$ 79
[1]During the measurement period, the goodwill for the acquisition of Unigranrio was adjusted by R$39,100 (R$130,073 initial goodwill) as a result of an increase of liabilities regarding tax contingencies.[2]On March 18, 2022, Afya announced that MEC authorized the increase of 28 seats of Centro Universitário São Lucas, in Ji-Parana located in the state of Rondônia. The earn-out related to the seats approval is R$800 per seat, adjusted by the CDI rate from the closing until the payment date, of which 50% was paid in April 2022 and the remaining amount is payable in cash in two equal installments through 2024.[3]On November 05, 2021 Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") authorized the operation of 120 medical school seats in Garanhuns, for which our shareholder Nicolau Carvalho Esteves entered into an agreement with Afya Brazil pursuant to which he assigned to Afya Brazil the right to develop the ITPAC Garanhuns greenfield unit, a medical school in the city of Garanhuns, State of Pernambuco. Management assessed the aspects of such transaction and concluded that the transaction does not fall under the definition of business, but an acquisition of license with indefinite useful life recognized in intangible assets. Total purchase price was R$108,000 of which 50% was paid in cash on the transaction closing date and 50% in two equal annual installments, adjusted by the CDI rate.[4]Refers to intangible assets written-off as result of lack of expectation of future use.[5]During the measurement period, R$8,637 of goodwill (R$38,446 initial goodwill) arising from the acquisition of RXPRO was reduced, in connection with management’s view of remote likelihood of RXPRO achieving the revenue goals stablished at the terms of the earn-out.

Intangible assets and goodwil_3

Intangible assets and goodwill (Details 1) - Carrying Amounts [Member] - BRL (R$) R$ in Thousands		Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Goodwill		R$ 1257045	R$ 1184336
Licenses with indefinite useful life		2,189,814	2,165,406
Cash generating units		4,814,424	4,355,135
I P T A N Instituto De Ensino Superior Presidente Trancredo De Almeida Neves S A [Member]
IfrsStatementLineItems [Line Items]
Goodwill		17,446	17,446
Licenses with indefinite useful life		57,214	57,214
Cash generating units		126,024	140,522
Instituto De Educacao Superior Do Vale Do Parnaiba S A [Member]
IfrsStatementLineItems [Line Items]
Goodwill		27,956	27,956
Licenses with indefinite useful life		81,366	81,366
Cash generating units		129,305	112,260
Centro De Ciencias Em Saude De Itajuba S A [Member]
IfrsStatementLineItems [Line Items]
Goodwill		4,664	4,664
Licenses with indefinite useful life		56,737	56,737
Cash generating units		53,540	49,030
Instituto De Ensino Superior Do Piaui S A [Member]
IfrsStatementLineItems [Line Items]
Goodwill		73,838	73,838
Licenses with indefinite useful life		179,693	179,693
Cash generating units		322,968	346,286
F A D E P Faculdade Educacional De Pato Branco Ltda [Member]
IfrsStatementLineItems [Line Items]
Goodwill		49,661	49,661
Licenses with indefinite useful life		70,606	70,606
Cash generating units		153,100	153,791
Instituto Educacional Santo Agostinho S A [Member]
IfrsStatementLineItems [Line Items]
Goodwill		58,903	58,903
Licenses with indefinite useful life		144,507	144,507
Cash generating units		314,967	302,330
Institutode Pesquisae Ensino Medicodo Estadode Minas Gerais Ltda [Member]
IfrsStatementLineItems [Line Items]
Goodwill		87,647	87,647
Licenses with indefinite useful life
Cash generating units		192,079	126,965
Instituto Paraensede Educacaoe Cultura Ltda [Member]
IfrsStatementLineItems [Line Items]
Goodwill
Licenses with indefinite useful life		108,000	108,000
Cash generating units		148,067	131,360
Uni Redentor [Member]
IfrsStatementLineItems [Line Items]
Goodwill		77,662	77,662
Licenses with indefinite useful life		121,477	121,477
Cash generating units		242,600	246,320
Uni S L [Member]
IfrsStatementLineItems [Line Items]
Goodwill	[1]	4,420	4,420
Licenses with indefinite useful life	[1]	273,795	249,387
Cash generating units	[1]	398,492	305,044
F E S A R [Member]
IfrsStatementLineItems [Line Items]
Goodwill		71,664	71,664
Licenses with indefinite useful life		141,616	141,616
Cash generating units		244,084	279,038
F C M P B [Member]
IfrsStatementLineItems [Line Items]
Goodwill		110,483	110,483
Licenses with indefinite useful life		235,018	235,018
Cash generating units		415,453	401,244
I T P A C Garanhuns [Member]
IfrsStatementLineItems [Line Items]
Goodwill
Licenses with indefinite useful life		108,000	108,000
Cash generating units		112,628	107,232
Medical Harbour [Member]
IfrsStatementLineItems [Line Items]
Goodwill			4,022
Licenses with indefinite useful life
Cash generating units			9,150
Medcel And C B B W [Member]
IfrsStatementLineItems [Line Items]
Goodwill		169,975	139,294
Licenses with indefinite useful life
Cash generating units		279,684	235,300
Practice Management Tools And Electronic Prescription [Member]
IfrsStatementLineItems [Line Items]
Goodwill		106,774	113,362
Licenses with indefinite useful life
Cash generating units		216,297	227,909
Clinical Decision Software [Member]
IfrsStatementLineItems [Line Items]
Goodwill		87,018	87,018
Licenses with indefinite useful life
Cash generating units		153,526	147,592
Cliquefarma [Member]
IfrsStatementLineItems [Line Items]
Goodwill		6,588
Licenses with indefinite useful life
Cash generating units		20,045
Moc [Member]
IfrsStatementLineItems [Line Items]
Goodwill		87,777	87,777
Licenses with indefinite useful life		190,247	190,247
Cash generating units		369,007	356,789
U N I G R A N R I O [Member]
IfrsStatementLineItems [Line Items]
Goodwill		169,173	130,073
Licenses with indefinite useful life		421,538	421,538
Cash generating units		854,861	630,185
R X P R O [Member]
IfrsStatementLineItems [Line Items]
Goodwill		29,809	38,446
Licenses with indefinite useful life
Cash generating units		36,675	46,788
Glic [Member]
IfrsStatementLineItems [Line Items]
Goodwill		15,587
Licenses with indefinite useful life
Cash generating units		R$ 31022
[1]See Note 12 for further details on goodwill changes between 2021 and 2022.

Intangible assets and goodwil_4

Intangible assets and goodwill (Details 2)	12 Months Ended
	Dec. 31, 2022
Customer Relationships Medicine [Member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	6 years
Customer Relationships Other Courses [Member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	4 years 6 months
Computer software [member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	5 years
Education Content [Member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	3 years
Brand names [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	2 years
Brand names [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	30 years
Technology-based intangible assets [member]
IfrsStatementLineItems [Line Items]
Estimated useful lives of intangible assets	5 years

Intangible assets and goodwil_5

Intangible assets and goodwill (Details Narrative)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Discount rate applied to cash flow projections		12.10%
Explicit projection period	5 years
Goodwill [member]
IfrsStatementLineItems [Line Items]
Description of key assumptions on which management has based cash flow projections	An increase of 25 basis points in management’s estimated discount rate applied to the cash flow projections of each CGU for the year ended December 31, 2022, or a decrease of 25 basis points on estimated EBITDA would have not resulted in significant impacts on these financial statements.
Bottom of range [member]
IfrsStatementLineItems [Line Items]
Discount rate applied to cash flow projections	13.14%
Bottom of range [member] | Brand names [member]
IfrsStatementLineItems [Line Items]
Perpetuity growth rate	3%
Top of range [member]
IfrsStatementLineItems [Line Items]
Discount rate applied to cash flow projections	15.40%
Top of range [member] | Brand names [member]
IfrsStatementLineItems [Line Items]
Perpetuity growth rate	7.30%

Financial assets and financia_3

Financial assets and financial liabilities (Details) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Trade receivables	R$ 495399	R$ 405793
Total	42,568	27,442
Financial assets at amortised cost, class [member]
IfrsStatementLineItems [Line Items]
Trade receivables	495,399	405,793
Total	495,399	405,793
Current	452,831	378,351
Non-current	R$ 42568	R$ 27442

Financial assets and financia_4

Financial assets and financial liabilities (Details 1) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Loans and financing	R$ 1882901	R$ 1374876
Lease liabilities	769,525	714,085	R$ 447703
Accounts payable to selling shareholders	528,678	679,826
Total	3,243,280	2,841,513
Financial liabilities at amortised cost, class [member]
IfrsStatementLineItems [Line Items]
Trade payables	71,482	59,098
Loans and financing	1,882,901	1,374,876
Lease liabilities	769,525	714,085
Accounts payable to selling shareholders	528,678	679,826
Lease liabilities	62,176	72,726
Advances from customers	133,050	114,585
Total	3,447,812	3,015,196
Current	706,080	581,685
Non-current	R$ 2741732	R$ 2433511

Financial assets and financia_5

Financial assets and financial liabilities (Details 2) - BRL (R$) R$ / shares in Units, R$ in Thousands				12 Months Ended				24 Months Ended
	Apr. 26, 2021	Dec. 23, 2020	Jul. 23, 2019	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Jun. 30, 2021	Oct. 23, 2020	Oct. 01, 2020
IfrsStatementLineItems [Line Items]
Loans and financing				R$ 1882901		R$ 1374876		R$ 1882901
Current				145,202		128,720		145,202
Non-current				1,737,699		1,246,156		1,737,699
Covertable preffered stock shares	150,000
Par value per share	R$ 0.00005
Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan	R$ 821805
Right-of-use assets, balance at beginning				663,686		419,074		419,074
Lease liabilities, balance at beginning				714,085		447,703		447,703
Right-of-use assets, additions				42,250		62,689
Lease liabilities, additions				42,250		62,689
Right-of-use assets, remeasurement				58,623		95,962
Lease liabilities, remeasurement				58,623		95,962
Right-of-use assets, business combinations						139,514
Lease liabilities, business combinations						139,514
Right-of-use assets, depreciation expense				(54,684)		(43,237)
Lease liabilities, depreciation expense
Right-of-use assets, interest expense
Lease liabilities, interest expense				88,571		67,212	R$ 44458
Right-of-use assets, payments of lease liabilities
Lease liabilities, payments of lease liabilities				(113,512)		(87,751)
Right-of-use assets, Write-off				(19,802)	[1]			(10,316)
Lease liabilities, Write-off				(20,492)	[1]	(11,244)
Right-of-use assets, balance at ending				690,073		663,686	419,074	690,073
Lease liabilities, balance at ending				769,525		714,085	R$ 447703	769,525
Right-of-use assets, current
Lease liabilities, current				32,459		24,955		32,459
Right-of-use assets, non-current				690,073		663,686		690,073
Lease liabilities, non-current				R$ 737066		689,130		737,066
Financiadorade Estudose Projetos F I N E P [Member]
IfrsStatementLineItems [Line Items]
Intrest rate									1.75%		1.62%
Loan amount			R$ 16153							R$ 30000
Borrowings amount first tranche		R$ 4130	6,734
Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan			R$ 150000
Institutode Pesquisae Ensino Medicodo Estadode Minas Gerais Ltda [Member]
IfrsStatementLineItems [Line Items]
Equal installments payables											R$ 500000
2025 [Member]
IfrsStatementLineItems [Line Items]
Financial institution				Banco Itaú Unibanco S.A.
Interest rate				CDI + 1.90% p.y.
Maturity				2025
Loans and financing				R$ 518134		510,972		518,134
2027 [member]
IfrsStatementLineItems [Line Items]
Financial institution				FINEP
Interest rate				TJLP p.y.
Maturity				2027
Loans and financing				R$ 8418		10,145		8,418
2024 [Member]
IfrsStatementLineItems [Line Items]
Financial institution				Banco Itaú Unibanco S.A.
Interest rate				CDI + 1.75% p.y.
Maturity				2024
Loans and financing				R$ 32252		31,199		32,252
2026 [Member]
IfrsStatementLineItems [Line Items]
Financial institution				Softbank
Interest rate				6.5% p.y.
Maturity				2026
Loans and financing				R$ 824258		822,560		824,258
2028 [Member]
IfrsStatementLineItems [Line Items]
Financial institution				Debentures
Interest rate				CDI + 1.80 p.y.
Maturity				2028
Loans and financing				R$ 499839				R$ 499839
[1]Refers to anticipated termination of real estate leasing contracts.

Financial assets and financia_6

Financial assets and financial liabilities (Details 3) - BRL (R$) R$ in Thousands

1 Months Ended

12 Months Ended

Apr. 05, 2022

Mar. 04, 2022

Nov. 05, 2021

Oct. 02, 2021

Aug. 04, 2021

May 13, 2021

Apr. 08, 2021

Nov. 09, 2020

May 05, 2020

Mar. 23, 2022

Mar. 18, 2022

Apr. 16, 2021

Mar. 25, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

May 23, 2022

Apr. 03, 2022

Apr. 03, 2021

Nov. 05, 2020

Nov. 03, 2020

Oct. 01, 2020

Apr. 03, 2020

Jan. 31, 2020

May 09, 2019

IfrsStatementLineItems [Line Items]

Opening balance

R$ 528678

R$ 679826

Current

261,711

239,849

Non-current

266,967

439,977

Opening balance

679,826

Ending balance

528,678

679,826

Additional license paid

R$ 30174

Defined benefit obligation

R$ 2206

R$ 4053

Transaction price allocated to remaining performance obligations

R$ 54000

R$ 1781

R$ 454

Non-current payables for purchase of energy

R$ 618956

Accounts Payable To Selling Shareholders [Member]

IfrsStatementLineItems [Line Items]

Opening balance

528,678

679,826

R$ 518240

R$ 300237

Opening balance

679,826

518,240

300,237

Cash flows

[1],[2]

(261,188)

(192,681)

(134,518)

Acquisition of IPEC

24,408

54,000

Interest

68,064

31,915

13,884

Reversals

(10,353)

Business combinations

243,816

343,140

Contingent consideration on Business combinations

27,921

24,536

Compensation of legal proceedings disbursement

(4,503)

Ending balance

528,678

679,826

R$ 518240

R$ 300237

Instituto Educacional Santo Agostinho S A [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[3]

41,581

Opening balance

[3]

41,581

Ending balance

[3]

R$ 41581

Ownership Interest

100%

100%

90%

Remaining accounts payable

R$ 29770

R$ 29770

R$ 39695

Institutode Pesquisae Ensino Medicodo Estadode Minas Gerais Ltda [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[4]

R$ 22654

R$ 30233

Opening balance

[4]

30,233

Ending balance

[4]

R$ 22654

R$ 30233

Ownership Interest

100%

100%

100%

Remaining accounts payable

R$ 45303

Equal installments payables

R$ 9061

Equal installments payables

R$ 500000

Uni Redentor [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[5]

R$ 72064

R$ 85506

Opening balance

[5]

85,506

Ending balance

[5]

72,064

85,506

Ownership Interest

100%

Remaining accounts payable

R$ 100000

Equal installments payables

4,503

Uni S L [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[6]

37,301

42,672

Opening balance

[6]

42,672

Ending balance

[6]

37,301

42,672

Ownership Interest

100%

Remaining accounts payable

R$ 60456

Equal installments payables

R$ 7816

R$ 1716

F C M P B [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[7]

111,755

149,175

Opening balance

[7]

149,175

Ending balance

[7]

111,755

149,175

Ownership Interest

100%

Remaining accounts payable

R$ 188894

Medicinae [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[8]

3,887

Opening balance

[8]

3,887

Ending balance

[8]

3,887

Contingent consideration from the acquisition

3,572

1,716

Ownership Interest

100%

Remaining accounts payable

R$ 4400

Medical Harbour [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[9]

4,053

6,801

Opening balance

[9]

6,801

Ending balance

[9]

4,053

6,801

Contingent consideration from the acquisition

R$ 6278

Ownership Interest

100%

Remaining accounts payable

R$ 9000

Cliquefarma [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[10]

3,050

Opening balance

[10]

3,050

Ending balance

[10]

3,050

Contingent consideration from the acquisition

R$ 2923

Ownership Interest

100%

Remaining accounts payable

R$ 3000

Shosp [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[1],[2]

2,206

2,141

Opening balance

[1],[2]

2,141

Ending balance

[1],[2]

2,206

2,141

Contingent consideration from the acquisition

R$ 1592

Ownership Interest

100%

Remaining accounts payable

R$ 1793

U N I G R A N R I O [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[11]

216,716

249,979

Opening balance

[11]

249,979

Ending balance

[11]

216,716

249,979

Ownership Interest

100%

R X P R O [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[12]

1,781

10,245

Opening balance

[12]

10,245

Ending balance

[12]

1,781

10,245

Contingent consideration from the acquisition

8,637

R$ 10171

Ownership Interest

100%

Remaining accounts payable

R$ 21000

Guaranhuns [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[13]

30,653

54,556

Opening balance

[13]

54,556

Ending balance

[13]

30,653

54,556

Alem Da Medicina [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[14]

11,996

Opening balance

[14]

Ending balance

[14]

11,996

Contingent consideration from the acquisition

R$ 11074

Ownership Interest

100%

Remaining accounts payable

R$ 19200

Equal installments payables

763

Defined benefit obligation

R$ 11074

Cardi Papers [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[15]

7,979

Opening balance

[15]

Ending balance

[15]

7,979

Glic [Member]

IfrsStatementLineItems [Line Items]

Opening balance

[16]

9,520

Opening balance

[16]

Ending balance

[16]

R$ 9520

Contingent consideration from the acquisition

R$ 8995

Ownership Interest

100%

Remaining accounts payable

R$ 12000

Defined benefit obligation

R$ 8995

I T P A C Garanhuns [Member]

IfrsStatementLineItems [Line Items]

Ownership Interest

100%

Remaining accounts payable

R$ 54000

Cardio Papers [Member]

IfrsStatementLineItems [Line Items]

Contingent consideration from the acquisition

R$ 7422

Ownership Interest

100%

Remaining accounts payable

R$ 15000

Equal installments payables

333

Defined benefit obligation

R$ 7422

[1]On May 13, 2021, Afya Brazil acquired 100 454 1,793 2,206 30,174 90 39,695 29,770 29,770 100 45,303 9,061 100 100,000 4,503 100 60,456 7,816 100 188,894 100 4,400 1,716 100 9,000 4,053 100 3,000 100 618,956 100 21,000 1,781 100 54,000 54,000 100 19,200 11,074 763 April 5, 2022 100 15,000 7,422 333 100 12,000 8,995

Financial assets and financia_7

Financial assets and financial liabilities (Details 4) - BRL (R$) R$ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Financial Assets And Financial Liabilities
Notes payable beginning		R$ 72726	R$ 76181
Payments	[1]	(15,008)	(11,068)
Monetary indexation		4,458	7,613
Notes payable ending		62,176	72,726
Current liabilities		62,176	14,478
Non-current liabilities			R$ 58248
[1]The amounts have been included on the investing activities of the cash flow statement.

Financial assets and financia_8

Financial assets and financial liabilities (Details 5) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Financial assets, at carrying amount	R$ 42568	R$ 27442
Financial assets, at fair value	42,568	27,442
Financial liabilities, at carrying amount	3,243,280	2,841,513
Financial liabilities, at fair value	3,294,674	2,853,773
Loans And Financing [Member]
IfrsStatementLineItems [Line Items]
Financial liabilities, at carrying amount	1,882,901	1,374,876
Financial liabilities, at fair value	1,934,295	1,387,136
Lease liabilities [member]
IfrsStatementLineItems [Line Items]
Financial liabilities, at carrying amount	769,525	714,085
Financial liabilities, at fair value	769,525	714,085
Accounts Payable To Selling Shareholders [Member]
IfrsStatementLineItems [Line Items]
Financial liabilities, at carrying amount	528,678	679,826
Financial liabilities, at fair value	528,678	679,826
Notes Payable[Member]
IfrsStatementLineItems [Line Items]
Financial liabilities, at carrying amount	62,176	72,726
Financial liabilities, at fair value	62,176	72,726
Trade receivables [member]
IfrsStatementLineItems [Line Items]
Financial assets, at carrying amount	42,568	27,442
Financial assets, at fair value	R$ 42568	R$ 27442

Financial assets and financia_9

Financial assets and financial liabilities (Details 6) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 42568	R$ 27442
Base rate	R$ 97094	R$ 111454
Floating interest rate [member] | Interest rate risk [member] | Debentures [Member]
IfrsStatementLineItems [Line Items]
Index - % per year	CDI + 1.80%
Base rate	R$ 77225
Floating interest rate [member] | Interest rate risk [member] | Loans And Financing [Member]
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 518134
Index - % per year	CDI + 1.90%	CDI + 1,62%
Base rate	R$ 80570	R$ 55032
Floating interest rate [member] | Interest rate risk [member] | Instituto De Ensino Superior Presidente Trancredo De Almeida Neves S.A. (IPTAN) [Member] [Default Label]
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 32252	R$ 31199
Index - % per year	CDI + 1.75%	CDI + 1,75%
Base rate	R$ 4966	R$ 3401
Floating interest rate [member] | Interest rate risk [member] | Loans And Financing Two [Member]
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 8418	R$ 10145
Index - % per year	TJLP	TJLP
Base rate	R$ 620	R$ 617
Floating interest rate [member] | Interest rate risk [member] | AccountsPayableToSellingShareholdersOneMember
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 491143	R$ 612121
Index - % per year	CDI	CDI
Base rate	R$ 67041	R$ 56009
Floating interest rate [member] | Interest rate risk [member] | Notes Payable[Member]
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 62176	R$ 72726
Index - % per year	IPCA	IPCA
Base rate	R$ 3600	R$ 531
Floating interest rate [member] | Interest rate risk [member] | Cash Equivalents [Member] | Increase in basis points +75 [Member]
IfrsStatementLineItems [Line Items]
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, assets	(4,504)	(4,814)
Floating interest rate [member] | Interest rate risk [member] | Cash Equivalents [Member] | Increase in basis points +150 [Member]
IfrsStatementLineItems [Line Items]
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, assets	(9,010)	(9,628)
Floating interest rate [member] | Interest rate risk [member] | Accounts Payable To Selling Shareholders Two [Member]
IfrsStatementLineItems [Line Items]
Balance as of ending		R$ 41581
Index - % per year		IPCA + 4,1%
Base rate		R$ 1708
Cash Equivalents [Member] | Floating interest rate [member] | Interest rate risk [member]
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 1011126	R$ 636847
Index - % per year	99.21% of CDI	100.38% CDI
Base rate	R$ 136928	R$ 5844
Debentures [Member] | Floating interest rate [member] | Interest rate risk [member]
IfrsStatementLineItems [Line Items]
Balance as of ending	R$ 499839
Loans And Financing [Member] | Floating interest rate [member] | Interest rate risk [member]
IfrsStatementLineItems [Line Items]
Balance as of ending		R$ 510972

Financial assets and financi_10

Financial assets and financial liabilities (Details 7) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Cash and cash equivalents	R$ 344520	R$ 296480	R$ 101833
Exposure [Member] | Currency risk [member]
IfrsStatementLineItems [Line Items]
Cash and cash equivalents	24,447
Increase in Foreign Currency Sensitivity +10% [Member] | Currency risk [member]
IfrsStatementLineItems [Line Items]
Cash and cash equivalents	2,445
Decrease in Foreign Currency Sensitivity -10% [Member] | Currency risk [member]
IfrsStatementLineItems [Line Items]
Cash and cash equivalents	R$ 2445

Financial assets and financi_11

Financial assets and financial liabilities (Details 8) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Loans and financing	R$ 1882901	R$ 1374876
Lease liabilities	769,525	714,085	R$ 447703
Accounts payable to selling shareholders	528,678	679,826
Liquidity risk [member]
IfrsStatementLineItems [Line Items]
Trade payables	71,482	59,098
Loans and financing	2,313,530	1,753,304
Lease liabilities	1,711,092	1,628,196
Accounts payable to selling shareholders	621,762	780,114
Notes payable	62,176	89,950
Advances from customers	133,050	114,585
Financial liabilities contractual undiscounted	4,913,092	4,425,247
Later than one year [member] | Liquidity risk [member]
IfrsStatementLineItems [Line Items]
Trade payables	71,482	59,098
Loans and financing	287,741	217,903
Lease liabilities	117,506	103,003
Accounts payable to selling shareholders	282,481	246,059
Notes payable	62,176	15,644
Advances from customers	133,050	114,585
Financial liabilities contractual undiscounted	954,436	756,292
Later than one year and not later than three years [member] | Liquidity risk [member]
IfrsStatementLineItems [Line Items]
Trade payables
Loans and financing	788,190	585,686
Lease liabilities	234,688	211,894
Accounts payable to selling shareholders	339,281	445,066
Notes payable		74,306
Advances from customers
Financial liabilities contractual undiscounted	1,362,159	1,316,952
Later than three years and not later than five years [member] | Liquidity risk [member]
IfrsStatementLineItems [Line Items]
Trade payables
Loans and financing	1,237,599	948,503
Lease liabilities	219,127	204,744
Accounts payable to selling shareholders		88,989
Notes payable
Advances from customers
Financial liabilities contractual undiscounted	1,456,726	1,242,236
Later than five years [member] | Liquidity risk [member]
IfrsStatementLineItems [Line Items]
Trade payables
Loans and financing		1,212
Lease liabilities	1,139,771	1,108,555
Accounts payable to selling shareholders
Notes payable
Advances from customers
Financial liabilities contractual undiscounted	R$ 1139771	R$ 1109767

Financial assets and financi_12

Financial assets and financial liabilities (Details 9) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Liabilities arising from financing activities, beginning	R$ 2088961	R$ 1065188		R$ 344872
Payments	(251,626)	(264,475)		(223,529)
Addition	617,494	986,838	[1]	716,929
Interest	216,130	136,121		54,489
Business combination		176,105		152,670
Other	(18,533)	(10,816)		(1,522)
Liabilities arising from financing activities, ending	2,652,426	2,088,961		1,065,188
Proceeds from loans and financing	822,569
Net of the transaction costs	13,030
Foreign exchange movement				21,279
Loans And Financing [Member]
IfrsStatementLineItems [Line Items]
Liabilities arising from financing activities, beginning	1,374,876	617,485		60,357
Payments	(118,378)	(158,076)		(155,090)
Addition	496,885	809,539	[1]	605,041
Interest	127,559	68,909		10,031
Business combination		36,591		75,815
Other	1,959	428		52
Liabilities arising from financing activities, ending	1,882,901	1,374,876		617,485
Foreign exchange movement				21,279
Lease liabilities [member]
IfrsStatementLineItems [Line Items]
Liabilities arising from financing activities, beginning	714,085	447,703		284,515
Payments	(113,512)	(87,751)		(55,455)
Addition	100,873	158,651	[1]	98,904
Interest	88,571	67,212		44,458
Business combination		139,514		76,855
Other	(20,492)	(11,244)		(1,574)
Liabilities arising from financing activities, ending	769,525	714,085		447,703
Dividends Payable [Member]
IfrsStatementLineItems [Line Items]
Payments	(19,736)	(18,648)		(12,984)
Addition	R$ 19736	R$ 18648	[1]	R$ 12984
[1]The additions of loans and financing include proceeds from the SoftBank transaction of R$ 822,569 13,030

Financial assets and financi_13

Financial assets and financial liabilities (Details Narrative) R$ in Thousands	12 Months Ended
	Dec. 31, 2022 BRL (R$) Number	Dec. 31, 2021 BRL (R$) shares	Dec. 31, 2020 BRL (R$)	Dec. 16, 2022 BRL (R$) shares	Sep. 28, 2022
IfrsStatementLineItems [Line Items]
Transaction costs	R$ 13030
Shares issued | shares		93,722,831		500,000
Par value				R$ 1
Aggregate amount				R$ 500
Debentures bear interest	100%
Interest rate	1.80%
Transaction costs	R$ 3115
Amount recognized lease expense from short-term leases and low-value assets	12,153	R$ 11229	R$ 2555
Notes payable	62,176
Currency risk [member]
IfrsStatementLineItems [Line Items]
Exposure risk	R$ 24447	R$ 23228
Percentage of sensitivity change in the Euro exchange rate	10%
Closing foreign exchange rate | Number	5.2171
Currency risk [member] | Euro Member Countries, Euro
IfrsStatementLineItems [Line Items]
Closing foreign exchange rate | Number	1
Bottom of range [member]
IfrsStatementLineItems [Line Items]
Contractual lease term	5 years
Top of range [member]
IfrsStatementLineItems [Line Items]
Contractual lease term	30 years
C D I [Member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Intrest rate					1.62%
C D I [Member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Intrest rate					1.90%

Fair value measurement (Details

Fair value measurement (Details) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Trade receivable (non-current)	R$ 42568	R$ 27442
Loans and financing	(1,934,295)	(1,387,136)
Lease liabilities	(769,525)	(714,085)
Accounts payable to selling shareholders	(528,678)	(679,826)
Notes payable	(62,176)	(72,726)
Level 2 of fair value hierarchy [member]
IfrsStatementLineItems [Line Items]
Trade receivable (non-current)	42,568	27,442
Loans and financing	(1,934,295)	(1,387,136)
Lease liabilities	(769,525)	(714,085)
Accounts payable to selling shareholders	(528,678)	(679,826)
Notes payable	(62,176)	(72,726)
Level 3 of fair value hierarchy [member]
IfrsStatementLineItems [Line Items]
Trade receivable (non-current)
Not measured at fair value in statement of financial position but for which fair value is disclosed [member]
IfrsStatementLineItems [Line Items]
Trade receivable (non-current)

Labor and social obligations (D

Labor and social obligations (Details) - BRL (R$) R$ / shares in Units, R$ in Thousands	1 Months Ended			12 Months Ended
	Sep. 30, 2022	Jul. 31, 2022	May 31, 2022	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Expected volatility	0%	0%	0%
Share price at the measurement date	R$ 72.59	R$ 48.24	R$ 55.54
Model used	Binomial	Binomial	Binomial
Weighted average fair value at the measurement date	R$ 34.86	R$ 17.98	R$ 19.13
Strike price at the measurement date	R$ 52	R$ 52	R$ 70
Bottom of range [member]
IfrsStatementLineItems [Line Items]
Expected volatility	48%	48%	48%
Risk-free interest rate		13%	12%
Expected life of stock options	1 year	1 year	1 year
Top of range [member]
IfrsStatementLineItems [Line Items]
Expected volatility	58%	59%	60%
Risk-free interest rate	12%	15%	13%
Expected life of stock options	5 years	5 years	5 years
Modified Plan [Member]
IfrsStatementLineItems [Line Items]
Strike price at the measurement date				R$ 76
Expected volatility				0%
Share price at the measurement date				R$ 48
Model used				Binomial
Weighted average fair value at the measurement date				R$ 53.06
Modified Plan [Member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Expected volatility				48%
Risk-free interest rate				13%
Expected life of stock options				1 year
Modified Plan [Member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Expected volatility				59%
Risk-free interest rate				15%
Expected life of stock options				5 years
Original Plan [Member]
IfrsStatementLineItems [Line Items]
Expected volatility				0%
Model used				Binomial
Weighted average fair value at the measurement date				R$ 49.22
Original Plan [Member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Strike price at the measurement date				R$ 85
Expected volatility				42%
Risk-free interest rate				5%
Expected life of stock options				1 year
Share price at the measurement date				R$ 80
Original Plan [Member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Strike price at the measurement date				R$ 126
Expected volatility				69%
Risk-free interest rate				13%
Expected life of stock options				5 years
Share price at the measurement date				R$ 145

Labor and social obligations _2

Labor and social obligations (Details 1)			1 Months Ended	12 Months Ended
	Sep. 14, 2022 Number	Jul. 11, 2022 Number	May 18, 2022 Number	Dec. 31, 2022 Number R$ / shares shares	Dec. 31, 2021 Number R$ / shares shares	Dec. 31, 2020 Number shares
Labor And Social Obligations
Outstanding at the beginning				R$ 92.33
Outstanding at the beginning | Number				3,086,728	2,510,983	2,364,214
Granted				R$ 53.02
Granted | Number	1,234,919	1,234,919	1,234,919	1,234,919	1,170,000	477,220
Exercised
Exercised | Number					(442,669)	(56,092)
Forfeited				R$ 107.25
Forfeited | Number				(365,749)	(60,000)	(274,359)
Expired				R$ 97.80
Expired | Number				(226,611)	(91,586)
Outstanding at the ending				R$ 79.47	R$ 92.33
Outstanding at the ending | Number				3,729,287	3,086,728	2,510,983
Exercisable				R$ 97.65
Number of stock options exercisable | shares				1,133,774	542,061

Labor and social obligations _3

Labor and social obligations (Details Narrative) R$ / shares in Units, R$ in Thousands				1 Months Ended			12 Months Ended
	Sep. 14, 2022 Number	Jul. 11, 2022 Number	Jul. 08, 2022 R$ / shares	Sep. 30, 2022 R$ / shares shares	Jul. 31, 2022 R$ / shares shares	May 18, 2022 Number	Dec. 31, 2022 BRL (R$) Number R$ / shares	Dec. 31, 2021 BRL (R$) Number	Dec. 31, 2020 BRL (R$) Number
IfrsStatementLineItems [Line Items]
Compensation of employees							R$ 24248	R$ 25587	R$ 9514
Strike price | R$ / shares			R$ 71.22
Average incremental fair value | R$ / shares							R$ 3.84
Number of stock option granted | Number	1,234,919	1,234,919				1,234,919	1,234,919	1,170,000	477,220
Granted | shares				4,678	442,546
Fair values at grant date | R$ / shares				R$ 72.59	R$ 48.24
social obligations liabilities							R$ 2167
Restricted Stock Units [Member]
IfrsStatementLineItems [Line Items]
Proportion percentage							10%
Restricted Stock Units 1 [Member]
IfrsStatementLineItems [Line Items]
Proportion percentage							20%
Restricted Stock Units 2 [Member]
IfrsStatementLineItems [Line Items]
Proportion percentage							30%
Restricted Stock Units 3 [Member]
IfrsStatementLineItems [Line Items]
Proportion percentage							40%
Share Based Compensation Plans [Member]
IfrsStatementLineItems [Line Items]
Share-based compensation expense							R$ 27242	R$ 43377	R$ 32610
Restricted Stock Units [Member]
IfrsStatementLineItems [Line Items]
Share-based compensation expense							R$ 4032

Equity (Details)

Equity (Details) - R$ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity
Outstanding, at beginning balance	1,654,927
Average price, at beginning balance	R$ 92.23
Repurchased	2,131,358	2,142,051
Average price repurchased	R$ 71.46	R$ 119.99
Transferred from exercise of stock options		(442,669)
Average price transferred from exercise of stock options		R$ 124.26
Transferred from shares contribution		(44,455)
Average price transferred from shares contribution		R$ 111.94
Outstanding, at ending balance	3,786,285	1,654,927
Average price, at ending balance	R$ 80.54	R$ 92.23

Equity (Details Narrative)

Equity (Details Narrative) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 16, 2022	Jan. 27, 2022	Oct. 27, 2021	Dec. 23, 2020
IfrsStatementLineItems [Line Items]
Share capital	R$ 17	R$ 17
Total number of shares	93,722,831
Total number of shares		93,722,831	500,000
Authorized capital	R$ 50	R$ 50
Dividend payable	66,828
Dividend distributed	47,092
Dividends paid to non-controlling interests	19,736
Cash outflow	R$ 152317	R$ 213722
Class A Ordinary Shares [Member]
IfrsStatementLineItems [Line Items]
Total number of shares	47,920,068	47,920,068
Repurchase of ordinary shares				1,874,457	1,383,108	1,015,844
Class B Ordinary Shares [Member]
IfrsStatementLineItems [Line Items]
Total number of shares	45,802,763	45,802,763

Earnings per share (EPS) (Detai

Earnings per share (EPS) (Details) - BRL (R$) R$ / shares in Units, R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share
Net income attributable to equity holders of the parent	R$ 373569	R$ 223326	R$ 292075
Weighted average number of outstanding shares	90,335,037	93,291,480	92,683,848
Effects of dilution from stock options and restricted share units	329,085	811,818	951,920
Weighted average number of outstanding shares adjusted for the effect of dilution	90,664,122	94,103,298	93,635,768
Basic earnings per share (R$)	R$ 4.14	R$ 2.39	R$ 3.15
Diluted earnings per share (R$)	R$ 4.12	R$ 2.37	R$ 3.12

Revenue (Details)

Revenue (Details) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue [abstract]
Tuition fees	R$ 2827567	R$ 2124589	R$ 1388735
Other	213,040	167,441	99,817
Deductions
Granted discounts	(241,404)	(229,254)	(89,017)
Early payment discounts	(92,234)	(49,879)	(29,299)
Returns	(45,402)	(42,373)	(11,437)
Taxes	(107,004)	(74,232)	(49,629)
PROUNI	(225,506)	(176,921)	(107,979)
Revenue from contracts with customers	2,329,057	1,719,371	1,201,191
Tuition, digital content and app subscription fees - Transferred over time	2,273,578	1,640,889	1,128,558
Other - Transferred at a point in time	R$ 55479	R$ 78482	R$ 72633

Revenue (Details 1)

Revenue (Details 1) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Types of services or goods	R$ 2329057	R$ 1719371	R$ 1201191
Tuition fees	2,131,776	1,559,094	1,104,252
Other	197,281	160,277	96,939
Timing of revenue recognition	2,329,057	1,719,371	1,201,191
Transferred over time	2,273,578	1,640,889	1,128,558
Transferred at a point in time	55,479	78,482	72,633
Undergrad [Member]
IfrsStatementLineItems [Line Items]
Types of services or goods	2,037,889	1,498,408	1,002,461
Tuition fees	2,023,128	1,486,111	997,055
Other	14,761	12,297	5,406
Timing of revenue recognition	2,037,889	1,498,408	1,002,461
Transferred over time	2,024,373	1,486,111	997,055
Transferred at a point in time	13,516	12,297	5,406
Continuing Education [Member]
IfrsStatementLineItems [Line Items]
Types of services or goods	108,806	72,983	107,197
Tuition fees	108,648	72,983	107,197
Other	158
Timing of revenue recognition	108,806	72,983	107,197
Transferred over time	108,806	72,983	107,197
Transferred at a point in time
Digital Services [Member]
IfrsStatementLineItems [Line Items]
Types of services or goods	189,984	151,958	93,152
Tuition fees
Other	189,984	151,958	93,152
Timing of revenue recognition	189,984	151,958	93,152
Transferred over time	145,939	81,795	24,306
Transferred at a point in time	44,045	70,163	68,846
Elimination of intersegment amounts [member]
IfrsStatementLineItems [Line Items]
Types of services or goods	(7,622)	(3,978)	(1,619)
Tuition fees
Other	(7,622)	(3,978)	(1,619)
Timing of revenue recognition	(7,622)	(3,978)	(1,619)
Transferred over time	(5,540)
Transferred at a point in time	R$ 2082	R$ 3978	R$ 1619

Expenses and costs by nature (D

Expenses and costs by nature (Details) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Expenses And Costs By Nature
Cost of services	R$ 859552	R$ 652300	R$ 434654
General and administrative expenses	(798,153)	(622,615)	(402,855)
Total	(1,657,705)	(1,274,915)	(837,509)
Payroll	(880,664)	(677,564)	(446,473)
Hospital and medical agreements	(66,065)	(37,449)	(37,988)
Depreciation and amortization	(206,220)	(154,220)	(108,744)
Lease expenses	(12,153)	(11,229)	(2,555)
Utilities	(17,682)	(10,643)	(5,892)
Maintenance	(76,475)	(47,141)	(20,746)
Share-based compensation	(31,274)	(43,377)	(32,610)
Tax expenses	(10,518)	(7,997)	(5,326)
Pedagogical services	(48,084)	(47,881)	(24,037)
Sales and marketing	(48,217)	(39,506)	(18,361)
Allowance for doubtful accounts	(42,708)	(47,819)	(32,081)
Travel expenses	(14,003)	(7,542)	(4,550)
Consulting fees	(35,326)	(38,818)	(31,276)
Other	(168,316)	(103,729)	(66,870)
Total	R$ 1657705	R$ 1274915	R$ 837509

Finance result (Details)

Finance result (Details) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finance Result
Income from financial investments	R$ 67810	R$ 35773	R$ 24479
Changes in fair value of derivative instruments			20,739
Interest received	27,197	23,040	11,876
Other	7,035	5,753	5,196
Finance income	102,042	64,566	62,290
Interest expense	(200,081)	(108,437)	(25,543)
Interest expense on lease liabilities	(88,571)	(67,212)	(44,458)
Financial discounts granted	(24,092)	(23,193)	(8,081)
Bank fees	(8,623)	(7,878)	(6,333)
Foreign exchange loss, net	(852)	(17,973)	(4,613)
IOF taxes (taxes on financial transactions)	(178)	(3,306)	(1,661)
Other	(27,496)	(15,797)	(7,580)
Finance expenses	(349,893)	(243,796)	(98,269)
Finance result	R$ 247851	R$ 179230	R$ 35979

Income taxes (Details)

Income taxes (Details) - BRL (R$) R$ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes
Income before income taxes		R$ 428433	R$ 273462	R$ 335054
Combined statutory income taxes rate - %		34%	34%	34%
Income taxes at statutory rates		R$ 145667	R$ 92977	R$ 113918
Reconciliation adjustments:
Tax effect on loss from an entity not subject to taxation		(32,859)	(37,794)	(8,474)
PROUNI - Fiscal Incentive	[1]	270,062	194,830	120,851
Unrecognized deferred tax assets		(117,377)	(86,233)	(41,319)
Presumed profit income tax regime effect	[2]	(1,549)	(7,066)	(2,640)
Permanent adjustments		(12,226)	(6,232)	2,567
Other		3,939	4,293	15,866
Income taxes expense – current		R$ 35677	R$ 31179	R$ 27067
Effective rate		8.33%	11.40%	8.08%
[1]The Company adhered to PROUNI, established by Law 11,096 / 2005, which is a federal program that exempt companies of paying income taxes and social contribution.[2]Brazilian tax law establishes that companies that generate gross revenues of up to R$ 78,000 in the prior fiscal year may calculate income taxes as a percentage of gross revenue, using the presumed profit income tax regime. The effect of the presumed profit of certain subsidiaries represents the difference between the taxation based on this method and the amount that would be due based on the statutory rate applied to the taxable profit of the subsidiaries.

Income taxes (Details Narrative

Income taxes (Details Narrative) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Unrecognized deferred income tax assets	R$ 778080	R$ 432226

Insurance contracts and conti_3

Insurance contracts and contingencies (Details) - BRL (R$) R$ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Legal proceedings provision		R$ 4232
Tax Contingencies		48,333
Legal proceedings contingent liability [member]
IfrsStatementLineItems [Line Items]
Balance as of beginning of the year		148,287	R$ 53139		R$ 5269
Business combinations			80,252		32,576
Additions		73,909	24,744	[1]	19,284
Reversals		(26,342)	(9,848)		(3,990)
Balance as of ending of the year		195,854	148,287		53,139
Legal proceedings contingent liability [member] | Labour [Member]
IfrsStatementLineItems [Line Items]
Balance as of beginning of the year		25,490	4,519		2,501
Business combinations			16,597		2,741
Additions		2,300	5,418	[1]	562
Reversals		(5,306)	(1,044)		(1,285)
Balance as of ending of the year		22,484	25,490		4,519
Legal proceedings contingent liability [member] | Civil [Member]
IfrsStatementLineItems [Line Items]
Balance as of beginning of the year		22,928	13,280		2,768
Business combinations			6,017		2,348
Additions		7,911	5,101	[1]	10,869
Reversals		(6,175)	(1,470)		(2,705)
Balance as of ending of the year		24,664	22,928		13,280
Legal proceedings contingent liability [member] | Taxes [Member]
IfrsStatementLineItems [Line Items]
Balance as of beginning of the year	[2]	99,869	35,340
Business combinations	[2]		57,638		27,487
Additions	[2]	63,698	14,225	[1]	7,853
Reversals	[2]	(14,861)	(7,334)
Balance as of ending of the year	[2]	R$ 148706	R$ 99869		R$ 35340
[1]The amount of R$ 4,232 48,333

Insurance contracts and conti_4

Insurance contracts and contingencies (Details 1) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Total	R$ 78448	R$ 66058
Legal proceedings contingent liability [member] | Labour [Member] | Types Of Risk [Member]
IfrsStatementLineItems [Line Items]
Total	13,914	5,098
Legal proceedings contingent liability [member] | Civil [Member] | Types Of Risk [Member]
IfrsStatementLineItems [Line Items]
Total	59,603	56,501
Legal proceedings contingent liability [member] | Taxes And Social Security [Member] | Types Of Risk [Member]
IfrsStatementLineItems [Line Items]
Total	R$ 4931	R$ 4459

Insurance contracts and conti_5

Insurance contracts and contingencies (Details Narrative) - BRL (R$) R$ in Thousands	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Judicial deposits	R$ 12693	R$ 18825
Other Assets Non Current [Member]
IfrsStatementLineItems [Line Items]
Judicial deposits	12,693	18,825
Contingencies correspondent amount	R$ 145300	R$ 135355

Non-cash transactions (Details)

Non-cash transactions (Details) - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Provision for legal proceedings with corresponding indemnification assets	R$ 48333	R$ 4232	R$ 9940
Additions and remeasurements of right-of-use assets and lease liabilities	100,873	158,651	98,904
P E B M E D [Member]
IfrsStatementLineItems [Line Items]
Issuance of shares for acquisition of Pebmed			17,531
I Clinic [Member]
IfrsStatementLineItems [Line Items]
Issuance of shares for acquisition of Pebmed		71,500
Cliquefarma [Member]
IfrsStatementLineItems [Line Items]
Issuance of shares for acquisition of Pebmed		3,000
R X P R O [Member]
IfrsStatementLineItems [Line Items]
Issuance of shares for acquisition of Pebmed		R$ 5112

Subsequent events (Details Narr

Subsequent events (Details Narrative) - Del Rey [Member] - BRL (R$) R$ in Thousands	12 Months Ended
	Dec. 31, 2022	Jan. 02, 2023
IfrsStatementLineItems [Line Items]
Percentage of acquisition		100%
Aggregate purchase price	R$ 825000
Payment of purchase price	575,000
Total annual installment	250,000
First annual installment	150,000
Second annual installment	50,000
Third annual installment	50,000
Transaction costs	11,860
U N I T Alagoas [Member]
IfrsStatementLineItems [Line Items]
Potential additional payment	R$ 1250